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ABSTRACT
Most studies o-f prognosis in epilepsy have been undertaken
in patients with chronic seizure disorders. In contrast
the patterns o-f seizure recurrence at the onset of the
illness and the prognosis during the early years of
treatment has received only scant attention in the
literature. Three aspects of the early prognosis of
epilepsy have been studied.
1). The prognosis for seizure control has been assessed in
106 patients with newly diagnosed previously untreated
epilepsy who were followed prospectively for a median of
66 months. Patients were treated with phenytoin or
carbamazepine monotherapy with extensive use of
anticonvulsant level monitoring. Twenty six patients
remained completely seizure free. Actuarial analysis
showed that 35% of patients entered a seizure free period
of at least two years at the start of treatment, 73% by
four years and B2% by the end of B years. Once a remission
had occurred relapses were usually isolated events, often
related to poor compliance. The presence of partial
seizures, a high pretreatment tonic clonic seizure
frequency, a positive family history of epilepsy and the
presence of Symptomatic epilepsy and associated
neurological, social and psychiatric handicaps predicted a
worse prognosis. In patients who continued to have
seizures during the first two years of treatment the
probability of subsequently achieving a remission had
fallen by one half.
2). The prognosis for seizure recurrence was assessed in a
series of 146 adults and children who presented within a
median of one day following a first ever tonic clonic
seizure. The cumulative probability of seizure recurrence
was 60% by 1 year, 69% by 2 years and 71% by 4 years.
Patients with symptomatic seizures and those who were aged
under 16 had a higher recurrence rate.
3). The intervals between seizures were measured in a
further series of 183 adults and children with two or more
untreated tonic clonic seizures. The second seizure
followed the first within a month in 30% and by one year in
87%. In patients with multiple untreated seizures the
interval between consecutive seizures appeared to decrease
with each seizure that occurred. The subsequent prognosis
on treatment deteriorated as the interval between the first
and second seizures shortened.
Following a first seizure the majority of patients are
likely to develop epilepsy. The second seizure usually
follows the first in rapid sucession and the early patterns
of seizure recurrence are important in determining the
subsequent prognosis. After starting treatment as many as
80% of patients rapidly enter a prolonged period of seizure
control, which in a substantial proportion of cases may be
permanant. The early years of treatment are of crucial
importance in determining the long term prognosis in
epilepsy. Three quarters of all one year remissions began
during the first year of treatment and the longer seizures
continued the harder they were to treat. Further studies
are needed to assess whether early or more effective
treatment at the onset of the illness might improve the
subsequent prognosis and reduce the proportion of cases who
develop chronic epilepsy.
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Amongst the many neurological disorders that afflict man,
it is difficult to overestimate the central importance of
epilepsy. It is one of the commonest disorders of the
nervous system, the prevalence rate for active epilepsy
being of the order of 4 per 1000 of the population
(Zielinsky, 1976). Assuming an incidence rate of 50 per
100,000 and a life expectancy of 50 years, over 37. of the
population can be expected to develop epilepsy at some
time during their life (Hauser & Kurland, 1975). This
figure excludes an even higher number who have only a
single seizure or only experience seizures in relation to
an acute precipitating event such as fever or alcohol
withdrawal.
Epilepsy is also important because of the diversity of the
disorder in terms of its causes, clinical features and
complications. In some patients it appears to arise
spontaneously in a perfectly healthy individual. In other
instances, seizures may be only a symptom of an underlying
acute neurological or systemic disorder or may arise as a
complication of a wide variety of central nervous system
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diseases. In those patients in whom the disorder becomes
chronic the occurrance of seizures may be only one aspect
of a disabling disorder with associated neurological,
social and pyschiatric handicaps. Because three-quarters
of cases occur before the age of 20, epilepsy (or its
treatment) may adversely affect growth and development.
Patients with epilepsy appear to be particularly prone to
psychological complications; cognitive impairment,
affective disorders and psychosis can all complicate the
course of epilepsy. A diagnosis of epilepsy still carries
with it a number of social implications, such as those
affecting driving and employment. Furthermore, by its very
nature, it often remains a hidden illness and the social
stigma which is attached to it unfortunately still plays a
part in the disease.
In this chapter a review of the literature relating to the
prognosis of patients with epilepsy will be presented. A
true understanding of the prognosis of epilepsy is of
crucial importance. It affects not only our understanding
of the nature of epilepsy but many diverse aspects of
patient managment and clinical practice ranging from the
appropriate counselling of individual patients and the
development of rational treatment strategems, to the
design and analysis of anticonvulsant trials. Once a
diagnosis has been established, many questions and worries
that understandably arise relate directly to the prognosis
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of the disorder. What is the likelihood that seizures
will be controlled? For how long will treatment be needed
and can epilepsy be cured? Because the patient is often a
young adult worries concerning driving, employment and
child bearing are particularly common. The illness is
still surrounded by much myth and misunderstanding. For
many people the diagnosis carries with it the implication
of a lifelong intractable disorder associated with mental
deterioration. Unfortunately, in attempting to find an
answer to these questions the physician will find little
help from the currently available literature on prognosis.
Much of it is highly contradictory in nature and virtually
all of it has been based on the observation of a small sub
group of patients with long standing chronic epilepsy.
The gloomier views on prognosis, often to be found in the
established textbooks, do not necessarily apply to the
generality of patients.
A knowledge of the natural history and prognosis of
epilepsy has a major bearing on two important treatment
decisions, both of which arise commonly in clinical
practice. Most neurologists in this country, recomend
treatment after the occurrence of two or more seizures,
particularly if they occur within the space of one year
(Reynolds, 1987). A reasoned basis for this policy,
however, cannot be found anywhere in the literature and
the appropriate management is highly controversial
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(Hauser, 19B6; Elwes & Reynolds, 19BB). The decision is of
importance because once started treatment is usually given
continuously for a period of many years. Although the
majority of patients <if treated appropropriately)
experience minimal toxicity it is only in comparitively
recent years that the chronic side effects of anti¬
convulsants have become more widely appreciated
(Reynolds, 1975). A broader qustion that will be
considered in some detail later is whether the timing of
initiation of treatment in any way affects long term
prognosis. If this is indeed the case then it would have
major implications on the way in which patients are
managed. Similar uncertainties surround the decision as to
when anticonvulsants should be discontinued (Chadwick,
1985). This important area has received even less
attention in the published literature. It is only in
comparatively recent years that the adverse factors
associated with relapse following drug withdrawal have
been more clearly delineated. The crucial questions as to
how long treatment should be given to patients who are in
remission and rate at which drugs should be withdrawn
remain unanswered.
A knowledge of the prognosis of epilepsy also has a direct
bearing upon other aspects of the rational treatment of
epilepsy. Effective drugs have now been available for over
a century. There is, however, remarkably little guidance
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in the literature concerning the comparative efficacy and
toxicity of the established anticonvulsant drugs. The
single most important reason for this has been the poor
design of anticonvulsant trials (Coatsworth, 1971). Most
importantly, virtually all of these have been undertaken
in patients with long standing intractable epilepsy where
the prognosis is extremely poor. It is unlikely that
meaningful results will be obtained by comparing efficacy
in groups of patients who essentially are drug resistant.
It is only in very recent years that trials have for the
first time been undertaken using monotherapy in newly
diagnosed patients. It is also important to appreciate the
limits of currently available treatment. In patients in
whom the chances of remission are low the physician is
under pressure to try the addition of more and more drugs
in an attempt to control what is, in fact, an intractable
disorder. Unfortunately, this tendency has accelerated in
recent years with the increasing number of new and
experimental drugs which are available. Although the
disadvantages of polytherapy are manifest, there is
remarkably little evidence that the use of multiple drugs
has any beneficial effect on the long term prognosis for
seizure control (Reynolds & Shorvon, 19B1).
Before considering the literature on the prognosis of
patients with epilepsy a number of general observations
should be emphasised. The prognosis of epilepsy has
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always been a subject of considerable controversy. In one
of the important 19th century texts, Reynolds (1861) opens
the chapter on the prognosis of epilepsy by quoting the
diametrically opposed views of two leading authorities:
"J'en ai gueri un tres grand nombre".
(Tissot, 1770)
"Elle conduit presque unfai11iblement a
1'incurabi1ite par de lentes degradations".
(Delasiauve, 1854)
The controversy has not abated with the passage of time.
Rodin (1968), in probably one of the most influential and
widely quoted works on the prognosis of epilepsy,
concluded that the disorder was likely to be chronic in as
many as 807. of patients. Although these views have been
influential they have not gone unchallenged. In a more
recent study, Annegers et al. (1979) concluded almost
exactly the reverse, namely, that nearly three quarters of
patients enter prolonged and usually permanent remission.
Between these two extremes every shade of opinion is to be
found. In patients presenting with single seizures the
recurrence rate has been reported to vary between 297 and
697 and similar uncertainty surrounds the reccurrence rate
following anticonvulsant withdrawal (Chadwick & Reynolds,
19B5).
There are probably two main reasons for this disagreement.
Firstly the outcome in epilepsy is indeed highly variable.
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Some patients appear to experience only one or a -few
seizures occurring over a short period of time. Following
effective treatment prolonged and sometimes permanent
remissions occurs. In others the disease progresses, for
reasons that are unknown, into a lifelong intractable
disorder. Because of the inherent variability of outcome
the methods of patient selection are of fundamental
importance in determining the results of prognostic
studies.If these are not clearly stated (and unfortunately
this is the case in a very large number of reports) then
interpretation of the results is rendered virtually
impossible. A similar consideration underlies the
widely varying reports of recurrence rates following a
first seizure. It will be argued at some length in the
experimental sections and the subsequent discussions that
this has been the single most important factor determining
the controversy surrounding the prognosis of epilepsy.
A second difficulty in interpreting the literature is the
heterogenicity of epilepsy. There is even difficulty in
reaching a satisfactory definition of the disorder. Some
authors include patients with acute symptomatic seizures
(Blom et al. 1978; Goodridge & Shorvon, 1983; Hirtz et al.
1984) whilst other authors include those with a single
attack and an abnormal EEG (Okuma & Kumashiro, 1981).
Under the broad heading of epilepsy it is possible to
identify groups of patients in whom the prognosis is known
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to differ widely. Although Rolandic seizures may appear
identical to focal motor attacks arising secondarily to
structural disease of the cortex, the natural history may
be very dissimilar (Lerman, 1985). Childhood absence
seizures may be difficult to distinguish from seizures
arising from discharges in the temporal lobe. In the
former, there is a striking tendency for the disease to
undergo spontaneous remission (Aidie, 1924) whilst the
latter is one of the commonest seizure types amongst
patients with chronic intractable epilepsy. In recent
years the International League Against Epilepsy has put
forward proposals for the classification of epileptic
seizures and also of the epilepsies and epileptic
syndromes (Commision on Classification & Terminology 1981
& 1985). The authors rightly admit that the classificat¬
ions are likely to be temporary and should be considered
a basis for further discussion. Despite this, they are an
important summary of our current knowledge. In the
first part of this chapter the historical and
theoretical basis for the proposed classification will be
briefly reviewed. The importance of this will subsequently
become apparent as it appears that many of the proposed
subdivisions have important prognostic implications.
Furthermore in many of the proposed epileptic syndromes
the prognosis is pivotal in establishing its nosological
position.
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It is impossible to consider the prognosis of epilepsy in
isolation from its treatment. Although methods such as
diet or surgery have an important role in small selected
groups, the use of drugs has always been, and still
remains, ths mainstay of treatment. There is now
overwhelming evidence that the currently available drugs
are highly effective in suppressing seizures. A central
part of this thesis is an attempt to assess the impact
that these drugs have had on the prognosis of patients
with epilepsy. Do they merely suppress seizures, or in
doing so do they actually alter the natural history of the
disorder and bring about a cure? An answer to this
question implies a knowledge of the natural history of
untreated epilepsy. There is virtually no guidance in the
literature on this and any attempt to explore this
experimentally is limited by obvious ethical and practical
considerations. If anticonvulsants do however alter the
natural history of epilepsy then there are many important
implications for the practical management of patients. A
related question is whether there are significant
differences in efficacy between the currently available
drugs. Although modern compounds such as carbamazapine are
probably less toxic, is there any evidence that they are
any better in controlling seizures? The difficulties in
establishing secular trends in prognosis will be examined,
particularly as some more recent studies have attributed
improvements in prognosis to advances in drug treatment
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(see for example, Okuma & Kumashiro, 1981).
In the literature review considered here and the
discussions to each of the chapters considerable emphasis
has been placed upon the historical literature. There are
a number o-f reasons -for this. The second half of the
Nineteenth Century was a time when a major expansion of
knowledge about epilepsy took place. Patients, who had
previously been incarcerated with the insane, benefited
from the humanisation of treatment that occurred in the
previous century (Temkin, 1971). Specialised institutions
such as the National Hospital for Paralysed and Epileptic
in London and similar hospitals in Europe and North
America were established. These institutions provided, for
the first time, the opportunity to observe large numbers
of patients with the disorder. The physicians who staffed
these hospitals, such as Hughlings Jackson, Delasiauve and
Reynolds produced monographs and books specifically
devoted to epilepsy. Their work has had a very major
impact on our understanding of the disorder. Difficulties
surrounding the diagnosis, classification, treatment and
prognosis are described with a clarity and force by these
authors which make them relevant to this day. The
specific area of interest in this thesis is the early
prognosis of epilepsy) the probability of seizure
recurrence following a first seizure, the patterns of
seizures at the onset and the early response to treatment.
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It is curious that until very recent years these aspects
of the natural history of epilepsy have received virtually
no attention in the Twentieth Century literature. Indeed,
the most detailed and complete account of this work is
probably found in historical literature written over a
hundred years ago by Gowers (1881). His work is of
particular interest because he was able to observe the
natural history of untreated epilepsy and subsequently
document the major impact of the introduction of bromides.
Gowers also stated that prior to the introduction of these
drugs spontaneous remission was most unusual, thus
implying that treatment did indeed alter the natural
history of epilepsy. Gowers' observations on the ealy
prognosis of epilepsy will be re-examined and their
implications for further research discussed.
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B. THE NATURE OF EPILEPSY: HISTORICAL LITERATURE
Throughout the ages the term epilepsy has been surrounded
by superstition and myth. The word itself is derived from
the Greek verb "epi1ambanen" meaning to seize or to
attack. During an epileptic seizure the victim was
thought to be seized by some demon or evil force. To
this day a dignosis of epilepsy still carries with
it a social stigma, and the concept that it is an unclean
disease has lingered on.
1. The Sacred Disease.
The first historical account that we have of the disorder,
which we now recognise as epilepsy, is to be found in the
Hippocratic Writings dating from around 400 B.C. (Temkin,
1971). The book "On the Sacred Disease" was written by a
physician but directed at a lay audience and was an attack
on popular superstitions and the magicians and charletons
who termed the disease "Sacred". According to the author
epilepsy was no more sacred or divine than any other
disease. It's causes lay within the brain and it was,
therefore, open to treatment by physical means. During the
second century A.D. the centres of knowledge moved to
Alexandria and the teachings of Galen (130-200 AD)
predominated. The cause of epilepsy was thought to be an
12
excess of moist humour or phlegm blocking the ventricles
of the brain. The seizure was the outward manifestation of
the body's attempt to rid itself of this blockage.
These teachings were of profound importance for the
subsequent development of our understanding of epilepsy.
They refuted the superstitious and demonical concept
and formed the basis of the development of rational
investigation that occurred during the enlightenment.
Although the theory of humours may strike us as
fanciful, the classification of the causes of epilepsy
proposed by the Ancients form the basis of modern theories
(see below).
2. The Falling Sickness
Temkin (1971) claims that during the Middle Ages little
was added to our understanding of epilepsy. Other
conditions losely described as states of possession,
raptures or prophetic trances, or indeed any disorder
which caused a sudden fall were included under the term
"morphus caducus", or the "falling sickness" well known
from Shakespeare's Julius Ceasar. Periodic states of
mania and epilepsy were not clearly distinguished from
each other and both were felt to be associated with
phases of the moon, a concept which still persists in
our use of the term lunacy. The horror and revulsion that
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were -felt by the ignorant who witnessed the unfortunate
victim during a seizure were propagated by the conviction
that epilepsy was a contagious disease. People would
spit upon the epileptic and refuse to eat or drink with
him. Epilepsy was classed along with the great contagious
diseases, leprosy, the plague and subsequently syphilis.
In the Gospel of St. Mark, Chapter 9, 14-29 Jesus casts
out an unclean spirit from an epileptic child who is cured
of the disorder. Throughout the Middle Ages the Church
tried to dispel the pagan beliefs of witchcraft and
lunacy. Certain saints, particularly St John the Baptist
and St. Valentine, became associated with epilepsy. In the
Fifteenth Century a hospital for epilepsy was built at the
Priory of St. Valentine in Rufuch, Alsace. The medieval
physicians accepted the force of evil without question and
a great debate arose as to the relationship of epilepsy to
possession, witchcraft and magic.
3. Idiopathic Epilepsy
The relationship of epilepsy to structural disease of the
brain has always been a subject of controversy. These
difficulties are well illustrated by tracing the
historical development of the term "idiopathic or
"essential " epilepsy. The origins of the debate lie in
the teachings of Hippocrates and Galen. The ancients
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recognised that epilepsy was a disease of the brain. In
true or idiopathic epilepsy the sustance of the brain was
normal and the seizures were caused by an obstruction of
viscous humours within the ventricles. However, it was
also recognised that seizures could arise from structures
outside of the brain. An "aura" or breeze could arise from
other organs, particularly the heart, and spread to the
brain causing a seizure. This type of epilepsy was termed
sympathetic.
With increasing knowledge, particularly of pathological
anatomy that occurred during the Renaissance, this
classification was modified. It became apparent that in
the great majority of cases of epilepsy, the post mortem
examination of the brain appeared normal. In the words of
Esquirol: ".... Let us admit frankly that up to now
pathological anatomy has shed little light on the
immediate seat of epilepsy". (Esquirol, 1838; quoted by
Temkin, 1971, page 273).
□n the other hand, by the Eighteenth Century it was known
that fractures of the skull, softening or haemorrhage into
the brain or syphylitic gummas could all cause seizures,
indistinguishable from those that occurred in epilepsy
(Penfield & Erikson, 1941). Furthermore, it was
subsequently appreciated that eclamptic convulsions could
occur in the context of other diseases. Most important of
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these were infantile eclampsia, puerperal eclampsia and
eclampsia that followed uraemia or Bright's disease
(Gowers, 1881). The ancient classification of epilepsy
was modified to take account of this new knowledge.
Thus Delasiauve suggested the following:
1. "Essential or idiopathic epilepsy, manifesting it¬
self merely in functioning deviations, without
lesion, corresponding to simple nervous afflictions
and, in a word, constituting a veritable neurosis.
2. Symptomatic epilepsy belonging to a more or less
appreciable cerebral lesion, the convulsive spasm
being here the symptom and not the disease.
3. Finally, a third epilepsy, called sympathetic, pro¬
duced by the radiation of abnormal impressions which
can have their seat in all parts of the body except
the brain or its appendages".
(Delasiauve, 1854; quoted by Temkin,1971, page 289)
Controversy continued to surround what constituted true or
essential epilepsy. Sieveking (1858) stated that it was
impossible to distinguish between essential and
nonessential, idiopathic and symptomatic epilepsy and the
classification should therefore be abandoned (quoted by
Temkin, 1971). On the other hand, Reynolds (1861)
considered only idiopathic epilepsy to be the true
disorder.
"In this volume I propose treating only of epilepsy
proper, viz. of that form of idiopathic convulsions
of which I believe alone the name epilepsy must be
applied.... We must employ the term epilepsy in a
restrictive sense implying only those cases which,




Hughlings Jackson chose to study seizures arising -from
well defined lesions of the cerebral cortex. In his later
work (Hughlings Jackson, 1873) he went on to conclude that
all seizures, whether focal or generalised, must have a
structural basis if only sufficient means were available
to detect them. In this sense he denied the existence of
idiopathic epilepsy (see Temkin, 1971 page 349 et seq.) .
Bowers, who was Hughlings Jackson junior colleague,
accepted his teaching that seizures were caused by
excessive discharges of grey matter. However he
classified epilepsy as a functional disorder of the brain
with disorders such as hysteria and chorea. Although
Bowers admitted that seizures could arise in the presence
of a gross lesion within the substance of the brain
epilepsy was, in his own words, "a disease of tissue not
of structure" (Bowers, 1881).
4. Epilepsy and Cerebral Localization
Our present understanding of the importance of cerebral
localization in causing the symptoms of epileptic seizures
originates from the work of Hughlings Jackson (Penfield &
Erickson, 1941). Prior to his most important papers,
published between 1850 and 1870 it was considered that in
true or essential epilepsy convulsive movements occurred
on both sides of the body and consciousness was lost
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(Reynolds, 1861). Hughlings Jackson, however, chose to
study unilateral convulsions which have, of course, been
eponymously named after him. In deference to the current
theories, he termed these attacks "epileptiform" to
distinguish them from true seizures, although he
subsequently made it clear that he considered that the
underlying mechanism in both were in fact the same
(Hughlings Jackson, 1873).
Hughlings Jackson attributed the first description of
unilateral seizures to Bravais in 1827. Bright, between
1831 and 1835 described unilateral seizures in which
consciouness was preserved, and furthermore that these
episodes could be associated with gross lesions affecting
the cerebral cortex opposite to the side that convulsed.
Most important of Hughlings Jackson's forerunners were the
Swiss Neurologist Herpin to whom he made many references.
Herpin based his analysis on 300 cases seen in a private
clinic (see Temkin, 1971 pages 324 et seq). He found that
in over half the cases minor attacks, cramps, spasms or
vertigos preceded the occurrence of major seizures.
Variable as these might be, they were remarkably constant
in any given patient. Herpin proposed that these were in
fact incomplete or abortive attacks. The aura was not a
sensation that started peripherally and spread to the brain
causing a seizure, but the start of the seizure itself.
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Hughlings Jackson's work was based upon a combination of
meticulous medical observation and pathological
examination. Broca had already proposed in 1861 that speech
was associated with left hemisphere function. Hughlings
Jackson found that unilateral motor seizures were usually
associated with lesions of the opposite precentral gyrus.
Similarly, in dreamy states a lesion was often found within
the temporal lobe (Hughlings Jackson & Colman, 1898). Thus
the symptoms of the attack depended upon the area of the
brain which was affected. If there was a destructive lesion
of the brain then paralysis would occur. A seizure was a
reverse of this process and the movements were due to the
excitability of the nervous elements. According to
Hughlings Jackson, seizures were due to "occasional,
sudden, excessive, rapid and local discharges of grey
matter" (Hughlings Jackson, 1873). A tumour, infarction or
some other gross lesion of the brain was necessary in order
to cause the excessive discharges and because of the
episodic nature of the symptoms, some other form of
irritation or reflex action was needed to bring about the
seizure. In 1870 Fritz and Hitzig described the
electrical excitability of the cerebral cortex in dogs.
They observed that electrical stimulation of the precentral
gyrus could cause muscular contractions and that more
prolonged stimuli produced convulsions. This in association
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with the work of Ferrier provided experimental evidence to
support Hughlings Jackson's theories and heralded the
modern era o-f the study o-f epilepsy.
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C. The Classification of Epilepsy
Although the occurrence of seizures is common to all types
of epilepsy, the individual features of the disorder may
differ greatly. Any attempt to classify epilepsy must take
account not only of seizure type, but also EEG features,
age of onset, associated clinical features, presumed
etiology and the response to treatment and prognosis. In
the current state of knowledge it is not possible to
classify epilepsy on the basis of disease states. The term
"disease" implies a known pathophysiology or morbid
pathology, a uniform set of clinical symptoms and signs and
a predictable outcome. As yet few diseases, such as might
be said to occur in Lafora body disease or Unverricht-
Lundborg disease, have been identified (Berkovic &
Andermann, 19B£>) . It is, however, possible to group
together patients on the basis of a particular feature or
group of features that occur sufficiently frequently to
constitute a syndrome. A syndrome does not necessarily
imply a single aetiology and the symptoms of one syndrome
may overlap with another.
In recent years the Commission on Classification and
Terminology of the International League against Epilepsy
(1981 & 1985) has attempted to summarise the current
knowledge and produce a broadly acceptable classification.
Because of the diversity of terminology found in the
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literature there is general agreement that a uniform method
of classification is needed to allow comparison of results
and to aid communication. The league initially proposed a
classification of epileptic seizures (in its original and
revised forms) which has now become widely accepted and
more recently a classification of the epilepsies and
epileptic syndromes.
A summary of the proposed classification is shown in Table
1:1. It should be noted that a number of disorders are
excluded from the broader definition of epilepsy and have
been placed under a separate heading in Section 4. These
include patients with seizures occurring in the context of
systemic precipitating factors such as fever, isolated
seizures and epilepsy characterised by specific modes of
precipitation, e.g. musicogenic epilepsy. The division of
the remaining epilepsies is made along the grounds
considered in the previous historical section, the
principle one being into partial (or focal) and generalised
epi1epsies.
1. Partial and Generalised Epilepsies
Partial epilepsies are defined as those in which the
symptoms of the seizure or the investigative procedures
such as EEG or neuroimaging show a localised origin for the
attacks. The focus may be either anatomical or functional.
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TABLE 1:1. THE CLASSIFICATION OF THE EPILEPSIES AND
EPILEPTIC SYNDROMES (Adapted -from Commision on Classi¬
fication and Terminology, 1985)
1 PARTIAL EPILEPSIES
A) IDIOPATHIC
Benign Epilepsy of Childhood with Centro-temporal
Spikes




Benign Neonatal Familial Convulsions
Benign Neonatal Convulsions
Benign Myoclonic Epilepsy in Infancy
Childhood Absence Epilepsy
Juvenile Myoclonic Epilepsy
Epilepsy with Grand Mai Seizures on Awakening
B> IDIOPATHIC or SYMPTOMATIC
West Syndrome
Lennox-Gastaut Syndrome
Epilepsy with Myoclonic-astatic seizures
Epilepsy with Myoclonic Abscences
C) SYMPTOMATIC
Malformations,eg. Sturge Weber Syndrome
IEOM eg. Phenyl Ketonuria
Storage Diseases eg. Tay Sachs, Cereboid
Lipofuscinosis
3 UNDETERMINED PARTIAL or GENERALISED EPILEPSIES
Neonatal Seizures
Epilepsy with Continuous Spike Waves during Slow
Wave Sleep
Acquired Epileptic Aphasia




Specific Precipitants, eg musicogenic epilepsy













It is also recognised that the focus may be poorly defined,
multiply or occur in different hemispheres as in the benign
partial epilepsies of childhood (Lerman & Kivity, 19B6).
The partial epilepsies are divided into different groups
pepending on the area that is involved in the ictal
discharge. These groups have been ascertained not only on
the basis of clinical observation and EEG and video
monitoring but also in some cases from the use of depth
electrodes. In addition to the more widely recognised
temporal lobe epilepsies, descriptions of 9 other partial
epilepsies are given in the classification.
Generalised epilepsies are those in which the first
clinical changes of the seizure indicate involvement of
both hemispheres. The ictal encephalographic pattern is
initially bilateral. It is accepted that there are
patients in whom it is not possible to determine whether
the epilepsy is partial or generalised and these are placed
in a separate section, no.3 in Table 1:1. These include
patients in whom both focal and generalised seizures do
indeed appear to occur together and those in whom the EEG
and clinical features do not permit classification.
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2. Idiopathic and Symptomatic Epilepsies
The partial and generalised epilepsies are further
subdivided into idiopathic and symptomatic forms. It is
rightly proposed that the terms primary and secondary
should not be used as these cause confusion, primary and
secondary generalised being more correctly a description of
seizure type. The authors admit that this distinction can
give rise to difficulties and that in many cases there
appears to be an interaction of causative factors such as
an hereditary disposition, structural brain disease or
acute exogenous factors.
3. Epileptic Syndromes of Childhood and Adolescence
An important aspect of the international classification is
the proposal of a number of specific epileptic syndromes.
It is striking that all of these are confined to childhood
or adolescence and indeed the classification places much
emphasis on age related onset. The syndromes are shown in
Table 1:2 where they have been arranged in chronological
order of maximum age of onset. Although there is some
overlap they may be conveniently divided into four main
groups: neonatal seizures, seizures occurring in infancy
and childhood, childhood seizures and finally those
occurring in adolescence (Roger et al, 1985). Neonatal
seizures constitute a specialised group and will not be
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TABLE 1:2 EPILEPTIC SYNDROMES OF CHILDHOOD AND ADOLESCENCE

















Spike Waves during Slow Wave
SI eep
Childhood Abscence Epilepsy
Benign Childhood Epilepsy with
Centro-temporal Spikes
D) CHILDHOOD AND ADOLESCENCE
Juvenile Abscence Epilepsy
Juvenile Myoclonic Epilepsy
Epilepsy with Grand Mai
on Wakening





























* From Roger et al, 1985.
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considered in detail here. Some of the syndromes are
extremely rare, such as epilepsy with continuous spikes and
waves during slow sleep (Tassinari et al, 1985) and
acquired epileptic aphasia (Beaumanoir, 1985(a)). Others,
particularly the syndrome of epilepsy with grand mal
seizures on awakening (Wolf, 1985) contain a very broad
group of patients and the nosological position remains
unclear. Five of the syndromes are different forms of
myoclonic epilepsy, yet according to Gastaut et al (1975),
these account for no more than 47. of cases in children
(after exclusion of the Lennox-Gastaut Syndrome) and a
similar proportion in adults.
Amongst the remaining epileptic syndromes there are four
that are of particular importance and the important
clinical features will be briefly presented here. West
Syndrome, consists of the triad of infantile spasms,
psychomotor retardation and the characteristic EEG finding
of hypsarrthmia (Gibbs & Gibbs, 1952). In the idiopathic
form, which occurs in one third of cases, there is normal
psychomotor development up to the time of onset of seizures
(Bellman, 1983). In the remaining cases it arises from a
wide variety of central nervous system disorders including
pre and perinatal damage, neurocutaneous syndromes
(especially tuberose sclerosis), cerebral malformations,
metabolic disorders and cerebral infections (Jeavons 19B6).
Mental retardation always occurs and is usually severe.
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The term "petit mal" was introduced by Esquirol in 1815 to
include all nonconvulsive epileptic seizures and was used
in this manner by other 19th Century authors such as Bowers
and Reynolds. The first description of what is now called
childhood absence epilepsy, was given by Tissot.
"In the intervals between major attacks, the
young female patient had frequently had very
short minor attacks which were recognised only by
an instaneous loss on consciousness which stopped
the patient's speech, accompanied by a very
slight movement in the eyes. Often, on recovery,
she completed the sentence which was interrupted;
on other occasions she had totally forgotten it".
(Tissot, 1770; quoted by Loiseau, 1985)
By the end of the Nineteenth Century petit mal was
recognised as a specific form of epilepsy in the German
literature and the term Friedman's disease was introduced.
The most striking feature of the disorder, characterised by
the large number of attacks which occurred, led to the use
of the term "pynknolepsy" derived from the Greek "pyknos"
meaning crowded or frequent (Sauer, 1916). In 1937 Gibbs,
Gibbs and Lennox described the three per second spike and
wave abnormality on the EEG that we now recognise as an
integral part of the syndrome.
Although this was a major advance in our understanding it
was subsequently proposed that the term "petit mal" should
be applied to all cases in which this abnormality was seen,
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regardless of the clinical picture. It became apparent that
other seizure types, particularly myoclonic and atonic
seizures, could occur as well as absence attacks and the
term "petit mal triad" was introduced (Lennox, 1945).
Matters were complicated -further when it was shown that
slow or atypical spike and wave could be associated with a
type o-f epilepsy that had a worse prognosis and a high
instance o-f associated neurological handicap, so called
petit mal variant (Lennox & Davies, 1950).
The clinical -features of petit mal variant were more fully
described by Gastaut and colleauges and is now widely known
as Lennox-Gastaut syndrome (Gastaut, 1982). The most
important feature of the syndrome appears to be the seizure
types. These take the form of tonic seizures, atypical
abscences and myoclonic or atonic attacks (Beaumanoir,
1985(b)). The seizures occur many times a day, falls and
injuries are particularly common and status epilepticus
occurs in as many as two thirds of patients. One third of
cases occur in otherwise healthy children and the remaining
have mental retardation or neurological deficits arising
from diverse aetiologies. In addition to showing the
characteristic slow spike and wave the background rhythms
are also slowed. The condition is usually resistant to
treatment with currently available drugs.
29
In comparitively recent years a number o-f epileptic
syndromes collectively known as the "benign partial
epilepsies o-f childhood" have been identi-fied. These are
characterised by striking -focal EEG abnormalities in the
absence of strucutural brain disease, a strong familial
tendency and a good prognosis. Benign partial epilepsy with
centro-temporal spikes (Rolandic Epilepsy) appears to be
the commonest and has received most attention (Lerman &
Kivity, 1986).
As in Lennox-Gastaut syndrome the EEG features were defined
before the characteristic clinical presentation was
identified. Gibbs & Gibbs (1959-1960) identified 739
patients who had mid-temporal spikes on their EEG. In
contrast to those with anterior temporal spikes, who tended
to have psycho-motor seizures and a poorer prognosis, it
was found that the EEG abnomalities in these patients
rarely persisted beyond the age of 15 years. A number of
studies have subsequently shown that mid-temporal spiking
on the EEG can occur in apparently normal subjects with no
evidence of clinical seizure disorders (Smith & Kellaway,
1964; Eeg-Olofsson et al, 1971; Cavazutti et al, 1980;
Lerham and Kivity, 1981).
The initial clinical description of the disorder has been
attributed to Nayra & Beaussart (1958). Important series
have subsequently been published by Lombroso (1967) and
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Lerhman & Kivity (1975). Three-quarters of cases occur
between the ages of 5 and 10 years; it is most unusual for
the onset to occur be-fore the age of 3 or a-fter the age o-f
15. The seizures often take the form of unilateral
parasthesiae around the mouth and twitching of the face,
lips and tongue. These attacks occur in complete clarity of
consciousness and are accompanied by speech arrest and
drooling of saliva. The seizures may become secondarily
generalised, especially during sleep and many cases may be
initially diagnosed as noctural grand mal epilepsy unless
the characteristic EEG features are identified. Although
the great majority of patients appear to have no associated
neurological abnormality this does not exclude the
diagnosis. Blom et al (1972) described 3 patients with
rolandic epilepsy who had a hemiparesis. Three patients in
the series of Lerhman and Kivity (1975) had cerebral palsy.
In as many as 40% of cases a family history of a seizure
disorder is obtained (Lerhman, 1985).
Epidemiological surveys of childhood epilepsies which have
used EEG criteria in classifying the seizure types have
suggested that rolandic epilepsy is not uncommon. Cavazutti
(1980) in a retrospective survey identified 178 children
between the ages of 5 and 14 who had experienced two or
more afebrile seizures. Twenty-four per cent had rolandic
epilepsy and 42% suffered other forms of partial epilepsy.
Heijbel et al (1975) identified 70 new cases of newly
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diagnosed seizure disorders in children between the ages of
1 and 15. Rolandic epilepsy was diagnosed on the basis of
EEB features alone. In 16% focal discharges occurred in
the rolandic area and an identical percentage had other
forms of partial epilepsy.
Other forms of benign partial epilepsy of childhood have
been proposed. Gastaut (19S5) has described 63 cases of
"benign epilepsy of childhood with occipital paroxysms".
The age of onset ranged from between 15 months to 17 years
of age. The great majority did not have evidence of
structural brain disease and a family history of epilepsy
was available in as many as one third of cases. Visual
ictal symptoms consisted of either formed or nonformed
halucinations and nearly one half had other seizure types.
The striking diagnostic feature was prominent occipital
spiking on the EEG that was very responsive to eye opening.
According to Gastaut a significant proportion of patients
develop hemicrania, nausea and vomiting whilst others
develop complex partial seizures. Complete seizure control
was achieved in 60% of cases. Benign partial epilepsy with
affective symptoms (Dalla Bernardina et al, 1985) and with
extreme somato-sensory evoked potentials (Tassinari & De
Marco, 1985) have been described. The term has been
expanded by Dalla Bernardina et al (1985) to include all
partial epilepsies occurring in childhood in which there is
no evidence of structural brain disease.
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D. THE TREATMENT DF EPILEPSY
1. Historical Literature
The remedies that have been used for the treatment of
epilepsy throughout the ages are legion. Each new theory
as to the nature or causes of epilepsy has led to novel
therapeutic endeavours. Temkin (1971), in his authorative
review of the historical literature, gives an extensive
account of the different treatments that have been used.
Reynolds (1861), writing before the introduction of
bromides, said this of the treatment of epilepsy.
"Perhaps no disease has been treated with
more perfect empiricism on the one hand, or
more rigid rationalism on the other, than has
epilepsy. Unfortunately, both methods have
often completely failed; the former as it
must do in a proportion of cases; the latter
in still larger numbers, because the theories
upon which it has rested have often been
abundantly wrong"
(Reynolds, 1861)
Although many of the treatments that have been used were
based on superstition, myth or theories that would now
strike us as bizarre, they are of importance because they
reflect the changing understanding of the nature of
epi1epsy.
Many of the treatments for epilepsy, which continued to be
used even until the middle of the Nineteenth Century, can
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be traced back to the ancient theories o-f Hippocrates and
Galen. As idiopathic epilepsy was caused by a collection o-f
moist phlegmatic humours within the ventricles of the
brain, treatments were directed at relieving this
obstruction. It was important that the correct -food should
be eaten; dry bread and herbs which were acrid and
cleansing were prescribed, whilst moist substances such as
cucumber and melon were -forbidden. Cauterization of the
scalp was performed prophylacticaly on children in the
Middle Ages to prevent the development of epilepsy.
Similarly purges, blood letting or application of leaches
to the scalp were all used to avoid the accumulation of
humours.
Epilepsy arising from other organs, so called sympathetic
epilepsy, needed different remedies. If a seizure started
in a limb then a ligature should be placed upon it or some
strong medicine such as mustard applied. Despite the
teachings of Hughlings Jackson, Bowers also advocated this
form of treatment. An extension of this concept led to
barberous practices. Following the reflex theories of Hall
and Brown Sequard, amputation of the limb, castration or
even tracheostomy to relieve respiratory obstruction was
carried out.
The use of drugs have always played a central part
in the treatment of epilepsy. According to Temkin the use
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of herbs, drugs or specifics were often particularly
associated with superstition and the occult. He quotes
the Greek physician Dioscurides who listed forty five
substances for the treatment of epilepsy. At least
thirteen of these had superstitious origins such as hare's
rennet, amulet of stones found in the stomach of swallows,
storks dung and other such remedies. Reynolds (1861) quotes
the following example of a specific remedy:
"Take the powder of Osmond, and the root
of peony and the powder of Moztegan, and
drinke all these with stale ale and let
them say their prayers; and as soon as
the Party falleth downe and give the sicke
to drinke with good ale that is stale,
and by God's grace he shall never have
the falling evil any more: proved."
(Leuens P. 1632)
With the enlightenment such remedies fell into disuse
although Reynolds himself was impressed by results of
mistletoe in the treatment of epilepsy and recommended
a new trial. The texts of the Nineteenth Century contain
lists of drugs that had been tried in the treatment of
epilepsy, with varying claims of success (Shorvon, 1987).
As the superstitious remedies of an earlier age were
discarded, others of an equally dubious nature were
introduced. Drugs such as strychnine were overtly dangerous
whilst salts of silver were extremely toxic and caused an
unpleasant discolouration of the skin. Many of the drugs
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such as chloroform, opium, belladonna, cannabis, selenium
(marsh parsley) and cotyledon umbilicus (pennywort) were
sedatives, and this was thought to be their mode o-f action
in the treatment of epilepsy (Friedlander, 1986). It was in
this context that probably the single most important
advance in the treatment of epilepsy occurred.
2. The Introduction of Bromides
Bromides were included in the British Pharmacopia of the
first half of the Nineteen Century for the treatment of
splenomegaly. Their introduction for the treatment of
epilepsy has been attributed to a remark made by Sir
Charles Lowcock. At a meeting of the Royal Medical and
Chirurgical Society in 1857, Sieveking presented an
analysis of 52 cases of epilepsy. Lowcock, who was
president of the society commented in the discussion
(Sieveking, 1857) that dentition and onanism were frequent
causes of epilepsy. He went on to say that epilepsy
associated with the menstrual cycle was particularly
difficult to treat and that he had previously read of some
work by a German doctor who had claimed that bromide of
potassium produced temporary impotence and loss of
virility. He (Dr. Lowcock) had therefore tried the drug in
fifteen cases of epilepsy in women associated with hysteria
and found that it had cured fourteen of them.
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Despite the rather dubious theoretical basis potassium o-f
bromide became widely used in the treatment o-f epilepsy.
The identity o-f the German doctor has never been
established and Lowcock has been credited with their
introduction although his contribution was small (Joynt,
1974). Four years later Wilks (1861) stated that he used
the drug in all new cases o-f epilepsy and that it was
"singularly efficacious". Gowers in 1881 wrote this o-f it:
"The indications of the prognosis have been
materially changed by the introduction of
Bromides. Not only do they arrest fits far
more frequently than any other remedy, but
they are effective in cases which, according
to experience previous to the introduction
of these remedies, would have been regarded
as most unpromising."
(Gowers, 1881)
According to Gordon Holmes, by the end of the Nineteenth
Century, 2.5 tons of the drug were used every year by the
National Hopsital, Queens Square (quoted by Temkin, 1971
page 299).
More recent testament as to their efficacy is available.
Pollock (1938) claimed that 61 out of 85 cases (72'/.) had a
remission of one year or more after treatment with sodium
bromide. Of particular interest is the paper by Arieff
(1951) in which he summarised his experience over a twelve
year period. It was his practice to start treatment
initially either with bromide or phenobarbitone given
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alone, and if these failed, phenytoin was substituted or
added. Out of 118 cases who were given sodium bromide
seizures were completely controlled in B3% for periods
ranging from six months to two years or longer. Similar
remissions <B0"/.> were obtained in 91 cases given
phenobarbitone. The use of phenytoin in those cases which
failed on treatment did little to improve the prognosis.
Livingston (1958) claimed the drugs were particuarly
efficacious in childhood epilepsy asociated with organic
brain disease, and that they were safe to use and free of
serious side effects if serum levels were monitored
(Livingston & Pearson, 1953).
3. Modern Anticonvulsant Drugs
It is probably correct to look upon bromides as the fore
runner of modern anticonvulsant drugs. In the last century
a whole series of drugs have been introduced which may be
divided into eight main groups as shown in table 1:3. Some
of them, such as phenturide, the different hydantoin
derivatives, troxidone and sulthiame are not now widely
used. It is beyond the scope of this review to consider all
of these drugs in detail but there are a number of
important principles that can be shown by briefly examining
the development of the more important compounds.
Barbituric acid was first synthesized in 1863 and
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TABLE 1:3 CONTEMPARY ANTICONVULSANT DRUGS, WITH DATE




























phenobarbitone, a stable derivative, was developed in 1912.
An extensive German literature confirmed its sedative
actions and paradoxically it was for this very reason that
it was introduced for the treatment of epilepsy (Hauptmann,
1912). During the first three decades of the Twentieth
Century barbiturates replaced bromides in the treatment of
epilepsy, largely because they were less toxic. The
discovery of the anticonvulsant properties of phenytoin by
Putman and Merritt was an important advance for two
reasons. Firstly, the drug was tested in an experimental
animal model prior to being given to human subjects.
Secondly, on the basis of animal experimentation and
clinical usage it became apparent that the sedative and
anticonvulsant properties of the drug could be separated
(lierritt et al , 1938; Merritt & Putnam, 1938).
According to Friedlander (1986), neither of these concepts
was new. The ability of absinthe, picrotoxin and metrazole
to cause seizures had already been established and used for
evaluating anticonvulsant drugs. Furthermore, non-sedating
treatments for epilepsy were available such as borotart-
rate, vital dyes and ketogenic diet. Merritt and Putman,
however, have been credited with both these discoveries
(Rowland, 1982) and the use of animal models for the
testing and development of new drugs has subsequently
become widespread.
40
Trimeth^dione was found to be effective in controlling
seizures not only in electro-shock models of epilepsy (as
was the case in phenytoin) but also in metrazole induced
seizures and the first trial was undertaken by Perlstein
(1945). Unlike bromides and phenytoin the drug was found to
be particularly effective in the treatment of petit mal.
Phensuximide (Zimmermann, 1952) and ethosuximide
(Zimmermann, 1958) were subsequently introduced and the
latter has remained an established drug for the treatment
of petit mal, largely because it was less toxic than the
previous therapies that were used in the treatment of
absence seizures.
The introduction of benzodiazepines for the treatment of
epilepsy bears a marked resemblance to the discovery of
phenobarbitone. The drugs were introduced during the early
1960s and used for their sedative and anxiolytic effects
and was subsequently found to have anticonvulsant
properties (Brock and Dyken, 1963). Diazepam was shown to
be effective in controlling status epilepticus in animals
and was given intravenously to humans by Naquet et al
(1965). The more modern 1-5 benzodiazepines such as
clobazam are said to retain anticonvulsant properties but
to be less sedative (Robertson, 1986).
Of more importance has been the development of carbamaz-
epine and sodium valproate. The first of these was derived
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from an antihistamine from which two important
compounds were obtained, imiprimine and carbamazepine. On
the basis of its chemical structure it was predicted to
have anticonvulsant properties and the first trials were
undertaken in the early 1960s (Lorge, 1963). Sodium
valproate (diproprionylacetic acid) was synthesised in 1B82
and used as an organic solvent for eighty years until its
anticonvulsant properties were discovered accidentally in
mice in 1963 and clinical trials were undertaken a year
later (Carraz et al, 1964).
4. Unsatisfactory Aspects of the Drug Treatment of
Epi1epsy
There is now a wealth of clinical and experimental
evidence, extending over a period of more than a century,
to show that the drugs currently available for treating
epilepsy are highly effective in suppressing seizures. It
might have been hoped that as the use of these drugs became
widespread a rational approach to the treatment of epilepsy
would have developed. Although many advances have been
made, particularly in the appreciation of the importance of
serum anticonvulsant level monitoring (Reynolds, 1980),
many unsatisfactory aspects of the drug treatment of
epilepsy remain. Reynolds (197B) has identified three areas
of particular difficulty which will be considered further
here.
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a. Choice of Drug
Amongst the drugs listed in table 1:3 there are four that
would now be considered first line treatments for epilepsy.
Although the use of phenobarbitone is probably declining it
remains popular, particularly in France and the United
States, and in view of its cheapness remains an important
drug for developing countries. In Britain phenytoin has
traditionally been the drug of choice, whilst Scandanavian
countries have favoured carbamazepine. Despite recent
worries concerning the hepatotoxicity and possible
teratogenic effects of sodium valproate it is likely to
remain a major drug for the treatment of epilepsy
(Dreifuss, 19S3).
There are few specific indications in determining the drug
of choice in epilepsy. Ethosuximide and sodium valproate
are the drugs of choice for the treatment of childhood
abscence seizures (Loiseau, 1984; Fromm & Crumrine, 1986),
the other major anticonvulsants being less effective in
patients with this seizure type. Clonazepam has been found
to be useful in controlling post anoxic myoclonus
(Chadwick et al. 1984). For the great majority of patients
with either partial or generalised epilepsies, either
idiopathic or symptomatic, there is remarkably little
reliable evidence as to the comparitive efficacy or
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toxicity of the major anti epi 1 ept i c drugs. The most
important reason -for this has probably been deficiencies in
the design and analysis of anticonvulsant trials.
i. The Design of Anticonvulsant Trials
Coatsworth (1971) has surveyed the published literature,
basing his analysis on 120 anticonvulsant trials. Of these
only two were found to have used a double blind random
allocation of drugs and appropriate statistical assessment.
Amongst the conclusions he stated that ... "sufficient
studies are not found in the literature to confidently test
the relationship between the use of a drug and its
influence on a particular seizure type".
Eleven years later Gram et al (1982) were able to review
fifty one randomised double blind studies in epilepsy.
These authors, unfortunately, reached a similar conclusion.
The deficiencies in study design identified included
failure to employ a washout period, marked heterogenecity
amongst patient groups and short duration of follow up.
Evaluation was further complicated because the majority of
studies were "add on" with concurrent treatments being
changed during the course of the trial. This method is
also likely to lead to unpredictable drug interactions and
also promotes unnecessary polytherapy. In a review of one
hundred and fifty five trials of phenytoin and
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carbamazepine, Shorvon et al (1981) emphasised the
difficulty in making appropriate comparisons between drugs
on the basis of a reduction in seizure frequency measured
over short periods of time.
ii. Trials of Monotherapy in Newly Diagnosed Epilepsy
Many of the difficulties arising from the design of
anticonvulsant trials discussed above can be overcome by
comparing the drugs, given as monotherapy, in newly
diagnosed previously untreated epilepsy. The use of
monotherapy allows a comparison of efficacy to be made
between individual compounds and avoids the difficulties
that arise from unpredictable drug interactions. Following
randomisation patients are followed up in parallel with no
need to employ a cross over or wash out period. Perhaps
most importantly because the drugs are given at the onset
of treatment it is possible to compare their action during
this crucial period of the natural history of epilepsy when
the majority of remissions occur. The need to assess
outcome in terms of arbitrary reductions in seizure
frequency is also avoided.
Following the initial report by Reynolds et al (1976) a
number of trials of monotherapy in newly diagnosed epilepsy
have been undertaken. They are summarised in Table 1:4. The
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TABLE 1:4 TRIALS OF MONOTHERAPY IN NEWLY DIAGNOSED EPILEPSY.
Author Drugs No o-f Follow-up, Seizure
Patients mean(range) Control
months ('/.)
Reynolds et al, 1976
Shorvon et al, 1978
Shorvon & Reynolds, 1982 DPH/CBZ 94 24(13-33) 50
Feely et al, 1979 DPH 13 NS 69
Stranjord &
Johannessen, 1980 CBZ 24 >7 83
Feely et al, 1982 STH 10 14(7-22) 80
Turnbul1 et al, 1982 + VPA 43 >12 58
DPH 45 58
Ramsay et al, 1983 + DPH 35 NS(6—24) 66
CBZ 35 63
Callaghan et al,1985 + DPH 58 NS<14-24) 67
CBZ 59 37
VPA 64 53




DPH = phenytoin. CBZ = carbamazepine. STH = sulthiame.
VPA = sodium valproate. PB= phenobarbitone. PRMD = primidone.
NS = not stated.
+ Randomised Studies
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earlier studies were either nonrandomised or based on small
numbers of patients. Outcome has usually been analysed by
comparing the percentage of patients remaining completely
seizure -free after starting treatment. Those with more
prolonged follow up (Shorvon & Reynolds 1982; Mattson et
al, 1985) have, in general, shown higher relapse rates on
treatment.
Four studies using a random allocation of the initial drug
in adult epilepsy have now been published. Turnbull et al
(1982) compared sodium valproate and phenytoin in 88
previously untreated newly diagnosed epileptic patients who
were followed for at least twelve months from the time of
randomisation. Treatment failure was defined as the
occurrence of unacceptable side effects or continuing
seizures despite a maximum tolerated dose. Both drugs were
equally effective in controlling tonic clonic seizures.
Although the percentage of patients with partial seizures
who remained seizure free was equal for both phenytoin and
sodium valproate there were twice as many treatment
failures in patients taking the latter drug. Ramsay et al
(1983) in a double blind randomized study compared
phenytoin and carbamazapine as initial therapy in 70 adult
patients. Thirty six percent of patients on carbamazapine
and 40% of those taking phenytoin were lost to follow up
and the remaining patients were only followed for 6 months.
Both drugs were equally effective.
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Callaghan et al (19B5) have reported a trial in which 181
adults were randomised to treatment with phenytoin,
carbamazepine or sodium valproate. Twenty one patients
■failed on treatment which was defined as failure to obtain
at least a 50X reduction in seizure frequency despite
anticonvulsant levels in the upper optimum range. After a
follow up of 24 months polytherapy was needed in only 6
patients. The authors concluded that all three drugs were
highly effective in controlling generalised seizures but
less so in those who had partial seizures. It appears,
however, that the percentage of patients with complete
seizure control was considerably higher for those receiving
phenytoin (see table 1:4), and this was particularly so in
those with generalised seizures. This observation is at
variance with other studies and was not commented upon by
the authors.
The most extensive investigation to be published has been
the Veterans Administration multi-centre trial (Mattson et
al, 1985). In this study primidone, phenobarbitone,
phenytoin and carbamazapine were compared in 421 adults
with epilepsy who were followed for at least two years or
until the time of treatment failure. It appears that
nearly one half of the patients did in fact receive some
form of treatment before randomization and 3251 were lost to
follow up. Overall treatment success was highest with
phenytoin and carbamazapine, intermediate for
4B
phenobarbitone and lowest with primidone. All the patients
had serum anticonvulsant levels in the therapeutic range,
regardless of seizure control. In those with continuing
seizures, the dosage was increased until toxicity occurred.
Amongst the 223 treatment failures, only 11 were due to
seizures alone, the rest arising from drug toxicity with or
without uncontrolled seizures. The main conclusions to
arise from the study appear to be more a reflection of
acute side effects arising from the drugs, rather than
their comparative efficacy. Some information, however, was
given regarding seizure control. There was no difference
between the drugs in patients with tonic clonic seizures.
In those patients with partial seizures 43% remained
completely seizure free amongst those who were taking
carbamazapine. The outcome was significantly better than
those randomised to primidone, phenobarbitone or phenytoin
where the corresponding results were 15%, 16% and 26%
respectively.
It is apparent that there are methodological difficulties
in each of these studies. These include small numbers of
patients, inadequate follow up, inappropriate statistical
assessment and the occurrence of toxicity as a major cause
of drug failure. The results from these initial studies do
suggest that there may be no difference between the major
anticonvulsants in their ability to control tonic clonic
seizures. It is possible, however, that patients with
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partial seizures do not respond in the same way with
carbamazapine being more effective than sodium valproate.
This is an important observation since it is this group of
patients in whom seizures are most difficult to control.
The design and undertaking of these trials call for a
considerable dedication of time and resources. Unlike cross
over studies undertaken over short periods of time in
chronic epileptic patients recruitment must continue over a
number of years and prolonged follow up is needed. The
results from these initial trials, despite the methodolog-
cal problems outlined above, are for the first time giving
some indication as to the comparative efficacy of the major
anticonvulsant drugs.
b. Polytherapy
The number of different treatments that have been used in
epilepsy is enormous. In the historical literature,
considered in the previous section, it was shown that many
of these were based on erroneous theories as to the causes
of epilepsy and others were either highly toxic or of
dubious efficacy. Following the introduction of bromides
large number of drugs have been shown to be effective in
treating epilepsy. These have been discovered either by
serendipidy, the screening of new compounds in animal
models of epilepsy, or predictions of efficacy made on the
basis of chemical struture. The discovery of novel
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anticonvulsant drugs has accelerated in recent years as
compounds are developed that act directly on inhibitory and
cumulative increase over recent years in new antiepi1eptic
drugs is shown in Figure 1:1. This graph is by no means
exhaustive and does not include the many compounds that
have been tested but failed to gain widespread usage.
In the face of such lage numbers of anticonvulsant drugs it
is not supprising that polytherapy continues to be
widespread. In a study of the drugs taken by 11,720
epileptic patients in four European countries it was found
that the average number of drugs per patient was 3.2, of
which 84% were anticonvulsants. Only 4% were taking a
single drug, 30% were taking two drugs and the remaining
two-thirds were receiving three or more medications (Guelen
et al, 1975). One patient was found to be taking twelve
different types of drugs! The majority of the patients in
this study were treated in Scandinavia but there is little
reason to suppose that treatment policies are any different
in other westernised nations.
The disadvantages of polytherapy have now become more
widely appreciated (Reynolds & Shorvon, 1981). There is
remarkably little evidence that combinations of drugs are
excitatory neurotransmitters (Meldrum, 1983) The
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FIGURE 1:1 CUMMULATIVE INCREASE IN ANTIEPILEPTIC DRUGS
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Key to Drugs in Figure 1:1 and Date of First Report
1. Bromide 1857 13 Primi done 1952
2. Phenobarbitone 1912 14 Methsuximide 1952
3 Methobarbitone 1932 15 Ethotoin 1956
4. Phenytoin 1937 16 Aminogluteth-
5. Trimethadione 1945 emi de 1958
6. Mephenytoin 1945 17 Ethosuximide 1958
7. Paramethadione 1946 IB Diazepam 1963
8. Phethenylate 1947 19 Carbamazepine 1963
9 Phenacimide 194B 20 Valproic Acid 1964
10 Methabarbitone 1948 21 CIonazepam 1969
11 Benzchlorprop- 1951 22 Chlorazepate
ami de Dipotassiurn 1974
12 Phensuximide 1951
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any more effective in controlling seizures than a single
drug given in optimum dosage. This is particularly so when
patients are on polytherapy and all the anticonvulsant
levels are below the therapeutic range. The use of
polytherapy, often in assosciation with complicated
dosaging regimes, can increase the probability of poor
compliance (Terrence & Alberts, 197B). Unpredictable drug
interactions can occur and precipitate acute anticonvulsant
toxicity (Perrucha, 19B2). Side effects may be additive,
particularly when sedating drugs such as barbiturates and
benzodiazepines are used together, leading to drowsiness
and behaviour disorders (Theodore & Porter, 1983). Perhaps
the most striking evidence against polytherapy is the
improvement that can occur in a substantial number of
patients following drug reduction.
Shorvon and Reynolds (1979) have reported a two year
prospective study in 40 adult outpatients with chronic
epilepsy. The mean number of drugs was reduced from 2.1 to
monotherapy in 29 patients. Amongst these 29, seizure
control improved in 16 (55%), was unchanged in B (2B%) and
deteriorated in only 5 (17%). These findings have now been
confirmed by a number of other investigators (Table 1:5).
In the study by Albright & Bruni (1985) few clinical
details concerning the outcome were given. In the
remaining studies all have shown that between a third and
three-quarters of patients experienced an improvement in
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TABLE 1:5 STUDIES OF POLYTHERAPY REDUCTION. THE PERCENTAGE
OF PATIENTS WITH IMPROVED SEIZURE CONTROL FOLLOWING DRUG
REDUCTION.
Author Number Drugs Follow up Improved
o-f Reduced (months) Control
Patients NC/.)








Callaghan et al, 1984 35
Lesser et al, 1984 28
Albright &
Bruni, 1985 90









seizure control after reduction of polytherapy for periods
ranging from 3 to 16 months.
In a proportion of patients it was difficult to reduce
polytherapy because of an exacerbation of seizures that
occurred during the period of drug withdrawal. This has
been reported to be a particular problem when barbiturates
or benzodiazepines are discontinued (Schobben 1979).
Shorvon and Reynolds (1979) found that it was impossible to
reduce polytherapy in 11 out of 40 patients (28'/.) and
similar figures were reported by Lesser et al (19B4).
Schmidt (1983) however, was able to reduce polytherapy
successfully in all his patients and attributed this to
slow anti-convulsant withdrawal. Although few details were
given it appears that most patients' drugs were reduced
over a period of 2 ot 20 weeks, which is in fact in broad
agreement with the policy of other authors. Similarly
Theodore & Porter (1983) did not experience this problem in
any of their patients, although in this study three-
quarters of cases were admitted to hospital and drugs were
reduced only to a mean of 1.7 per patient.
The benefits of drug reduction are not restricted to
improvements in seizure control. Shorvon & Reynolds (1979)
reported improvement in mental functions, particularly
alertness, mood and sociability in 53% of patients
following reduction of polytherapy. Theodore & Porter
55
(1983) only withdraw sedating drugs, viz. bromides,
barbiturates and benzodiazepines. They reported evidence
o-f reduced toxicity, particularly ataxia and nystagmus.
Patients also appeared more alert and there was a lower
incidence o-f behaviour disorders. Thompson and Trimble
(1982) carried out a battery of neuropsychological
evaluations in 20 patients with chronic epilepsy in whom
drugs were reduced from a mean of 2.8 to 1.6 per patient.
Marked improvement in mood and cognitive function occurred,
particularly in those tests which appeared to measure speed
of mental processing.
c. Chronic Toxicity
Patients with epilepsy are particularly prone to the
chronic toxic effects of medication. The drugs affect a
wide variety of metabolic pathways and cause both
idiosyncratic and dose related side effects (Reynolds,
1975). In patients who have intractable seizure disorders,
treatment is given in high doses, often as a combination of
drugs. There can be no other group of patients who are
subjected to such a large number of potentially toxic drugs
throughout the period of a lifetime. Because epilepsy is
commonest in children, three-quarters of cases occurring
before the age of 20 years, particularly worries exist as
to the possible adverse effects on growth and development.
56
The ability o-f phenytoin to cause chronic changes in
connective tissue, particularly gum hypertrophe, was
recognised shortly after its introduction, (Kimball, 1939).
It is curious, however, that many of the chronic side
effects of barbiturates and hydantoins were not recognised
until many decades after their introduction. Reynolds
(1975) has reviewed the chronic toxicity of antiepi1eptic
drugs, listing their diverse side effects under nine main
headings. Figure 1:2. shows the delays that have occurred
in the recognition of such important toxic effects as
folate deficiency, metabolic bone disease and encephal¬
opathy. It is likely that further chronic side effects
will be discovered, particularly following the
prolonged usage of newer drugs such as sodium valporate
and carbamazepine.
Phenytoin has a number of neurotoxic effects.
Cerebellar dysfunction was reported shortly after its
introduction and has been reported to be irreversible
(Reynolds, 1975; Dam, 1982). It is now well recognised
that phenytoin can cause dyskinaesias and peripheral
neuropathy (Trimble & Reynolds, 1984). Glaser (1972) has
described a chronic or subacute encephalopathy where signs
of disturbed mental functioning may be associated with
worsening seizure control and focal neurological signs
which are reversible when the drug is withdrawn. The
syndrome is associate with marked slowing of the EEG
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FIGURE1:2TIMTAK NOREC G ISECHRONICT XEFFECTSFBARBITURATEND HYDANTOINANTICONVULSANTS(-fromReynolds,1975)
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(Roseman, 1961) and can occur with anticonvulsant levels
within the accepted therapeutic range.
An area of particular importance is the effects of
anticonvulsants on cognitive function. Lennox (1942)
listed drugs as a possible cause of mental decay, along
with other factors such as heredity, brain injury
antedating the onset of seizures, psychological handicaps
and the seizures themselves. Trimble and Reynolds (1976)
subsequently reviewed the published literature on
psychological function in relation to anticonvulsant
drugs and concluded that many, but not all, of the studies
had shown that medication had an adverse effect on mental
processes. Often the effects were subtle and appropriate
psychometric assessments have been developed to detect
them. When given to normal volunteers for periods of up to
one month, phenytoin, carbamazepine, sodium valporate and
clonazepam have all been shown to impair cognitive
function in a dose dependent manner with anticonvulsant
levels within the optimum range (Thompson & Trimble,
1982). It also appears that there may be important
differences between the drugs (Dodrill and Troupin, 1977;
Reynolds, 1983; Andrewes et al, 1986). In a recent long
term prospective evaluation of psychometric functioning in
children with epilepsy, Bourgeois et al (1983) concluded
that the number of drugs to which the patient had
59
experienced toxic reactions was the best predictor o-f
outcome in those patients in whom intelligence quotient
deteriorated.
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E. THE PROGNOSIS OF EPILEPSY
The prognosis o-f patients with epilepsy can be considered
under three broad headings. Firstly, the prognosis of
patients who present with a single seizure. This group
give rise to a common clinical dilemma and because they
are often untreated are of particular interest to the
subject of this thesis. Secondly the prognosis of patients
in whom the illness has become established. This is, by
definition, the outcome in those patients who have
experienced two or more attacks and relates largely to the
long term response to treatment. Finally, the prognosis
following anticonvulsant withdrawal. This important aspect
has received only scant attention until comparitively
recent years and will be reviewed in the final section.
The literature considered here deals primarily with
seizure relapse and seizure control rather than the
cognitive, psychological and social difficulties that
can complicate the course of epilepsy.
1. PROGNOSIS FOLLOWING A FIRST SEIZURE
a. Historical Literature
It has long been appreciated that following the first
seizure the tendency towards further attacks will remain.
Areteus (quote by Temkin, 1971, page 42) stated that the
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isolated paroxym was an acute affliction. More often than
not, however, it would repeat itself and the disease take
on a chronic form; consequently after the cessation of the
first attack, the physician would still suspect its latent
presence within the body. A similar sentiment was expressed
by Gowers. On the opening page of "Epilepsy and Other
Chronic Convulsive Diseases" he states:
"When one attack has occurred, whether in apparent
consequence of an immediate excitement or not
others usually follow without any traceable cause...
If an individual suddenly has an epileptic con¬
vulsion for the first time, for which no cause
can be discovered, central or peripheral, it is
probably the commencement of epilepsy".
(Gowers, 1881)
He went on to say that there was no means of discovering,
on any considerable scale, the proportion of patients who
might experience only one seizure. He did, however, give an
analysis of the intervals between the first and second
seizures in a series of 160 patients (Table 1:6). The
second seizure followed the first within a month in one
third of cases, within a year in a further third and
exceeded one year in the remaining one third. Occasional
cases were seen where the two seizures occurred decades
apart.
It is curious that since the time of Gowers' work, there
has been remarkably little study of this important aspect
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TABLE 1:6 INTERVALS BETWEEN THE FIRST AND SECOND SEIZURES
IN 160 CASES OF EPILEPSY (Gowers, 18B1)
Less than 1
1 week to 1
1 month to 3
3 months to
6 months to
1 year to 2
2 years to 3



















55 cases under one month.
52 cases more than a month
and less than a year.
53 cases more than a year
vi z,
6 years 3 cases
7 years 9 cases
8 years 1 case
10 years 3 cases
11 years 1 case
14 years 1 case
16 years 1 case
18 years 2 cases
20 years 1 case
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o-f the natural history of epilepsy until very recent years.
Williams (1975), in his lecture on "The Borderlands of
Epilepsy Revisited" considered the single seizure to be an
isolated event of little significance. Livingstone (1958)
reported in a review his experience with 200 children with
a single seizure but this work was apparently never fully
published.
□ur current understanding of the subject has been derived
from two main sources. Firstly from the epidemiology of
epilepsy. Although community surveys have rarely examined
the early prognosis of epilepsy in detail, a number of
them have attempted to identify from an unselected
population the proportion of patients who experience only
a single attack. Secondly a number of prognostic studies
have been undertaken in recent years examining the
probability of seizure recurrence in groups of patients
presenting with a single seizure either in the community
or to hospital outpatients or EEG departments.
b. Epidemiological Surveys
Only epidemiological surveys have, in addition to
identifying cases of epilepsy, included patients with only
a single seizure (Table 1:7). The methods of case
ascertainment in all of these have differed widely.
Matha.i, et al (1968) conducted a field survey amongst the
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Mathai et al, 196B
van den Berg &
Yerushalmy, 1969 +
Hauser & Kurland, 1975
Blom et al, 1978 *
Goodridge & Shorvon, 1983
Hirtz et al, 1984 +













+ Based on the -follow-up o-f a cohort of live births
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Chomorro people on the Marina Islands. Because of
communication difficulties, due to cultural and language
differences, only those who had experienced major seizures
were identified. Two of the surveys (Van den Berg &
Yerushfllmy, 1969; Hirtz et al, 19B4) were follow-up studies
of a cohort of live births up to the ages of 5 and 7
respectively. Although not strictly undertaken as
epidemiological surveys they have been included here as both
were based on identification of cases from an unselected
sample of the population. Prospective evaluation was used
and detailed documentation of clinical characteristics were
given, particularly in the latter study. The remaining
three studies have been retrospective analyses based on
general practioner records in South East England (Goodrige &
Shorvon, 1983) and a continuous register of cases in
Rochester, Minnesota (Mauser & Kurland, 1975) and Greater
Aarhus, Denmark (Juul-Jensen & Foldspang, 1983). Three
studies included patients who experienced seizures in
association with acute central nervous system disorders,
head injury or alcohol withdrawal (Blom et al, 1978; Hirtz
et al, 1984; Goodrige & Shorvon, 1983).
Despite these methodological differences there appears to
have been good agreement that in 60X to 807. of cases
identified from an unselected population, seizures are
likely to be recurrent. The higher recurrence rate reported
by three of the authors (Hauser & Kurland, 1975; Juul-Jensen
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& Foldspang, 1983; Goodridge & Shorvon, 1983) may be due to
the retrospective nature of the survey. Such studies may
miss milder cases and those with single seizures. Only in
the study by Hirtz et al (1984) were any details given
concerning the timing of the occurrence of the second
seizure or of the factors that were thought to be of
prognostic significance. These authors found that following
the first afebrile seizure the second followed within a six
months in 74%, by one year in 87% and by two years in 96%.
Children with neurodevelopmental abnormalities were not any
more likely to experience recurrent seizures. Curiously
those patients with an initial symptomatic seizure had a
lower recurrence rate, possibly because patients with
seizures arising as a cause of acute trauma, toxic
encephalopathy and electrolyte disturbances were included.
c. Follow up Studies of Patients presenting with a Single
Seizure
i. Seizure Recurrence
The results of the nine prognostic studies of patients
presenting following a first seizure are summarised in Table
1:8. The highest recurrence rate was reported by Johnson et
al (1972) who studied 77 enlisted navy personnel who were
admitted to hospital with the complaint of a "single
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TABLE 1:8. PROGNOSTIC STUDIES OF PATIENTS PRESENTING WITH A
SINGLE SEIZURE
Author Number of Follow-up Percent
Patients Mean(Range) Recurrence
months
Thomas, 1959 42 NS(42-102) 27
Johnson et al, 1972 77 36 64
Saunders & Marshall, 1975 33 26(10-48) 33
CI el and et al, 1981 70 57(36-120) 39
Hauser el al, 1982 244 12 16*
24 21
36 27
Todt et al, 1985 179 12 59
Cam-field et al , 1985 16B NS 52
Annegers et al, 1986 380 12 36 *
36 4B
60 56
Hopkins et al, 1988 + 100 12 39 *
24 49
36 52
+ Patients seen within one week o-f an initial seizure
* Actuarial estimates
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convulsion, seizure or unexplained loss of consciousness."
Although a recurrence was reported in 49 (64%) it appears
that in 19 o-f these the -final diagnosis was either a
psychiatric illness, syncope or some other disorder. As the
most important prognostic factors were an initial history
suggesting a seizure, post ictal confusion and epileptiform
abnormalities on the EEG, it appears that the development of
epilepsy was most strongly related to the initial event
indeed being a seizure. If those patients in whom the
diagnosis were in doubt were excluded the recurrence rate
fell to 39"/..
Four of the studies (Thomas, 1959; Saunders and Marshall,
1975; Clelland et al, 19B1; Hauser et al, 19B2) have all
reported that seizures recurred in around one third of
patients. In the largest of these Hauser et al (19B2),
studied 244 patients who were seen in a hospital clinic over
a four year period following a first ever "unprovoked"
seizure. Patients with a seizure related to systemic
metabolic dysfunction, acute neurological insult or alcohol
withdrawal were excluded. Patients with a past history of
such seizures and who subsequently had an apparently
unprovoked attack were, however, included. Four hundred and
thirty five patients were ineligible because they had
experienced two or more seizures at the time of first
diagnosis. The cumulative probability of seizure recurrence
was 16% at 12 months, 21% at 24 months and 27% by 36 months.
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The studies by Thomas (1959), Saunders & Marshall (1975) and
Cleland et al (1981) were based on patients attending EEG or
neurology outpatient departments and it is likely that a
similar form of patient selection occurred with patients who
experienced an early recurrence being excluded.
More recent studies have reported higher recurrence rates of
between 50% and 60'/.. Todt et al (1985) studied 179 children
who were seen in an EEG department within two weeks of a
first ever tonic clonic seizure. None of the patients was
treated. The reported recurrence rate of 59% may well have
been an underestimate as those patients who experienced a
recurrence after the first year of follow up were apparently
excluded.
Camfield et al (1985) reported that the recurrent rate in
168 children who were referred to an EEG department
following a single afebrile seizure was 52%. The study was
retrospective and no indication of the time for which
patients were followed from the time of the first seizure
was given. Although it was claimed that patients were likely
to come from an unselected population, 94% were in fact
referred by paediatricians and neurologists. It is likely
therefore that there was a considerable delay between the
first seizure and inclusion in the study as 141 patients had
experienced more than one attack before an EEG was
perf ormed.
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The study by Annegers et al (19B5) is of interest as it is
the only one that has been community based. The records
linkage system of the Mayo Clinic Mas used to
retrospectively identify 849 individuals as having
"potentially an initial seizure" whilst residents in
Rochester, Minnesota between 1935 and 1979. Four hundred and
twenty five patients who had experienced multiple attacks
were excluded from the analysis. Although the record system
apparently included all in-patients, out-patients, casualty
attendances and home visits the proportion which were
identified from either hospital or community sources was not
given. It is unfortunate that further details on case
selection were not provided as the age structure of the
population was unusual. Fifty-eight per cent were apparently
aged 55 or over at the time of the first seizure. A further
difficulty is that no mention was made of the methods used
to validate the diagnosis, which is likely to be of
importance in a retrospective study spanning a period of 50
years. Unlike other studies, however, appropriate actuarial
statistical methods were used.
Hopkins et al (1988) have recently reported a multicentre
study of 408 adults presenting to a neurology outpatients
departments with a single seizure. Patients with seizures
occurring in the context of acute precipitating factors such
as alcohol were included and 31 patients were treated
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following the first attack. The cumulative probability of
seizure recurrence by four years was 45% for males and 46%
for females. The total number of patients excluded because
they had epilepsy when first seen was not stated but 25
subjects had their second seizure after referral but before
attending the outpatients department. In those patients seen
within one week and eight weeks the recurrence rates were
52% and 22% respectively.
Most of the studies are in agreement that the majority of
recurrences occur within one year of the first seizure (see
Table 1:9). The lower figures reported by Cleland et al
(1981) and Hauser et al (1982) may be due to the fact that
many patients who experienced an early relapse were
excluded. Camfield et al (1985) and Johnson et al (1972)
reported that three-quarters of patients who went on to
develop epilepsy did so within one year and it appears that
late relapses were uncommon. Annegers et al (1986) found
that in 117 subjects who remained seizure free for at least
five years only 7 of them subsequently experienced a
recurrence.
ii. Prognostic Factors
There has been little systemic study of the prognostic
factors that are of importance in determining recurrence
rates following a first seizure. In the earlier studies
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TABLE 1:9. PROGNOSIS FOLLOWING A FIRST SEIZURE. THE
PERCENTAGE OF PATIENTS EXPERIENCING A RECURRENCE BY ONE
YEAR OF FOLLOW UP
Author Recurrence rate Total
by One Year of Recurrence
Follow-up C/.) Rate <"/.)
Johnson et al, 1972
Cleland et al, 1981
Hauser et al, 1982
Camfield et al, 1985
Todt et al, 19B5
Annegers et al, 1986








* All patients followed for one year
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listed in table 1:8 the documentation of patients Mas
generally poor and the total numbers insufficient to give
clear guidance. Patient selection, differing treatment
policies and innapropriate statistical analysis also make
interpretation of the results difficult.
There is, however, a degree of agreement that patients with
symptomatic seizures or associated neurological handicaps
have a higher recurrence rate. Annegers et al (1986) found
that amoung 287 patients with idiopathic seizures the
recurrence rate by 5 years was 45%, compared to 77% for the
remaining 122 patients in whom a cause was established.
Those with neurological deficits present since birth had a
particularly bad outcome with 92% developing epilepsy. A
similar finding has been reported by Todt et al (1985).
Patients with post natally acquired neurological handicaps
have also been reported to have a worse prognosis (Camfield
et al, 1985; Todt et al, 1985; Annegers et al, 19B6).
Because it is unusual to present folowing a single partial
seizure some authors have specifically excluded patients
with this particular seizure type. Camfield el al (1985)
found that amoungst 168 children who were referred to an EES
department 19 had complex partial seizures. In this group
the recurrence rate was significantly higher than in those
with tonic clonic seizures. Hauser at al (19B2), however,
found that seizure type was not significantly associated
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with outcome. Patients with symptomatic seizures were
excluded from the analysis and the clinical material was
unusual in that 47 presented following a single simple
partial seizure compared with 18 in whom the initial attack
was a complex partial seizure. Annegers et al (1986)
reported that patients with partial seizures had a higher
recurrence rate but the numbers with this seizure type were
not given.
The importance of the initial EEG as a useful prognostic
indicator is disputed. In the study by Annegers et al (1986)
only a third of patients had this investigation performed
which may have led to bias in the results. Hauser et al
(1982) reported that a small subgroup of 13 patients with
generalised spike and wave the recurrence rate was higher
but other features of the initial EEG was of little use in
predicting outcome. Using a broader definition Cleland et
al (19B1) found that the recurrence rate was higher in
those in whom the EEG was abnormal compared to those in whom
it was normal. Similarly Todt et al (1985) reported that
the recurrence rate was 59% in those with normal EEGs




The percentages of patients who were treated -following the
first attack are summarised in Table 1:10. It is apparent
that there has been little agreement on this aspect of
patient management. There is tendency for the more recent
North American authors to report that as many as two-thirds
of patients were given medication (Hauser et al, 1982;
Camfield et al, 1985; Annegers et al, 1986). In none of the
studies, however, were any details given as to the period of
time for which the drugs were taken. Poor compliance, which
is likely to have been widespread, was not commented upon.
It is difficult to detect any impact that treatment may have
had on seizure recurrence from the studies shown in table
1:10. In the study by Annegers et al (1986) the recurrence
rate appears to have been considerably higher in those
patients who were given medication ( 60% vs. 41% for those
patients who were not treated). Other authors have reported
no significant difference in outcome (Hauser et al, 1982;
Hirtz et al, 1984; Camfield et al, 1985 ). Selection bias
may have been of considerable importance as it is likely
that patients who were thought to be at higher risk of
developing epilepsy were more likely to be treated (Tucker &
McJunkin, 1984).
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TABLE 1:10. PROGNOSTIC STUDIES OF PATIENTS PRESENTING WITH
A SINGLE SEIZURE. PERCENTAGES OF PATIENTS TREATED FOLLOWING
THE FIRST SEIZURE
Author
Johnson et al, 1972
Saunders & Marshall, 1975
CI el and et al, 1981
Hauser et al, 1982
Hirtz et al, 1984
Cam-field et al , 1985
Todt et al, 1985
Annegers et al, 1986
Hopkins et al, 1988
* Unstated number o-f patients
■from the study
Number o-f Patients Recurr
Patients treated rate (,'/.)
NC/.)
77 none 64
33 none * 33









2 THE PROGNOSIS FOR SEIZURE CONTROL IN EPILEPSY
a. Historical Literature
The earliest reference to the prognosis of patients with
epilepsy is be found in the Hippocratic writings (Tekin,
1971 pages 45 et seq.). Epilepsy dating from birth was
thought to be incurable. If, however, it began before
puberty it might cease around that time. Epilepsy that
started in adolescence had a worse prognosis, although even
here cures could be obtained. Epilepsy that began after the
age of 25 lasted until death, and the occurrence of seizures
in the elderly was often fatal. The Hippocratic view of
prognosis was, therefore, rather gloomy, although it was
recognised that the prognosis could be better in cases
arising in childhood.
The prognosis was particularly poor if the disease had taken
on a chronic form. Areteaus stated: "but if the mischief
lurk there until it strike root, it will not yield even to
the physician or the changes of age, so as to take its
departure, but lives with the patient until death". It was
therefore of great importance to treat the disease before it
became chronic, a view that was also expressed by
Hippocrates (Temkin, 1971 page 65).
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During the Eighteenth Century the movement by Pinel in
France and Tukes in England led to humanization o-f the
treatment of the insane. This benefitted those suffering
from epilepsy as they had often been incarcerated together.
During the first half of the Nineteenth Century special
wards were established within asylums for the insane for
those patients suffering from epilepsy. This subsequently
led to the setting up of separate institutions for those
with epilepsy, such as the National Hospital for the
Paralysed and Epileptic, Queen Square, London in I860. There
was a rapid increase in knowledge about epilepsy and for the
first time statistical assessments based on the observation
of large numbers of patients were undertaken. A number of
important monographs such as those by Tissot, Delasiauve,
Esquirol, Reynolds and at a later date Gowers were
published.
This increase in knowledge was not unfortunately accompanied
by any general agreement as to the prognosis of epilepsy.
Reynolds (1861) opens his chapter on prognosis by quoting
the opposing views of Tissot and Delasiauve:
"J'en ai gueri un tres grand nombre". (Tissot, 1770)
"Elle conduit presque infai11iblement a 1'incurabi1ite
par de lentes degradations". (Delasiauve, 1854)
Reynolds (1861) gave the results of treatment in eighty one
cases, of whom eight recovered completely. Recovery was
79
defined as perfect restoration of health which lasted for at
least four years. Esquirol at the Salpietriere subjected
thirty patients each Spring and Autumn to some new treatment.
The results were not promising:
"Toujours une nouvelle medication suspenduit les acces
pendant quinze jours; chez les unes pendant un mois;
deux mois chez autres et meme pendant trois mois.
Apres ce terme les acces reparaissent sucessivement
chez toutes nos femmes je n'ai pu obtenir de
guerison".
(Esquirol E, 1B3S. Quoted by Reynolds, 1861)
In marked contrast to Esquirol, Delasiauve and Reynolds,
Herpin believed the prognosis was good.He based his work on
three hundred patients who attended his private clinic.
His books were widely quoted both by Gowers and Hughlings
Jackson. He is probably best remembered for his work on
Epileptic Auras and in particular defining minor seizures
or "Acces Incomplete". His other major work "du Prognostic
et du Traitment Curatif de 1'Epi1epsie", in itself had an
optimistic title. He advocated the use of zinc oxide in
the treatment of epilepsy.
"Que la medecine peut intervenir utilement chez les trois
quarts des malades; qu'elle peut en guerir plus de la
moitie, et procurer une amelioration plus ou mois durable
dans un cinquieme des cas; enfin que le nombre des
epilepsies rebelles aux traitements diriges avec
perseverance est d'un quart seulement".
(Herpin, 1852 quoted by Temkin, 1971)
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Herpin believed that it was possible to treat three quarters
of cases satisfactorily. His results, however, were subject
to scathing criticism by Delasiauve on the basis of incorrect
diagnosis in many patients, doubts as to the soundness of his
cure and also the inclusion of patients who had experienced
only a single seizure. A note of caution was introduced into
the controversy by Marshall Hall (Temkin, 1971). He admitted
that cases of epilepsy due to diseases within the cranium
were often incurable. These were the cases frequently met
with in institutions, and hence observers of the disease who
gathered their material at such places inclined to the belief
that epilepsy could not be cured. This controversy
surrounding prognosis in epilepsy has continued for almost a
century and curiously the solution proposed by Marshall Hall
may be equally relevant today.
b. The Introduction of Modern Anticonvulsant Drugs
During the second half of the Nineteenth Century a major
therapeutic advance occurred with the discovering of
bromides. All authorities agreed this drug had a very
considerable impact on the treatment of epilepsy. This was
followed in 1912 by the introduction of phenobarbitone
(Hauptmann, 1912) and subsequently by phenytoin (Merritt et
al, 1938). As these drugs gained widespread usage a number of
reports were published giving experience of their usage in
large number of patients. Arieff (1951) summarised his
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experience in 311 patients seen over a twelve year period.
The use o-f bromide or phenobarbi tone, alone or in
combination, led to remissions in 61% o-f cases and the
addition of newer drugs (phenytoin and mesantoin) increased
the remission rate to 68%.
Equally good results were reported for phenytoin. Merit and
Putman (1938) found that in 267 cases, 54% had their seizures
"completely relieved". Yahr et al (1952) reported that the
use of phenytoin and phenobarbitone resulted in control or
improvement of seizures in 79% of patients.
Gibbs (1947) in a review of the new drugs available to treat
epilepsy stated that "the informed practionner will be able
to treat successfully 75% of patients with seizures". Other
authorities were equally enthusiastic. Lennox and Lennox
summarised their experience as follows:
"Considering only metabolic epilepsy, the
following is doubtless an understatement:
at least three fourths of patients can be
relieved of at least three fourths of the
seizures they would have had without drug
therapy. Of these, perhaps one half will
be completely free. Those with organic
epilepsy will fair less well. Perhaps the
proportion greatly benefitted or freed will
be one half or two thirds, instead of
three fourths".
(Lennox & Lennox, 1960)
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Livingston (1972) reported his considerable experience in
treating twenty thousand epileptic children over a thirty
■five year period. The results were similar to those o-f
Lennox. Sixty per cent had complete control of seizures, 257.
had a significant reduction in seizure frequency or severity
and in only 15% were seizures refractory to all therapeutic
regimens.
c. The Work of Rodin.
In 1968 Rodin published an important critical review of the
previous work on the prognosis of patients with epilepsy. His
book has been very influential and his conclusions widely
quoted and because of their importance they will be
considered in some detail in this section.
Rodin (1968) examined the claims that 80% to 85% of patients
could be controlled with medication. Rodin (1968) attributed
this statement to a paper published by Yahr et al (1952).
These authors found that "the use of diphenylhydantoin sodium
and phenobarbital in this group of three hundred and nineteen
patients resulted in seventy nine per cent control or
improvement of seizures regardless of causation. The addition
of other anticonvulsants added 6%, giving an overall rate of
85% improvement or control". However, as Rodin observed,
further analysis of the results showed that only 48% of the
patients were completely controlled for periods varying from
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less than six months to -five and a halt years. In the
remaining 37% there was an "improvement" in seizure control.
A second problem arose due to failure to take account of
duration of follow up. In the study by Yahr et al (1952) a
considerable proportion of patients had only been followed
for periods of up to six months. A similar criticism applied
to the results of Merritt and Putman (1938) and also those of
Arieff (1951). Rodin (1968) emphasised that in epilepsy the
course of the disorder is often one of remission and
exacerbation and that statements on prognosis could not based
on such short follow-up. To emphasise this point he quoted
the results of Bridge (1949) who followed 472 epileptic
children for periods of five years or more. Although 46% had
been seizure free for six months or more with increasing
follow up the remission rate fell such that only 17% had been
seizure free for a total of five years or more.
Rodin (1968) stipulated that conclusions concerning the
prognosis of epilepsy could only be made on the basis of
prolonged follow-up. Furthermore, imprecise statements such
as "improvement" or "reduction in seizure freqency" were
inadequate. Only those studies which gave the proportion of
patients who at the end of follow up had been completely
seizure free for at least one year were considered. The
results of the studies that Rodin found had met these
criteria are shown in Table 1:11. It was striking that Turner
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TABLE 1:11 STUDIES DF THE PROGNOSIS FOR SEIZURE CONTROL
EPILEPSY. THE PERCENTAGE OF PATIENTS EXPERIENCING A
TERMINAL REMISSION OF AT LEAST ONE YEAR (Modified from
Rodin, 1968)
Author Number Minimum Duration Percent in
of remission Remission
iermaas, 1901 937 2 10
ner, 1907 87 2 32
iss, 1930 125 10 11
sten, 1942 174 3 22
itrom, 1950 897 5 22
obos, 1959 228 1 38
irboe, 1960 130 4 32
ibst, 1960 83 2 31
ille, 1960 799 2 37
Jensen, 1963 969 2 32
1964 177 2 34
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in 1907 in a series -from the National Hospital reported
identical results using bromides to the more recent study of
Juul-Jensen (1963) . In fact the best results were reported
by Strobos(1959) who found that only 38% of patients were in
one year remission at the end of follow up.
Rodin (1968), therefore, found little evidence to support the
optimistic views that the introduction of new drugs had led
to significant improvements in prognosis. For the great
majority of patients epilepsy was a chronic disorder.
"Eighty per cent of all patients with epilepsy
are likely to have a chronic seizure disorder.
This does not rule out short term remissions
or changes in seizure pattern, it merely
re-emphasises that epilepsy should be regarded
as a chronic condition with remissions and
exacerbations" (Rodin,1968)
In contrast to the controversy that had surrounded the long
term outcome in epilepsy Rodin found that there was a
reasonable degree of agreement concerning the nature of
adverse prognostic factors in epilepsy. These had been
identified shortly after the introduction of bromides. Gowers
(1881), for example, found that patients with hemiplegic
epilepsy, minor seizures or a long duration of epilepsy all
appeared to respond less well to treatment. In view of their
importance Rodins' main conclusions are given in full below.
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"1. Approximately one third of all epileptic patients are
likely to achieve a terminal remission of at least two
years.
2. The percentage rises to between 50 and hOV. if one
considers only those patients who have grand mal seizures
without associated minor attacks.
3. It drops to approximately 20 to 30 per cent if one
deals with patients who have psychomotor seizures.
4. The percentages of patients who are regarded in terminal
remission stand in marked indirect relationship to the
length of follow up.
5. The longer the illness has lasted, the less likely will
control be achieved.
6. The more seizures the patient has experienced prior to
his first visit to the physician, the less likely will be
complete control.
7. The more different seizure types a given patient has
experienced, the less likely control.
8. The more abnormal the neurological examination, mental
status examination, and the lower the IQ, the more
difficult will it be to control the patient.
9. The younger the patient at the time of onset of the
illness, the less likely will complete control be achieved:
but there are some authors who feel that age at time of
onset is not a good prognostic indicator.
10. The initial EEG is of limited value for prognosis, but
a persistently abnormal EEG during treatment tends to be
associated with poor seizure control. Opinions are more
divided between authors on the importance of heredity,




d. Subsequent Prognostic Studies in Epilepsy
A number of important prognostic studies have been published
since the time of Rodin's reveiw of the literature. The
results have been summarised in table 1:12. Only those
studies which were based on one hundred or more patients and
in which the percentage achieving one or more years
completely seizure-free was clearly stated have been
included. Interpretation of the results is often difficult
because most have been retrospective surveys and the basis
upon which patients were selected is often not clearly
stated.
Currie et al (1971) retrospectively identified 666 cases of
temporal lobe epilepsy who had attended an adult neurology
outpatients department between 1949 and 1967. The mean
duration of epilepsy at entry into the study was six years
and patients were followed for a mean of seven years. Forty
per cent of patients achieved a one year period completely
free of all seizures, results which are in broad agreement
with the conclusions of Rodin. A more recent study, however,
suggested a far better prognosis. Schmidt et al (1983)
described the clinical course and the long term prognosis in
a 155 patients with complex partial seizures who were
followed for a mean of ten years. Ninety-six (62%) had
complete control of seizures, including auras, for a minimum
of two years. Patients with tumours and previous
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TABLE 1:12 RECENT STUDIES OF THE PROGNOSIS FOR SEIZURE
CONTROL IN EPILEPSY
Author Number of Duration of Percentage
Patients Remission, in Remission
(years)
Currie et al,1971 * 666 1 40
Janz, 1972 533 1 44
Ohtahara et al,1977 + 431 3 76
Okuma &
Kumashiro, 1981 1838 3 58
Sofijanov, 1982 + 512 2 50
Schmidt et al, 1983 * 155 2 62
* Temporal lobe epilepsy
+ Childhood epilepsy
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neurosurgical interventions were excluded. They all attended
the private practice of one of the authors, but the selection
criteria were not stated.
Janz (1972), in a retrospective study, identified 900
patients with epilepsy who attended his clinic during three
one year periods in 1953, 1957 and 1961. One hundred and
seventy two patients who were lost to follow up, 86 had died
and 95 cases of "acute epilepsy" were excluded. The remaining
533 cases with chronic epilepsy were studied. Chronic
epilepsy was defined as a minimum duration of illness of two
years and at least six major attacks during this time. The
duration of follow up was not stated. Forty four per cent
were found to have been seizure free for one year or more.
Two of the studies have been confined to childhood epilepsy,
□htahara et al (1977) studied 431 patients seen in a
paediatric outpatient department, all of whom had experienced
two or more seizures in the three years prior to first
assessment. Seventy four per cent were aged 6 years or less.
The analysis of prognosis appears to have been retrospective.
After a total follow up period of at least 5 years 327 (76'/.)
had complete control of seizures for three or more years. It
appears however that an unstated number of patients with
"minor" seizures were controlled for only six months, perhaps
explaining the high remission rates found in this study.
Sofijanov (1982) studied 512 children who had experienced at
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least two afebrile convulsions separated by a minimum of 24
hours. The methods of case selection, which were presumably
retrospective, were not given. Patients were followed for
between four and ten years and actuarial statistical analysis
was used. Seven years after the diagnosis the probability of
being in two year remission was fifty percent.
The most extensive work published has been the report of the
Japanese Multi-institutional Study (Okuma & Kumashiro, 1981),
which was based on 1838 patients. Unlike the studies
described above the methods of case selection were carefully
defined. Initially three groups of patients who attended ten
years, five years, and three years prior to the onset of the
study were obtained. Amongst these, only those patients in
whom the onset of seizures had been within five years of the
first visit were selected. In this manner all patients
entered had a duration of epilepsy not exceeding five years.
An unstated number of patients with single seizures and an
abnormal EEG were included. Unfortunately, 58% were lost to
follow up and the mean duration of follow up was not given.
In 58% seizures were controlled for three or more years.
e. Community Surveys of Prognosis in Epilepsy
Four community surveys of prognosis in epilepsy, based on an
unselected sample of the population, have been undertaken.
All of them were retrospective, in some instances relying on
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the identification of cases diagnosed many decades
previously. Details of clinical characteristics have in
general been scanty.
Annegers et al (1979) used the record linkage system of
the Mayo Clinic to identify all cases of epilepsy
diagnosed in Rochester, Minnesota between 1935 and 1974.
Epilepsy was defined as two or more seizures and those in
whom an acute provoking cause could be established were
excluded. From a total of 618 cases identified, 93 died and
in a further 68 follow up or documentation was inadequate. Of
the remaining 457 patients, 328 were followed for at least
ten years and 141 for at least twenty years. Actuarial
statistics were used to analyse the percentage of patients in
remission. Ten years after the diagnosis the probabality of
being in five year remission was 617. and at twenty years was
707.. Twenty years after the diagnosis 507 of patients were in
remission and off medication. The authors considered three
possible reasons for the good prognosis. Although prolonged
follow up may have contributed this was not considered
important as most remission occurred early in the course of
the illness. As the study was community based a wide variety
of patients with epilepsy were included. The most important
factor, however, was felt to be identification of patients
from the onset of the disorder.
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Closely similar results were obtained by Goodrige & Bhorvon
<1983). One hundred and twenty two patients were
retrospectively identified from general practioner records.
It appears that in the analysis of prognosis 22 patients with
single seizures and an unspecified number with seizures
occurring in the context of an acute cerebral disturbance
such as head injury or alcohol withdrawal were included.
Regardless of medication status the probability of being in
two year remission 15 years after the diagnosis was sixty
eight per cent.
The study of Sillanpaa (1983) was conducted in South West
Finland and was confined to children. Only patients who had
undergone hospital treatment were included. Epilepsy was
defined as at least three seizures occurring at intervals of
at least one week. An unspecified number was seen by the
author and follow up data was obtained by contact through the
post. After a mean follow up of 21 years 66% had been seizure
free for one year or more. Another community based survey in
children has recently been reported from Sweden (Brorson &
Wrane, 1987). Two thirds of cases were identified
retrospectively and patients were followed for periods of up
to 12 years. Fifty-six percent experienced a remission of at
least 3 years. In a further series of 68 patients who were
identified on the basis of incidence rates and followed
prospectively the outcome was better with 78% achieving
remission. Seizures were classified into focal, petit mal,
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minor motor, grand mal and "others" but the proportion with
each seizure type and any effect on prognosis was not
commented upon.
f. Prognosis in Childhood Epilepsies
Amongst the childhood epilepsies there are a number of
syndromes in which the prognosis has been studied in some
detail. The classification and clinical features of these
syndromes have been given in a previous section (see page 35 >
and the outcome of the most important of these will be
briefly considered here.
i. West Syndrome
There is general agreement that the prognosis in children
with West Syndrome is poor. The studies that have examined
this group of patients are summarised in Table 1:13. Only
those in which the prognosis for both seizure control and
neurological development was given, and which were based on
100 or more patients have been included. The overall case
fatality is of the order of 20%. Infantile spasms invariably
disappear by the age of 5, whether or not treatment has been
given (Jeavons, 1985). As many as 50% develop chronic seizure
disorders, including Lennox-Gastaut Syndrome. The outlook in
terms of cognitive and physical disability is particularly
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them severely so, and about one-third having physical
handicaps, usually cerebral palsy. The outcome is worst
amongst patients in whom the illness develops before the age
of four months and those with symptomatic seizures and
developmental delay prior to the onset of seizures (Bellman,
1983).
ii. Lennox—Gastaut Syndrome
The prognosis is also poor in Lennox-Gastaut Syndrome and the
disease is said to become chronic in the majority of cases,
although in idiopathic cases the outlook may be better
(Beaumanoir, 1985,b). A complete seizure free recovery has
been reported to occur in only 77. of cases (Gastaut et al ,
1973). In Oiler Daurella's series (1973) only one patient
became seizure free and had a normal EEG. The outlook is
particularly poor in those patients with symptomatic
seizures, cases which are preceded by West Syndrome and those
with onset before the age of 3 (Baumanoir, 1985,b). The
presence of severe slowing of background rhythms on the EEG
is also associated with a poor outcome but the proportion of
the EEG which is occupied by slow spike and wave is not of
prognostic value (Blume et al, 1973). In general very few
prognostic studies have been undertaken in Lennox-Gastaut
Syndrome, possibly because of continuing uncertainty about
its nosological position. A number of authors have included
small numbers of patients, of the order of 40 to 60, amongst
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unselected series of patients with childhood epilepsy
(Sofijanov, 19B2; Okuma & Kumashiro, 1981). In none of them
were diagnostic criteria given. All have reported higher
remission rates, of the order of 40% suggesting that the
series of Gastaut et al (1973) and Oiler Daurella et al
(1973) may have included a disproportionate number of chronic
intractable cases. Kurokawa et al (1980) found that 42 out of
123 cases of Lennox-Gastaut who were followed for at least
five years became seizure-free.
iii. Childhood Abscence Epilepsy (Petit Mai, Pynknolepsy)
The first description of petit mal in the English speaking
literature appears to have been that of Aidie (1924) who
noted the tendancy of the condition to undergo spontaneous
remission.
"In ordinary epilepsy spontaneous recovery
does not occur in more than 2% or 3% of
cases (k'raepelin); a spontaneous termination
of the disease is an event too rare to be
reasonably anticipated in any given case (Gowers);
in the cases of Pyknolepsy that conform to the
strict requirements that I shall lay down later,
spontaneous termination is a rule to which I have
been unable to find a single exception."
Aidie (1924)
Although it has generally been assumed that petit mal has a
good prognosis the published literature on the subject is, in
fact, highly contradictory. The prognostic studies are
summarised in table 1:14. The remission rates refer to
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TABLE Is 14 PROGNOSIS IN CHILDHOOD ABSCENCE EPILEPSY. THE
PERCENTAGE OF PATIENTS WITH COMPLETE CONTROL OF ABSENCE
SEIZURES FOR AT LEAST ONE YEAR
Author Number of Follow-up Percent
Patients (years) Seizure
Free
Hollowach et al , 1962 88 1-12 37
Hertoft, 1963 50 8 48
Currier et al, 1963 32 18 37
Livingston et al, 1965 117 5 79
Gordon, 1965 70 2-6 51
Gibberd, 1966 139 NS 42
Dalby, 1969 161 5 79
Loiseau et al, 1983 90 16 63
Gastaut et al, 1986 26 30-37 19
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control of abscence seizures alone. As can be seen the
prognosis has been reported to be favourable in a widely
differing proportion of cases.
A number of authors have included cases who in all likelihood
did not suffer from petit mal. In the study by Hollowach et
al (1962) 247. of the patients had associated neurological
handicaps and only 357 had 3 per second spike and wave on the
initial EEG. It is likely that a considerable proportion of
the patients suffered from partial epilepsy. In only two
studies (Currier et al, 1963; Loiseau et al, 1983) were
patients with neurological deficits clearly excluded and in
only half of the remaining studies did all the patients meet
the diagnostic criteria relating to EEG abnormalities
Hertoft, 1963; Livingston et al, 1965; Dalby, 1969). Loiseau
el al (1983) reported that 637 of patients had been free of
absence attacks for two or more years after a mean follow up
of 16 years. However, a quarter of the patients also had
myoclonic seizures, and if these patients were excluded, the
overall prognosis was considerably better. Similarly, Gibberd
(1966) reported that 18 patients in his series had "frequent
myoclonias" although similar information concerning other
seizure types was not supplied by any of the other authors.
The five studies which reported a poor prognosis (Hertoft,
1963; Currier et al, 1963; Gordon, 1965; Gibberd, 1966;
Gastaut et al, 1986) were based on patients attending adult
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neurology clinics or EEG departments. This method of
selection will, o-f course, lead to a strong bias in favour of
those patients in whom seizures persist into adulthood. In
all of these studies virtually all the patients were aged 15
or over at the time of inclusion into the follow-up period.
A factor that complicates prognosis in petit mal epilepsy is
the development of tonic clonic seizures. Tonic clonic
seizures are said to occur in about one third to one half of
patients (see Table 1:15). The higher figures reported by
Gibberd (1966) and Gastaut et al (19S6) are almost certainly
due to patient selection. There is good agreement that in the
majority of cases tonic clonic seizures occur for the first
time between the ages of 10 and 15 years, usually about five
years after the onset of absence attacks. Occasional cases
have been reported where tonic clonic seizures developed
after the age of 20 years (Gibberd, 1966). All authors are in
agreement that a later age of onset of abscence attacks (over
the age of 10 years) is associated with a higher risk of
developing tonic clonic seizures.
Few studies have either had a long enough duration of follow
up or adequate documentation of outcome to assess the
prognosis for control of tonic clonic seizures. Currier et
al (1963), Gordon (1965) and Loiseau et al (1983) stated that
seizures ceased in about one half of patients. All authors
have said that the attacks can usually be easily controlled
on medication, or occur at very infrequent intervals
(Gibberd, 1966; Gastaut et al, 1986).
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TABLE 1:15 PROBNOSIS IN CHILDHOOD ABSENCE EPILEPSY. THE
PERCENTAGE OF PATIENTS DEVELOPING TONIC CLONIC SEIZURES
Author Total number Patients with
of patients tonic clonic
seizures
N C/.)
Llowach et al, 1962 72 24<33)
-toft, 1963 50 19(38)
-rier et al, 1963 32 12(38)
/ingston et al, 1965 117 54(46)
-don, 1965 70
3berd, 1966 139
L by, 1969 161 74(46)
iseau et al, 1983 90 (36) *





iv. Benign Partial Epilepsies o-f Childhood
There is complete agreement in the literature on the
uniformly good prognosis in Rolandic Epilepsy. Most of the
early series were based on patients identified by EEG
features alone. Gibbs & Gibbs (1959-1960) studied 739
patients who had mid-temporal spikes on their EEG. In
contrast to those who had anterior temporal spikes, who
tended to have psycomotor seizures and a poorer prognosis, in
these patients it was found that the EEG abnormalities rarely
persisted beyond the age of 15 years. Smith & Kellaway (1964)
found that in 200 children with centro-temporal spike
discharges the abnormality rarely persisted for more than 4
years. Longitudinal studies of children with Rolandic spikes
but no seizures (Cavazutti et al, 19S0) suggest that there is
a strong tendency for the abnormality to disappear
spontaneously.
The most carefully documented study has been that of Blom et
al (1972). Forty cases were followed between 11 and 16 years.
Thirty—eight were seizure free for periods ranging from 4 to
13 years and 28 had discontinued medication. One patient had
a recurrence of seizures related to poor compliance with
medication and another had an isolated attack 3 years after
stopping treatment. In a subsequent study based on the
analysis of the same patients 10 years later (Blom & Heijbel,
1982) only one patient was still on medication and one had
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developed seizures related to alcohol abuse. A more recent
study (Loiseau et al, 1983) has confirmed a uniformly good
prognosis. In benign partial epilepsy with occipital
paroxysms complete seizure control is said to occur in 60'/. of
cases (Gastaut, 1985).
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3 PROGNOSIS FOLLOWING ANTICONVULSANT WITHDRAWAL
a. Seizure Recurrence
The most important published studies that have examined
prognosis following anticonvulsant withdrawal are summarised
in table 1:16. It would appear that the relapse rate is not
i nconsi derabl e, and has been reported to occur in 207. to AO'/.
of patients on stopping medication. Most recurrences happen
during or shortly after the actual period of drug withdrawal.
Juul-Jensen (196B) found that amongst 79 patients
experiencing a recurrence, 35 did so during drug reduction
and a further 23 by one year of follow-up. Similarly Todt
(1984) reported that 86X of all recurrences had taken place
within one year after drug reduction. In the study by
Thurston et al (1982) patients were followed for prolonged
periods of time, ranging from 13 to 23 years. From a total of
41 patients who relapsed, 22 (53%) did so by one year and 33
(807.) by five years. Late relapses were seen only rarely.
There appears to be little risk of precipi tating uncontrollable
epilepsy following drug withdrawal in patients who have
been seizure free for at least two years. Juul-Jensen
(1968) found that all patients who relapsed responded
immediately to reinstitution of therapy. Todt (1984)
reported that in 157 children who relapsed, 143 were placed
back on medication immediately and of these 123
104
TABLE 1:16 STUDIES OF ANTICONVULSANT WITHDRAWAL. PERCENTAGE
OF PATIENTS EXPERIENCING A SEIZURE RECURRENCE FOLLOWING DRUG
REDUCTION
Author No o-f Remission Rate o-f Follow-up Relapse
Patients (years) drug (years) Rates
withdrawal (%)
(months)
Zenker et al, 1957 * 117
Juul-Jensen, 1968 196




et al, 1976 138
Van Heycop
Ten Ham, 1980 150
Emerson et al, 1981 * 68
Thurston et al, 1982 * 14B
Todt, 1984 * 433
Shinnar et al, 1985 * 88













































subsequently had no -further seizures. In 30 patients, the
outcome was "problematic" but only one, an adolescent -female
with tonic clonic seizures, developed intractable epilepsy.
Interestingly, Todt (19B4) found that in the fourteen
patients who remained off medication despite a relapse none
had further seizures.
Six of the studies shown in table 1:16 were based on a
paediatric population, probably reflecting the greater
willingness to withdraw drugs in children who have been
seizure-free for prolonged periods. All of the studies were
hospital based. Shorvon (1984) has argued that this will lead
to an unduly gloomy view when compared with epilepsy in the
community. Although this criticism is in general correct,
studies of anticonvulsant withdrawal will obviously select
only those milder cases which are in remission. In the study
by Todt (1984) for example 78% of cases had a duration of
epilepsy of less than two years, a result similar to the
community survey of Goodridge & Shorvon (1983) where patients
were selected from general practice records. None of the
studies have included a control group on treatment. There is
little information in the literature on the relapse rates
amongst patients in prolonged remission who are maintained
on treatment. Annegers et al (1979) found that the
probability of relapse for patients who had experienced a
five year remission was 247. by ten years. These results are




There is good agreement that a long duration of active
epilepsy or a large total number of seizures prior to control
is associated with a higher recurrence rate following drug
withdrawal. Similarly, patients with associated neurological
handicap and those with partial seizures have been reported
to have a worse prognosis, although there is not complete
agreement on the latter (Janz & Sommer-Burkhardt, 1976).
These factors are in good agreement with those identified by
Rodin (1968) as being associated with a poor prognosis for
seizure control in patients with chronic epilepsy.
Opinions have differed concerning the importance of the EEG
in predicting seizure recurrence. In the study by Juul-Jensen
(1968) only half the patients had this investigation
performed immediately prior to drug withdrawal. A small
number of patients, seven in all, with delta foci, focal
spikes or bilateral paroxysmal changes had a significantly
higher recurrence rate. Thurston et al (1982) and Janz &
Sommer-Burkhardt (1976) found that the EEG was of little
prognostic significance. Shinnar et al (1985), in childhood
epilepsy, reported that the relapse rate was double amongst
those with an abnormal EEG compared to those in whom it was
normal. The presence of specific electroencephalographic
features such as spikes or slow wave abnormalities were of
greater use in predicting outcome. Todt (1984) found that
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children with paroxysmal changes on the EEG were particularly
likely to relapse. This author also emphasised the importance
of an improvement in consecutive recordings in determining a
good prognosis -following drug withdrawal.
Similarly little agreement exists concerning the importance
o-f age of onset of epilepsy in determining the prognosis
following anticonvulsant withdrawal. Two of the studies shown
in table 1:16 which found a high recurrence rate
(Juul-Jensen, 1968; Janz & Sommer-Burkhardt, 1976) were
conducted in adults. Both of these, however, used a shorter
period of remission prior to drug withdrawal than most of the
other studies. Although prognosis is known to be particularly
good in petit mal and the benign partial epilepsies of
childhood, anticonvulsant withdrawal studies have in general
only included small numbers of children with these disorders.
Two studies that compared relapse rates by specific age
groups found no significant difference between them (Todt,
1984; Thurston et al, 1982). Juul-Jensen (1968) reported a
higher recurrence rate in the age group 0 to 9 whilst Janz &
Sommer- Burkhardt (1976) and Shinnar et al (1985) found that
the median age of those who relapsed was higher than those
who remained seizure free.
An area of particular importance is the influence of duration
of remission and the rate of anticonvulsant withdrawal in
determining relapse rates. These are important practical
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issues in patient management yet they appear to have received
only scant attention. It is the usual clinical practice iH
this country to consider anticonvulsant withdrawal in
patients in whom all seizures have been suppressed -for a
minimum period of two years. The drugs are usually withdrawn
over a period o-f two to three months. This was the criterion
used by Juul-Jensen (196B) and this paper has probably been
important in determining current practice. Juul-Jensen (1968)
stated that duration o-f remission had no influence upon
recurrence -following anticonvulsant withdrawal. Few details,
however, concerning this important aspect o-f management were
given, and no randonmization procedure was used. Other
studies, particularly those -from North America (Emerson et
al, 1981; Thurston et al, 1982; 011er-Daurel1 a et al 1976),
have used longer remission periods o-f 4 to 5 years, and all
o-f these have reported lower recurrence rates o-f the order o-f
20"/.. Similarly, both Thurston et al (1982) and 011 er-Daurel 1 a
et al (1976) used a much slower rate o-f anticonvulsant
withdrawal. In the -former the drugs were reduced over a
period of 9 months and this was done sequentially in those
who were on polytherapy.
Groh(1975) reported that the proportion of patients relapsing
following drug withdrawal was inversely related to the
previous period of remission. This study was based on a
retrospective analysis which may bias the results as
treatment may have been continued in those patients in whom
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relapse was thought to be less likely to occur. Todt (1984),
however, used randomisation to determine both the seizure
free interval prior to withdrawal and the rate at which the
drugs were reduced. The results have been reproduced in
table 1:13. There is a very clear direct relationship between
slower anticonvulsant withdrawal and an increasing period of
terminal remission with a subsequent lower relapse rate. If
these findings are confirmed a more cautious approach to
anticonvulsant withdrawal may be appropriate.
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TABLE 1:17 THE INFLUENCE OF DURATION OF REMISSSION OF
SEIZURES AND RATE OF DRUG REDUCTION ON THE RELAPSE RATES
FOLLOWING ANTICONVULSANT WITHDRAWAL, (adapted from Todt,
1984)
Seizure Free Total Number No. of Patients
















In the previous chapter a general review o-f the literature
relating to the prognosis of patients with epilepsy was
presented. Before considering the specific topics which form
the experimental basis of this thesis a number of general
observations should be emphasised. Firstly, and most
importantly, virtually all the studies that have examined
prognosis have been based on the observations of patients
with chronic long standing epilepsy. The natural history of
the disorder in this group of patients has been studied in
considerable detail. The most important work in this area has
been undertaken by Rodin (1968) who in addition to describing
the general prognosis of epilepsy has identified a number of
factors that are of importance in predicting prognosis in
chronic epilepsy.
In marked contrast, the prognosis of epilepsy during the
early years of treatment has been virtually ignored in the
literature. Only one author appears to have commented upon
the initial response to treatment and this was in relation to
the law concerning driving licences (Kuhl et al, 1967).
There has been no previous study of the patterns of seizure
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recurrence at the onset of the disorder in either treated or
untreated epilepsy. Nor has the implication that this may
have for subsequent prognosis been examined. Although a
number of authors have studied the outcome in patients
presenting with a single seizure, the results have been
widely conflicting and at variance with data obtained from
the epidemiology of epilepsy (see tables 1:7 & 1:8).
A number of other inadequacies are to be found in the
literature that have led to difficulty in the interpretation
of the results of prognostic studies. Some authors have
included patients with seizures occurring in the context of
acute metabolic or neurological disturbances (Blom et al,
1978; Hirtz et al 1984;, Goodridge & Shorvon, 1983). Others
have excluded from the definition of epilepsy patients with
symptomatic seizures or those with evidence of structural
brain disease (Strobos, 1959 ). The definition of epilepsy
has varied from three or more seizures occurring at intervals
of one week (Sillanpaa, 1983) to a minimum duration of two
years with at least six major attacks occurring during this
period (Janz, 1972) whilst others have included patients with
a single seizure and an abnormal EEG (Okuma & Kumashiro,
1981). The literature abounds with such inprecise terms as
"minor" seizures (Ohtahara et al, 1977), "fainting spells"
(Trolle, 1960) or "acute epilepsy" (Janz, 1972). In analysing
prognostic factors, some authors have based classifications
upon the EEG alone (Gibbs & Gibbs, 1959-1960; Smith &
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Kellaway, 1964; Strobes, 1959) , with little reference to
associated clinical features, whilst others have introduced
novel classifications to suit the purposes of the particular
study (Annegers et al, 1979; Brorson & Wranne, 19B7 ). The
problems of heterogenicity and varying definition have been
particularly prominent amongst prognostic studies in
childhood epilepsy. Many of the prognostic studies that have
been undertaken both in adults and children have been
retrospective surveys. The outcome has been couched in such
inprecise terms as "improved" or "reduction in seizure
frequency". Not only is it very difficult to reach clear
conclusions concerning prognosis on the basis of such
statements but it is virtually impossible to subject them to
any meaningful form of statistical analysis. Most prognostic
studies have analysed outcome in terms of crude remission or
relapse rates, rather than using life table calculations.
Treatment has, in general, received only scant attention in
prognostic studies. The tendency to include patients who
were treated following a first attack amongst those who
suffered from epilepsy has given rise to controversy in
historical literature. Similarly current practice concerning
the initiation of treatment appears to differ widely (see
table 1:10), which itself is largely due to the lack of clear
data on the early prognosis of epilepsy. Many studies that
have examined the outcome make either no mention of treatment
or at most give a list of drugs that were used. The
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continuing use of polypharmacy and other unsatisfactory
aspects of treatment makes interpretation of results
difficult. There havebeen no previous prognostic studies that
included anticonvulsant level monitoring to assess either
optimal use of drugs or poor compliance with medication. It
is very difficult on the basis of the current literature to
assess the impact that the currently available drugs have had
on the prognosis of epilepsy. It is even harder to determine
secular trends that could be attributed to advances in drug
development or to determine differences in efficacy of the
currently available compounds.
B. THE EARLY PROGNOSIS OF EPILEPSY
The patients who formed the basis of the experimental work in
this thesis were all consecutive new referrals to an adult
neurology outpatients department with previously untreated
epilepsy. All the patients seen were considered for inclusion
into trials of monotherapy conducted by Dr. E. H. Reynolds at
Kings College Hospital, London. The author's interest in the
early prognosis of epilepsy developed during the recruitment,
assessment, randomisation and subsequent follow-up of
patients entered into these trials. An analysis of the
prognosis in these patients provided a unique oppertunity to
study the natural history of epilepsy at the onset of the
disorder in a hospital based population.
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Three aspects of the early prognosis of epilepsy have been
studied:
1) The prognosis -for seizure control in a series of 106
patients with newly diagnosed epilepsy who were followed
prospectively for periods of up to eight years.
2) The prognosis fallowing a first seizure in a series of
214 patients who were consecutively referred to the depart¬
ment with recent onset of one or more tonic clonic seizures.
3) An analysis of the intervals between seizures in a
further series of 183 patients with two or more untreated
tonic clonic seizures.
It will become apparent from the work considered here that
the patterns of patient referral, the selection criteria used
and the timing of the initiation of anticonvulsant medication
may all have a crucial impact on the results of prognostic
studies in epilepsy. Although each of the chapters considers
a specific aspect of the early prognosis of epilepsy the
patients that form the bases for each study were drawn from
the same source. A general description of the patients and
methods which are common to the three studies will be given
below. The appropriate modifications that were needed to suit
the particular aspect of the early prognosis of epilepsy
under study will be given at the start of each chapter. Each
chapter is followed by a discussion which broadly covers the
interpretation of the results and a comparison with the
results of previous prognostic studies.
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In the final chapter the most important conclusions will be
emphasised and the broader issues that have arisen from all
three studies will be discussed.
C PATIENTS AND METHODS
1. Trials of Monotherapy in Newly Diagnosed Epilepsy
Reynolds et al (1976) initially reported the outcome in 31
adult outpatients who were treated with phenytoin alone with
the aid of anticonvulsant level monitoring. The initial
studies were subsequently extended to include patients taking
carbamazapine (Shorvon et al. 197B). The response to single
drug therapy was analysed in a series of 94 patients after a
median interval of 32 months (Shorvon & Reynolds, 1981).
Twenty four patients had their seizure controlled with
suboptimal levels of either phenytoin or carbamazepine and 22
patients with optimum anticonvulsant levels. Twenty six
patients experienced seizures initially but were subsequently
controlled when the dosage was increased and optimum
anticonvulsant levels were achieved. Six patients failed to
achieve optimum anticonvulsant levels and 16 patients (17% of
the total) failed on monotherapy.
□n the basis of the results of this pilot study an MRC trial
was initiated and patient recruitment was started in 1981.
Both adults and children were included. The latter were
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patients attending the paediatric department at Kings College
Hospital, and at Guys Hospital under the care of Dr. B.
Neville. Subsequently adult patients were recruited from
Walton Hospital, Liverpool under the direction of Dr D.
Chadwick. The patients studied in this thesis were adults and
children under the care of the neurology outpatients
department at Kings College Hospital. In contrast to the
pilot study patients were stratified on the basis of seizure
type and associated neuropsychiatric handicaps. They were
randomised to treatment with either phenobarbitone,
phenytoin, sodium valproate or carbamazapine. The use of
phenobarbitone in children was subsequently abandoned because
of a high incidence of side effects, particularly behaviour
disorders (MacArdle et al, 19B7). In patients who failed to
respond to monotherapy the potential for adding a second drug
was assessed. Patients were followed prospectively in a
special clinic established for this purpose. These studies,
which are currently in progress, will be analysed to assess
the comparative efficacy and toxicity of the established
anti- convulsant drugs given as monotherapy in adults and
children. Particular emphasis has been placed on the
comparative effects of the drugs on cognitive function.
Prior to treatment and at regular follow up intervals a batch
of specifically designed psychometric assessments were
undertaken (Andrewes et al, 1986).
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The initial pilot study represented a unique group of
patients who had been identified and followed as a cohort
prospectively from the onset of the illness for the period of
almost a decade. Detailed documentation of the numbers, types
and timing of seizures whilst on treatment were undertaken.
Because of this they provided an opportunity to examine the
early prognosis of epilepsy on the basis of carefully
gathered prospective data. Furthermore, unlike all other
prognostic studies a consistent policy treatment with
extensive use of anticonvulsant level monitoring was used
throughout follow up. The outcome of the patients entered
into the pilot trial is given in Chapter 3. Patients who were
considered for entry into the subsequent MRC trial formed the
basis of the analysis of the patterns of seizure recurrence
at the onset of epilepsy that is given in chapters 4 and 5.
2. Referral of Patients
The patients who were entered into the monotherapy trials
described above all had newly diagnosed previously untreated
epilepsy and were referred under the care of the adult
neurology clinic at Kings College Hospital. Kings College
Hospital is a District General Hospital in South-East London
serving an urban population. The patients were referred
directly by general practitioners or casualty offficers in
about equal numbers. The studies were carried out with the
cooperation of the other consultant neurologists in the
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department and all the patients sent to the hospital were
referred under the care of Dr E. H. Reynolds to assess their
suitability -for inclusion. Following the initial referral
letter a period of about 4 weeks usually elapsed before they
were seen in the neurology outpatients department. Although
every effort was made to see patients as soon as possible
this period corresponded to the time spent on the general
neurology outpatients waiting list. If it was felt that
patients required anticonvulsant medication initial
investigations were undertaken and patients were started on
treatment after a period of about 3 to 4 weeks.
The referral patterns described above are likely to be
broadly similar to those encountered by other consultant
neurologists in this country, the majority of whom see
patients referred to district general hospitals by general
practitioners or casualty officers. Although the department
at Kings College Hospital had a specific interest in the
treatment of epilepsy the patients seen were likely to be
representative of those seen in contemporary neurological
practice. Available evidence suggests that the majority of
patients in the community who develop seizures de novo are
referred to a neurology department for assessment,
appropriate investigation and advice concerning initiation of
treatment (Hopkins & Scrambler, 1977; Bodridge & Shorvon,
1983).
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All patients entered into the trials were consecutive new
referrals with previously untreated seizures. Cross-sectional
selection was avoided in that patients already attending the
department -for treatment o-f epilepsy were not considered.
Some patients, although presenting with recent onset of
seizures, gave a history of one or more attacks, often
occurring many years previously. These were considered for
inclusion only if they had never received anticonvulsant
medication at any time.
3. Patients Excluded
The following groups were excluded from the study:
a. Those with a progressive neurological disorder such as
brain tumour which was apparent at the time of diagnosis. A
number of patients developed tumours during the course of
follow-up and these have been included in the analysis of
prognosis.
b. Seizures occurring in the context of acute metabolic
disturbance such as hypoglycaemia, uraemia or liver failure.
c. Seizures occurring in the context of an acute
neurological disorder such as meningitis, stroke or
immediately following head injury.
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d. Seizures precipitated by drugs or ocurring in the context
o-f alcohol dependence.
e. Febrile convulsions. Patients who gave a past history o-f
febrile convulsions and subsequently presented with a history
of apparently unprovoked seizures were included.
4. Assessment of Patients
At the time of first assessment in the neurology outpatients
department a full history and a general and neurological
examination was undertaken in the usual manner. In each case
particular attention was paid to obtaining a full witnessed
history of the seizures that had occurred. The dates of
individual seizures were obtained from the patient and these
were supplemented by information obtained from the referring
general practitioner or casualty officer. In many instances
the date of the first and often subsequent attacks had been
recorded by the referring doctor.
In patients who entered the pilot study and the MRC trial the
fallowing investigations were undertaken in all cases.
-Haematology: a full blood count was performed in the
haematology laboratory at Kings College Hospital. Serum
Vitamin B12 levels and serum and red cell folate estimations
were carried out at Northwick Park Hospital in the laboratory
of Dr I. Chanarin.
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-Biochemical Screen: an automated analysis o-f urea and
electrolytes, random blood glucose, calcium, phosphate and
serum proteins and liver enzymes was carried out in the
hospital laboratory.
-Syphylis serology: a routine screen o-f VDRL and TPHA was
carried out. As the catchment area contained a high
proportion of patients of Afro-Caribbean origin a number
showed false positives due to cross reaction with yaws. These
patients were admitted to hospital for CSF examination to
exclude active syphilis.
-Pre treatment EEG. These were done by the tecnical staff in
the neurophysiology departments at the Maudsley and Kings
College Hospitals. Routine 16 channel records were obtained
in the resting state and following hyperventilation and
photic stimulation. The records of patients entering the MRC
trial were reported upon by the author.
CT brain scans were carried out on the majority of patients
entering the pilot study and all those in the MRC trial.
F'retr eatment psychometric assessment, which included
performance, verbal and full scale ID and a further battery
of tests to examine the effects of anticonvulsant drugs on
cognitive function were performed on all patients entering
the MRC trial.
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5. Data Collection and Definitions
The clinical data relating to each of the patients was
recorded on a proforma which has been reproduced in Appendix
1. The -following de-finitions were used.
i. Age of Onset: The age at the time of the first afebrile
seizure.
ii. Classification of Seizures: Seizures were classified on
clinical grounds in accordance wtih the revised version
proposed by the Commission on CIassification and Terminology
of the International League against Epilepsy <1981). Tonic
clonic seizures were diagnosed on the basis of sudden loss of
consciousness with convulsive movements of the limbs, tongue
biting and incontinence. They were classified as partial
seizures secondarily generalised if there was evidence of a
significant aura or post ictal localising signs such as Todds
paralysis. Partial seizures were diagnosed on clinical
grounds and designated complex or simple using the criteria
of the international classiflcation. Petit mal was diagnosed
on the basis of a characteristic history of absence seizures
occurring in childhood in association with three per second
spike and wave seen on the EEG.
iii Symptomatic Epilepsy: Epilepsy was considered symptomatic
if there was evidence from the past history or examination,
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or evidence on C.T. scan, o-f a cerebral lesion likely to
cause seizures. Post traumatic epilepsy was diagnosed on the
basis o-f a past history of a significant head injury
associated with skull fracture or a prolonged period of
unconciousness greater than 24 hours (Caveness et al , 1979) .
Epilepsy related to CNS infection was diagnosed if there was
a clear history of previous bacterial meningitis or viral
encephalitis.
iv. Family History: Epilepsy in first degree or second degree
relatives was defined as the occurrence of two or more
afebrile seizures, regardless of causation.
v. Associated Handicaps: A neurological handicap was
defined as the presence of significant neurological deficit
such as a hemiparesis or the presence of cognitive impairment
with a full scale ID of below 85. A pyschiatric handicap was
defined as previous psychiatric illness or a similar disorder
arising during treatment of epilepsy which was of sufficient
severity to justify referral to a psychiatrist. A social
handicap was said to occur if social difficulties arose that
were of sufficient severity to justify referral to a social
wor ker.
vi. EEG Features: The abnormalities on the pretreatment EEG
were classified following review of the records. The
abnormalities on the EEGs for patients entered into the pilot
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study were listed as -follows: the presence or absence of
epilepiform abnormalities; the presence or abscence of slow
wave changes which were subdivided into focal or generalised
and were graded in severity as + ,++ or +++. In patients
entering the MRC trial the records were graded into abnormal
or normal. Abnormal records were further subdivided into
those with slow wave or epileptiform abnormalities, either
focal or generalised.
6. Treatment and Follow up
It was the general treatment policy throughout the
period of pilot study and the MRC trial to initiate
medication only after the occurrence of two or more seizures.
In view of the lack of clear guidance in the literature
decisions were often made on the basis of individual clinical
assessment. In a patient who had experienced two apparently
unprovoked seizures during the space of one year there was
general agreement that treatment was needed. If however only
a single seizure had occurred, the intervals between attacks
exceeded one year or some of them were related to acute
precipitating events such as lack of sleep then treatment was
often witheld and the patient kept under observation. In a
small number of patients, particularly children in whom the
initial attack was a prolonged generalised convulsion,
treatment was given following a single seizure. The decision
to start treatment in patients with partial seizures was made
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on the basis o-f clinical judgment alone. In the great
majority o-f instances these patients had experienced a large
number of attacks, often occurring over a prolonged period of
time, and the decision to treat presented few problems. A
number of patients with partial seizures, particularly if
these were not associated with any disturbance of
consciousness, declined treatment.
It was the treatment policy during the period of both pilot
study and the MRC trial to use a low starting dose of drug
which was then increased on the basis of clinical response.
The total daily starting doses for phenobarbitone, phenytoin,
sodium valproate and carbamazepine were 60 mg, 200 mg, 400 mg
and 200 mg respectively. Each of the drugs were given as
twice daily divided dosages. If seizures continued the dose
of the drug was increased until an optimum anticonvulsant
level was obtained. The increments in dosage for phenobarb-
itone, phenytoin, sodium valproate and carbamazepi ne were
30mg, lOOmg, 200mg and 200mg respectively. If seizures were
controlled on a suboptimum anticonvulsant level no further
adjustment were made to the dosage. Patients who experienced
two or more seizures despite an optimum level, in the
abscence of evidence of poor compliance, were considered to
have failed on monotherapy. In these patients the potential
for addition of a second drug was considered.
Following the initial assessment in the general neurology
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outpatients department patients were subsequently -followed in
a special epilepsy clinic. Patient were initially seen at
intervals of two to three months. This policy was modified
depending on clinical response. Some patients who presented
difficulties in seizure control were seen at shorter
intervals whilst those who entered prolonged remission were
given six month follow-up appointments. Every effort was made
to maintain complete follow up. Patients who failed to attend
were written to personally and if no response was obtained
from two letters information concerning outcome was obtained
from their general practitioner.
7. Analysis and Statistics
As was noted previously there are a number of difficulties in
developing appropriate statistical methods for analysing
prognosis in epilepsy. Throughout this thesis widespread use
has been made of actuarial statistics. The technique was
initially developed to measure survival rates amongst groups
of people with particular risk factors such as smoking or
hypertension and is widely used in this manner by insurance
companies. They gained particular importance in medical
research in analysing outcome in trials of cancer treatment
where the endpoint being measured was death of the patient
(Peto et al, 1977). There first application to analysing
prognosis in epilepsy was carried out by Alstrom (1950) who
measured the actuarial percentage of patients achieving five
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year remission by duation of -follow-up. They were
subsequently used by Annegers et al (1979) to analyse outcome
in a community based study carried out in Rochester,
Minnesota.
Actuarial analysis has two main advantages. The probability
of the event occurring during each interval of follow up is
related to the number at risk. This method, therefore, takes
account of variable follow up using all available data.
Secondly, the first occurrence of the event, for example, one
year remission on treatment, is measured and the survival
curve indicates the temporal relationship of remission to
duration of follow up.
The method of derivation of the survival curve is simple. The
total period of follow-up is divided into appropriate
intervals, for example two or six months (Elwes et al, 1982).
During each interval there are two possible outcomes. The
patient may end or be lost to follow up, or the particular
event that is being measured (the event of interest), for
example death of the patient, may occur. One hundred
patients may enter the study and during the first two month
interval of follow up five will die and a further five will
end follow up. The probability of dying during the first
interval is 0.05. The probability of surviving is 1 - this
measure, or 0.95. Ninety patients enter the next follow-up
period, the so called number "at risk" for this interval.
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Similar probabilities of survival are calculated for those
those at risk for each succesive interval and are multiplied
to give the cumulative probability of survival. This gives
rise to the characteristic stepwise decrease of the survival
curve. A further adjustment is needed as it is assumed that
if patients end follow up during an interval it will, on
average, occur in the middle of that interval. Using these
principles a computer programme was written by the author to
analyse some of the prognostic variables considered in the
following chapters (see appendix 2).
The following prognostic parameters have been analysed using
actuarial statistics: seizure recurrence following a first
seizure; first seizure recurrence after starting treatment;
first one and two year remission on treatment and first
seizure recurrence after achieving remission. A number of
general observations relating to the interpretation of
survival curves should be empasised. It is of crucial
importance that the number of patients at risk be clearly
indicated on the figure. As was explained above this
figure does not nessesarily correspond to the number of
patients being followed up. When the number of patients at
risk becomes small, it is unusual for the event of interest
to occur. This leads to a prolonged flattening of the curve
and a tendency for large variations and unreliable data at
the end of follow up . Secondly it should be emphasised that
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survival curves measure the cumulative probability of the
occurrence of the £ir5t_eyer event o-f interest. For example
each time a patient enters a -first ever one year remission
the curve rises and that patient is subsequently discounted
from the analysis. The actuarial percentages given in the
figures and quoted in the text refer to the cumulative
probability of ever having been in remission, not those in
remission at the particular point in time.
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CH^R-TER THREE
THE PROGNOSIS FOR SEIZURE CONTROL IN NEWLY DIAGNOSED
EPILEPSY
A. INTRODUCTION
Virtually all the literature on the prognosis -for seizure
control in epilepsy has been based on the observation of
patients with chronic epilepsy. In many of these patients,
who accumulate in considerable numbers in specialised
neurology or epilepsy clinics, the outlook for seizure
control is poor. This has led many authors to emphasise
the gloomier and less satisfactory aspects of prognosis in
epilepsy (Rodin, 1968). In contrast the initial response
to treatment and the prognosis during the early years of
epilepsy have received only scant attention in the
literature. In this Chapter an analysis of the outcome in
106 patients, who were followed prospectively from the
onset of the disorder for periods of up to eight years,
will be presented. The results will be presented with the
following aims:
1. To analyse the prognosis for seizure control in newly
diagnosed epilepsy
2. To assess the factors that are useful in
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predicting prognosis at the onset of treatment
3. To assess the importance of the initial response
to treatment in determining the subsequent prognosis
in epilepsy
B. PATIENTS AND METHODS
The patients who form the basis of this study were all
new referrals to the adult neurology clinic at Kings
College Hospital seen over a five year period between
1974 and 1979. One hundred and six patients were
identified and entered into a pilot study of
monotherapy in newly diagnosed epilepsy. The details
concerning the methods of patient selection, assessment
data collection and treatment have been described in the
previous chapter.
All patients were consecutive new referrals with
previously untreated seizures. Cross-sectional selection
was avoided in that patients already attending the
Department for treatment of epilepsy were not
considered. Each patient had experienced at least
two tonic clonic seizures in the previous year and/or
sufficient partial seizures to warrant treatment. The
following groups of patients were excluded from the
133
study: patients with petit mal or myoclonic epilepsy;
patients with progressive neurological disorders which were
apparent at the time of -first diagnosis; patients with
seizures occurring in the context of fever or acute metabolic
or neurological disorders.
A proforma was produced for each patient (see Appendix 1)
recording the appropriate details concerning seizure history,
past medical, social, psychiatric and drug history as well as
the general and neurological examination and the results of
initial investigations. The data for all 106 patients are
shown in Appendix 3.
Following the initial assessment and investigations,
treatment was started with phenytoin or carbamazepine on a
non-randomised basis. The starting doses were 200 to 300
mg. for phenytoin and 200 to 600 mg. for carbamazepine, both
in two divided doses. If seizures continued the dose was
increased by 50 to 100 mg. increments for phenytoin and 100
to 200 mg. increments for carbamazepine until optimum
anticonvulsant levels were obtained. If seizures were
controlled on a sub-optimum level no further adjustment was
made to the dosages. Optimum concentrations for phenytoin
were 40 to 80 micromol/1 and for carbamazepine were 16 to 32
micromol/1.
Patients were followed prospectively in a special epilepsy
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clinic at intervals of two to three months although this
varied depending on clinical need. For those patients who
■failed on treatment with monotherapy the policy was to add
another drug and increase the dosage in an attempt to
control seizures; i-f this occurred the initial drug was
subsequently withdrawn.
In analysing seizure control all patients were included,
regardless of medication status, up to the time of the last
follow up. The occurrence of partial or tonic clonic
seizures was noted at each clinic visit. If the timing of a
seizure during the previous interval of follow up was
uncertain it was assumed to have occurred in the middle of
that interval. A preliminary analysis was undertaken by
dividing the total follow-up period into six month intervals
(Elwes et al, 19S2). The prognosis for seizure control was
assessed by measuring the actuarial percentage of patients
achieving one and two year remission. On the basis of these
initial results a more detailed study was done. The total
follow up period from the time of starting medication was
divided into two month intervals and the presence or absence
of tonic clonic, partial or both seizure types for each two
month interval period was recorded, see Appendix 4. The
analysis of prognosis presented in this Chapter is based
upon these data.
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Kaplan - Meier Survival Curves were used to analyse the
outcome (Kaplan & Meier, 195S). The following parameters
were used: Time to first seizure, first one year remission
and first two year remission and time to first seizure after
periods of one, two, three and four years seizure free. The
analysis was performed for partial seizures, tonic clonic
seizures and all seizures combined. Factors of prognostic
significance were assessed by comparing the actuarial
percentages of patients achieving one year remission. The
significant values of prognostic factors were assessed using




The characteristics o-f the patients entered into this study
are shown in Table 3:1. Fifty-one patients (487.) were male
and 55 (52%) were -female. The median age at -first seizure
was 23, with a range o-f onset between 6 and 77 years. Fifty
nine patients (557.) had experienced tonic clonic seizures
alone prior to treatment, 22 (217.) had partial seizures
alone and 25 (247.) patients had partial and secondarily
generalised seizures. Eighty four patients experienced tonic
clonic seizures. In assessing pre-treatment tonic clonic
seizure frequency three patients who experienced only one
seizure and two patients with poor documentation of the
total number of attacks were excluded from the analysis. In
the remaining 79 patients, 45 (57%) had a high pretreatment
seizure frequency, defined as two or more seizures per month
and 34 patients (437.) had a low seizure frequency.
Thirty five patients (33%) had symptomatic epilepsy. The
commonest causes of epilepsy were cerebrovascular disease in
7 patients, post traumatic in 4, central nervous system
infection (meningitis or encephalitis) in 5 and a birth
injury in a further 5 patients. One patient with
achondroplasia was found to have a benign tumour, the nature
of which was not established, and two patients developed
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TABLE 3:1 CHARACTERISTICS AND FOLLOW-UP INTERVALS IN 106





Median Age At Diagnosis(years) 23(Range 6-77)
Seizure Type
Tonic Clonic Alone 59(55)
Partial Seizures Alone 22(21)
























Median Follow-up, months 66 (range, 6-96)
Total 106(100)
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gliomas during the course of treatment. One patient had
tuberous sclerosis and another had an undiagnosed
syndrome with mental retardation associated with a
-familial neuropathy. Abnormalities were found on CT brain
scan in 8 patients which consisted of generalised cortical
atrophy in in 3 patients, focal atrophy in 2 patients and
enlargement of one temporal horn in a further three
patients.
An associated neurological handicap was present in 11
patients. Amongst these patientsp 8 were mentally retarded,
3 had acquired cognitive deficits and 3 patients had a
hemiplegia. Thirty one patients developed psychological
disorders of sufficient severity to warrant referral to a
pyychiatrist. The commonest diagnosis was an affective
disorder, usually depressive illness (19 patients), or a
pesonality disorder (7 patients). One patient developed
anorexia nervosa and two developed psychotic illnesses.
Routine 16 channel pre-treatment EEGs were undertaken prior
to treatment in all patients. In 14 patients the resting
record and the response to overbreathing and photic
stimulation was normal. Forty one patients had epileptic
abnormalities which were generalised spike and wave in 8
patients and focal abnormalities, mostly in the temporal
region, in the remaining records. Eighty two of the EEGs had
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abnormalities of the background rhythms which were
classified as minor in 38 instances and moderate or severe
in the remaining 44. On completion of the study, eight
patients had been lost to follow up after a median of 1.9
years. Five patients were followed for less than two years,
14 patients between two and four years, 48 patients between
four and six years and the remaining 39 between six and
eight years. The median follow up was six and a half years.
2. Treament Outcome
Sixty one patients were treated with phenytoin and 45
with carbamazepine. Anticonvulsant levels were monitored
and the dosage only increased if further seizures
occurred with anticonvulsant levels below the optimum range.
Patients who experienced two or more seizures despite
an optimum anticonvulsant level were considered to have
failed on monotherapy and the addition of a second drug was
considered. Nine patients continued to have seizures and
never achieved an optimum anticonvulsant level despite
progressive increases in dosage, presumably because of poor
compliance. Twenty one patients failed on treatment, by one
year in 13, by two years in 19 and by six years in further
two. At the end of the study, after a median follow up
of five and one half years, 78 patients were still on
monotherapy of whom 70 were taking the original prescribed
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drug. Ten patients were taking two drugs and treatment had
been discontinued in eighteen. Six patients underwent
successful planned anticonvulsant withdrawal and twelve
patients stopped treatment of their own accord.
3. First Seizure Recurrence
The majority of patients experienced at least one further
seizure after starting treatment. Amongst the 80
patients who had a recurrence 35 did so by two months, 44
by four months, 51 by six months and 82 by one year. One
patient was seizure free and lost to follow up at
six months.
The actuarial percentage of patients who remained
seizure-free by duration of follow-up is shown in Figure
3:1. Fifty per cent remained seizure-free by six months,
40"/. by one year, 347. by two years, 247. by four years and
217. by eight years.
The pre-treatment tonic clonic seizure frequency had a
marked effect on the probability of remaining seizure
free after starting treatment. Figure 3:2 shows the
actuarial percentage seizure free by duration of follow up
for those with a high and low pre-treatment tonic
clonic seizure frequency. Not only did those with a high
seizure frequency relapse more quickly but 247 remained
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FIGURE 3:1 PROGNOSIS IN NEWLY DIAGNOSED EPILEPSY : THE




FIGURE 3:2 ACTUARIAL PERCENTAGE OF PATIENTS REMAINING
SEIZURE FREE ON TREATMENT: THE INFLUENCE OF PRETREATMENT
TONIC CLONIC SEIZURE FREQUENCY
Broken Lines = Patients with a low pretreatment seizure
■frequency (Less than two seizures per month). N=34
Solid Lines = Patients with a high pretreatment seizure
frequency (Two or more seizures per month). N=45
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seizure -free, compared to 41% amongst patients with a low
pre-treatment -frequency < = 5.44, d.f. = 1, p = 0.02). No
other clinical feature was significantly associated
with the probability of remaining completely seizure-free
from partial seizures, tonic clonic seizures or all
seizure types.
4. Seizure Control
The prognosis for seizure control was assessed by analysing
the actuarial percentage of patients in whom seizures were
suppressed completely for periods of one and two years
(Figure 3:3). The figures represent the cumulative
probability in actuarial percentages of ever having been
seizure free. A one year seizure free period occurred in 40%
by one year, in 73% by two years, in 84% by three years, in
88% by four years, and in 89 and 92% by five and eight years
respectively. The majority of remissions occurred shortly
after starting treatment; at the end of the first year of
treatment, 75% of patients who were going to remit were
either in or entering a one year remission period.
The results for two year remissions were similar as the
majority of patients who were seizure-free for one year
subsequently went onto a second year with no seizures. The
actuarial percentage of patients achieving two year
remission was 35% by two years, 57% by three years, 73% by
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FIGURE 3:3 THE ACTUARIAL PERCENTAGE OF PATIENTS SEIZURE























Solid lines - One year seizure-free
Broken lines = Two years seizure-free
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■four years, 797. by -five years and 827. by eight years.
5. Relapse Rates following First Remission
In the previous section the prognosis was determined by
analysing the actuarial percentage of patients in whom all
seizures were controlled for periods of one and two years.
Using this method of analysis, once a remission had occurred,
the data relating to further follow up was censored. It was
apparent, however, that following remission a number of
patients subsequently experienced a seizure relapse.
The numbers of patients achieving one, two, three and four
year remission and the subsequent relapse rates for each
group are shown in Table 3:2. In the 89 patients who
experienced a one year remission, the relapse rate was not
inconsiderable. It occurred in 227. by one year of follow up,
327. by two years, 447. by three years and 487. by 4 years. With
increasing periods of remission, however, the relapse rate
fell such that in patients who had been seizure free for four
or more years only 177 experienced a subsequent seizure
recurrence.
The prognosis has been examined in more detail in 76 patients
who achieved two year remission and in whom further follow up
data were available. Relapses occurred in 25 patients. In
17 cases these were isolated events consisting of one or two
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TABLE 3:2 THE PERCENTA6E OF PATIENTS EXPERIENCING A RELAPSE
AFTER PERIODS OF ONE, TWO, THREE AND FOUR YEARS SEIZURE-FREE
Remission Number o-f Number Actuarial Recurrence Rates
1 89 29 (33) 22 32 44 48
2 76 25 (33) 14 27 36 39
3 59 11 (19) 17 26 31 31
4 42 6 (14) 8 17 17 17
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seizures and in 16 could be directly related to poor
compliance with medication. The combined -follow up for all
76 patients following the first two year remission was 253
years. If the total follow up period was divided into 2 month
intervals then seizures occurred in 52 of these intervals,
that is to say only 37. of the total. It appeared that once a
two year remission had occurred the prognosis was extremely
good and no patient developed intractable epilepsy.
6. Patients Failing to Achieve Remission
Patients who failed to achieve a period of at least one year
completely free of all seizures had a uniformly poor
prognosis. They were followed for a total of 63.5 years. In a
similar manner to the previous section this was equivalent to
a total of 376 two month intervals of follow-up. During each
of these intervals no seizures occurred on only 39 occasions,
or 107 of the total follow-up.
7. Prognostic Factors
An analysis of the factors that were useful in predicting
prognosis were performed by comparing the percentages of
patients who achieved one year completely free of all
seizures. The results are summarised in table 3:3 and figure
3:4. The presence of partial seizures (Log - Rank Statistic:
9.1, d.f 2, p = 0.011); a family history of
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Male 51(48) 40 77 95
Female 55(52) 48 70 84
Age of Onset (years)
10-19 33(31) 35 69 83
20-29 2B(26) 40 65 81
30+ 39(37) 46 71 96
Seizure Type
Tonic Clonic Alone 59(56) 46 B3 97
Partial Seizures Alone 22(21) 23 54 73
Mixed 25(24) 38 66 89
Pretreatment Tonic Clonic
Seizure Number
Two 24(30) 57 65 95
Three 24(30) 54 83 96
Four or More 32(40) 54 83 83
Pretreatment Tonic Clonic
Seizure Frequency
Hi gh 45(57) 36 74 93
Low 34(43) 56 88 100
Symptomatic Epilepsy
Present 35(33) 26 62 84








































Minor Slow Wave Changes 38(36)








FIBURE 3:4 THE ACTUARIAL PERCENTAGE OF PATIENTS SEIZURE
FREE FOR ONE YEAR: PROGNOSTIC FACTORS
YEARS OF FOLLOW UP
151
epilepsy ([X = 5-4, d.f. = l,m p = 0.02); a high -frequency
of tonic clonic seizures before treatment ( JC*~= 5.3, d.f. =
- £
1, p = 0.02); symptomatic epilepsy ( Jv, = 3.8, d.f. = 1, p =
t.
0..05), or a social ( tX = 11.6, d.f. =1, p < 0.001),
,r-l.
or a psychiatric handicap ( 0^ = 4.3, d.f. =1, p =
0.038) predicted a worse prognosis.
Age at onset of seizures was not of prognostic value. Patient
with noctural seizures had a better prognosis and those with
a high pretreatment number of tonic clonic seizures tended to
do worse but in neither instance did this reach significance.
The pretreatment EEG appeared to be of little value in
predicting prognosis. The presence or absence of epilep¬
tiform features was not associated with outcome. Patients
with moderate of severe slow wave abnormalities in the pre
treatment EEG tended to respond less well to treatment but
this again failed to reach statistical significance.
8. The Early Response to Treatment
The influence of the early response to treatment on
subsequent seizure control was also assessed (figure 3:5).
Ninety two per cent of all patients achieved a one year
period completely seizure free. In 63 patients who had
seizures during the first year of treatment, 77% were
controlled and in 32 who continued to have seizures during
the second year 577. were controlled. If seizures continued
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FIGURE 3:5 THE INFLUENENCE OF DURATION OF SEIZURES ON THE
















YEARS OF FOLLOW UP
6 8
105 27 15 11 8 5 4
S3 60 19 19 10 7 5
20 20 13 9 6 4
Solid lines = All patients from the start of treatment
Broken lines = Patients with seizures in the -first year o-f
fol1ow-up
Dotted lines = Patients with seizures in the second year of
fol1ow-up
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for up to two years after the start o-f treatment, the
probability of a subsequent achieving a remission had fallen
by about one half.
9. Poor Compliance with Medication
An assessment of compliance with medication was undertaken in
95 patients in whom adequate data was available. Three
criteria were used to identify patients who were thought to
comply poorly with medication.
a. Patients who admitted to seizures related to abrupt
withdrawal of anticonvulsants on two or more
occasions.
b. Patients in whom an optimum anticonvulsant level was
never achieved despite progressive increase in
dosage.
c. Patients who showed variable anticonvulsant levels
whilst taking a constant dose of a drug. Variable
drug levels were defined as two or more instances
on which the level showed a greater than 507.
variation about the mean whilst on any given dosage.
154
Complete data was available in 95 patients. Using these
definitions 15 patients experienced two or more withdrawal
seizures, 9 patients failed to achieve an optimum
anticonvulsant levels and 29 had varying drug levels whilst
on any given dosage. Forty two patients (44/1) had evidence of
one or more of these factors.
An analysis was undertaken to identify groups of patitnts in
whom poor compliance was more prevalent (table 3:4). Sex,
age, seizure type, etiology of epilepsy or associated
handicaps were not significantly associated with poor
compliance. Poor compliance however was commoner amongst
patients taking phenytoin and also those who gave a history
of one or more episodes of acute anticonvulsant toxicity.
Amongst 60 patients taking phenytoin, 33 (55"/.) showed poor
compliance and 9 out of 35 (25%) in those taking carbamaz-
apine (^ = S.86, p = 0.01). Acute toxic effects were
recorded in 26 patients of whom 17 (65%) showed poor
compliance compared with 25 out of 69 (36%) with no such
history (^ = 7.69, p — 0.01).
The influence of poor compliance on prognosis was assessed by
comparing the actuarial percentage of patients achieving one
and 2 years completely free of seizures. There was no
significant difference in outcome between the two groups.
Poor compliance did, however, appear to be important in
determining relapses in patients who were in remission. Of
1 crcr1 wJuJ
TABLE 3:4 POOR COMPLIANCE WITH MEDICATION; PREVALENCE AND
CLINICAL CHARACTERISTICS AMONG 95 PATIENTS WITH NEWLY
DIGNOSED EPILEPSY










Age of Onset of Epilepsy
16 years or less 19











































All patients 95 42(44)
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the 79 patients who achieved two years completely seizure
-free, -follow up was available in 76. Q-f these 25 experienced
a relapse and in 16 cases this was due to an abrupt
withdrawal of drugs. In a further 4 evidence of widely
varying anticonvulsant levels was found.
10. Prognosis in Patients Treated with Polytherapy.
Eleven patients who failed on monotherapy were treated with
polytherapy for a period exceeding 6 months. Nine patients
had initially received phenytoin and two were given
carbamazepine. The median duration of follow-up on
polytherapy was 2.5 years (range, 0.5 to 5.5 years). Six
patients continued to have seizures in every two month
interval of follow-up. A further 3 had an initial 2 month
seizure free period but subsequently relapsed with an
intractable seizure disorder. Two patients achieved a period
of at least one year seizure free whilst on polytherapy.
Both had complex partial seizures of temporal lobe origin,
were started on treatment with phenytoin and within one year
were given carbamazepine. It is difficult to reach a firm
conclusion on the possible benefits of polytherapy on the
basis of these data. The numbers of patients requiring
polytherapy was small, treatment decisions were not made on a
randomised basis and the statistical analysis did not take
account of short term changes in seizure frequency. They do
suggest, however, that about one fifth of patients who fail
on monotherapy subsequently achieve a prolonged remission of
seizures following the addition of other drugs.
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D. DISCUSSION
1. Remission Rates in Epilepsy
In this study the prognosis for seizure control in newly
diagnosed epilepsy was good. Twenty six patients remained
completely seizure -free -for a median period of 64 months. At
the end of follow up the cumulative probability of ever
having been two years completely free of all seizures was
B2"/.. After a two year remission had been achieved the
subsequent prognosis was good and most patients remained
seizure free for as long as they were followed. Relapses,
when they occurred, were usually isolated events often
related to poor compliance.
The most authoritative and widely quoted work on the
prognosis of patients with epilepsy is that published by
Rodin (1968). In view of its importance, it was discussed in
some detail in Chapter 1. Rodin's initial, and possibly most
important conclusion, was that only one-third of all
epileptic patients are likely to achieve a terminal remission
of at least two years. Rodin based this statement on a review
of the literature and the results of the most important
prognostic studies have been summarised in Table 1:11.
However, if the methodology in each of these studies is
subjected to more careful analysis, a number of important
deficiencies are apparent.
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Di -f f i cul t i es have arisen in the i nterpretat i on of previous
prognostic studies -from a number o-f causes. These have
included retrospect i ve analyses, di-f-fering methods o-f
classification and de-finiition of epilepsy and poor
documentation of treatment methods. The single most important
consideration, however-, has been patient selection. All
previous prognostic studies have been based on the cross
sectional selection of patients attending specialised
epilepsy or neurology clinics; that is to say patients who,
at a particular point in time, were attending a clinic or
institution for treatment were selected for follow up. The
major deficiency of this method is that such clinics or
institutions will be strongly biased towards following up
patients with chronic epilepsy whose seizures have proved
difficult to control.
This can be illustrated by examining the mean duration of
epilepsy prior to entry into the follow-up period in some of
the prognostic studies that have been undertaken (Table 3:5).
In the study by Alstrom (1950) the mean duration of active
epilepsy was 13.5 years and only 22% acieved remission. In
the others most patients have suffered from epilepsy for
periods of at least 2 to 6 years and the outlook is equally
poor. Unfortunately a number of authors have not supplied
this crucial information and the results are therefore
difficult to interpret and have been excluded from the Table.
Is is clear from a careful reading of the methodology that
159
TABLE 3:5 HOSPITAL BASED STUDIES OF THE PROGNOSIS OF
EPILEPSY. DURATION OF ILLNESS PRIOR TO INCLUSION OF
PATIENTS INTO THE STUDY
Author Duration o-f Percentage in
Epilepsy, years Remission
Alstrom, 1950 13.5 22
Strobos, 1959 6 38
Kiorboe, 1960 <5 32
Kuhl et al, 1961 1.25 61
Trolle, 1961 3.2 37
Juul-Jensen, 1963 >2 32
Currie et al, 1971 6 40
Janz, 1972 >2 44
Okuma & Kumashiro, 1981 <5 58
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all of them contain a high proportion of cases with chronic
intractable epilepsy.
The impact that this form of patient selection may have had
is illustrated by the only two studies that have examined
prognosis in epilepsy of short duration. Both of these
studies showed a considerably better prognosis than that
suggested by Rodin(1968). Kiorboe (1960) studied 156 patients
with onset of seizures after the age of seventeen. The author
stated that, unlike other prognostic studies, patients with
epilepsy of short duration (less than five years) were
selected. After a follow up of four to seven years 14 had
died and 12 were lost to fallow up. Df the remaining 130
patients, 41(31%) had been completely seizure free. However,
a further 27 patients, after an initial relapse, subsequently
became seizure free, giving a final remission rate of 68 out
of 130 or 52"/.. In a further publication Kuhl et al , (1967)
added another 60 patients to the original series using a
similar method of selection. The mean duration of epilepsy
before entering into the study was 1.25 years. One hundred
and five patients (61%) had a period of at least one year
completely seizure free. The Japanese Multi Institutional
Study (Okuma ?< Kumashiro, 1981) used a similar method of
selection to the previous authors, namely a duration of
epilepsy less than five years in all patients entered. The
authors note that their remission rate of 58% cent was
considerably higher than that quoted by Rodin (1968). They
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attributed this to advances made in treatment, although no
details concerning which methods were actually used were
given anywhere in the paper. It is more likely that the
favourable outcome was the result of patient selection.
2. Relapse Rates Following Remission of Seizures
In his text Rodin (196S) emphasised the tendency of epilepsy
to relapse. Although a period of satisfactory seizure control
may occur, the usual course is that after a period of time
seizures will recur. Because of the tendency of epilepsy to
relapse Rodin thought that the disease was likely to be
chronic in as many as 80X of cases.
In contrast to Rodin's conclusion, in the present study all
the determinants of outcome showed improving prognosis with
increasing duration of follow up. Remission rates, although
highest in the first one to two years of treatment, continued
to increase on further follow up (see Figure 3:3). It was a
striking observation that once a remission had occurred
within the first few years the subsequent development of an
intractable seizure disorder was most exceptional. Although
a third of patients experienced at least one more seizure
after achieving two year remission these were almost always
isolated events. On prolonged observation these patients
only experienced seizures in 3% of the subsequent follow up
intervals. Furthermore, in a high proportion of these cases
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seizures would be directly related to poor compliance with
medication and with increasing duration of remission the
probability o-f experiencing a relapse tell progressi vel y (see
Table 3:2).
The present study was based on follow up of patients for
periods of up to eight years from the time of initial
diagnosis. It is possible that over time a number of cases
would have experienced a recurrence of active epilepsy.
There are few studies in the published literature that have
provided both prolonged follow up and have attempted to
carefully document relapse rates. In the retrospective
community based survey by Annegers et al. (1979) patients
were followed for periods of up to 20 years. Relapse rates
were measured by comparing the percentage of patients who had
ever been in remission with those whose seizures were
controlled at the end of follow up. At no time was the
difference between these two figures greater than 10%.
Goodridge & Shorvon (1983) in a similar study found that once
a remission had occurred it was usually permanent.
If after an initial good response to treatment seizures
recur, the possibility of brain tumour must always be
considered, particularly if a new seizure type develops. In
assessing patients with chronic long standing epilepsy a
history of a previous remission of seizures is occasionally
obtained. Some patients claim that sometime in the past they
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have been seizure -free -for periods o-f two, three or more
years- In the author's experience this course of events is
usually shown to be incorrect -following careful scrutiny of
the individual case history. Sometimes the initial seizures
occurred early in childhood and subsequently prove to have
been febrile convulsions. The period of remission may have
been in fact a change in seizure type which can occur during
the course of chronic epilepsy. A witnessed history
subsequently shows that during this supposed period of
remission the patient continued to have short lived attacks
that were often unnoticed. Prolonged remission of seizures
followed by the development of an apparantly intractable
seizure disorder may be particularly common amongst patients
who are subsequently discovered to have pseudo seizures or in
whom poor compliance or alcohol abuse is a cause of the
recurrence.
3. Treatment
Treatment has, in general, received only scant attention in
prognostic studies. It is apparent that in the retrospective
surveys reviewed in Chapter 1 treatment was often undertaken
by a number of doctors with no consistent management policy.
Many authors (Kirstein, 1942; Kiorboe, 1960; Probst, 1960;
Janz, 1972; Ohtahara et al, 1977; Okuma & Kumashiro, 1981;
Sofijanov, 1982) made no mention at all of treatment whilst
others only give a list of drugs used ( Strobes, 1959;
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Currie et al , 1971). Serum anticonvulsant level monitoring
is only mentioned by Schmidt et al. (19S3) yet even here it
was apparent that this was undertaken in only a small
proportion of patients. This deficiency was even greater in
the retrospective community based surveys. Annegers et al.
(1979), Sillanpaa (19B3) and Brorson & Wranne (19S7) make no
mention of treatment methods whilst Goodrigde & Shorvon
(1983) found that surveillance and audit of treatment was
generally poor, drug concentrations rarely measured and that
there was, in general, "an insoucient attitude to many
aspects of treatment."
Rodin (1968) identified two aspects of treatment which were
of crucial importance in determining the prognosis of
epilepsy. Firstly the need to monitor anticonvulsant levels
such that drugs were used to optimum effect and secondly the
impact of poor compliance with medication on seizure
control.
a. Anticonvulsant Level Monitoring
In the present study all patients were initiated on treatment
with monotherapy with a low starting dosage. Anticonvulsant
levels were checked and if seizures continued the dosage was
increased until the level was in the optimum range. A second
drug was added only if two or more attacks had occurred
despite an optimum anticonvulsant level. In those patients
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who took their prescribed medication on a regular basis,
treatment was, there-fore, optimised.
Therapeutic serum levels have now been established -for the
major anticonvulsant drugs and are in wide clinical usage.
In describing the response to treatment in this thesis the
term "optimum" rather than "therapeutic" anticonvulsant level
has been used. The reason tor this is that the optimum
treatment -for any given patient is not necessarily the
establishment o-f a therapeutic anticonvulsant level. As many
as one quarter of patients with newly diagnosed epilepsy
achieve complete control o-f seizures with anticonvulsant
levels below the the therapuetic range (Shorvon et al, 1978).
Anticonvulsant level monitoring is most firmly established
for phenytoin (Chadwick, 1987). This drug displays non linear
kinetics (Richens & Dunlop, 1975) and small increments in
dosagage can precipitate acute toxic reactions, which on
occasion are irreversible (Reynolds, 1975; Dam 1982). In the
case of carbamazepine seizure control does not appear to be
so closely related to serum concentrations, possibly due to
the presence of active metabolites (Troupin, 1983). Serum
levels of sodium valproate tend to fluctuate because of the
short half life of the drug and there appears to be a delayed
onset in effect, that is independant of anticonvulsant levels
(Dreifuss, 1983). With both these drugs useful improvements
in seizure control without side effects can sometimes be
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achieved with anticonvulsant levels above the therapeutic
range. Conversly other patients may experience unacceptable
toxicity even with levels within the quoted therapeutic
range.
Reynolds St Shorvon (1981) have emphasised that anticonvulant
level is an important help in avoiding and reducing
polytherapy. In patients whose seizures are not controlled on
a single drug, blood concentrations will help identify poor
compliers and those who are being suboptimally treated
allowing the clinician to use the initial drug to maximum
effect before attempting to add another. Similarly, in
patients already on polytherapy, it is not an uncommon
experience that all the anticonvulsant levels are in the
suboptimum range. In these patients useful improvements in
seizure control occur when one drug is given in the correct
dosage and the others are withdrawn.
b. Poor Compliance with Medication
Poor compliance has been identified as a major cause of poor
seizure control by a number of authors and the prevalence of
this problem is said to be as high as 50% of patients (Kutt
et al , 1966, Shope, 1981; Liske St Greene, 1985). These
findings were confirmed in the present study. Twenty-nine
patients showed 50% variations in anticonvulsant levels on
two or more occasions whilst taking the same dosage; 8
patients failed to achieve optimum anticonvulsant levels
despite progressive increases in dosage and 15 patients
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experienced 2 or more withdrawal seizures. Forty-two patients
(427) had evidence of one or more of the above criteria.
Similar evidence of the extensive degree of this problem has
been reported in other prognostic studies. Kuhl et al,(1967)
found that 75 patients who had poor control of seizures, 40
(437.) either did not take any medication or were inadequately
treated. Currie et al, (1971) reported that among 666
patients with temporal lobe epilepsy 75 (127.) took drugs
irregularly whilst in the community survey by Sillanpaa
(1983) poor compliance was said to have occurred in 277 of
patients.
In the present study poor compliance was more common in those
patients with a history of anticonvulsant toxicity and also
in those taking phenytoin rather than carbamazepi ne. These
results however do not necessarily imply a causal
relationship. Because the relationship of dosage to
anticonvulsant level appears to be closer for phenytoin than
for carbamazepine, variability in drug concentrations may be
a more sensitve indicator of poor compliance in patients
taking the former drug. Furthermore, in the same way that
withdrawal seizures may follow poor compliance, if the dosage
is subsequently increased acute toxicity may be precipitated.
The impact of poor compliance with medication on the long
term prognosis for the group as a whole proved hard to
assess. There was a strong clinical impression that it was
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particularly widespread in the early years of treatment in
those who -failed to respond to monotherapy (Chesterman et al ,
1987). In patients whose seizures were poorly controlled
there was often a history of missed follow up appointments or
that the patient had run out of drugs and failed to obtain a
repeat prescription. These patients were often unsure as to
the- dose of drugs they should be taking or had failed to
carry cut previous instructions about changes in therapy.
Others who claimed to be taking a drug on a regular basis
were found to have undetectable serum anticonvulsant levels.
In the present study an attempt was made to use more
objective criteria based on anticonvulsant level monitoring.
Using the methods described above 42 patients were thought to
show significant evidence of poor compliance with medication.
It was an unexpected observation that the long term prognosis
for seizure control did not differ amongst these patients
compared to those who appeared to be taking their medication
on a regular basis.
There are two possible reasons for this. Firstly, it is
notoriously difficult to identify and quantify the degree of
poor compliance in individual patients. It is likely to
occur to some extent in all patients and any attempt to
divide them into "good" and "poor" compliers is to a certain
extent arbitrary. Varying anticonvulsant levels is often a
useful clinical measure and has been reported to correlate
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well with data obtained from questionaires about poor
compliance (Leppik et al. 1980). However this method was
not validated by such measures in the present study.
Secondly, and of particular interest, it is possible that
poor compliance was indeed equally prevalent amongst those
whose seizures were satisfactor i 1y controlled. There is
evidence to support this as the majority of relapses that
occurred after a two year remission had been achieved could
be directly related to patients stopping anticonvulsants
abruptly against medical advice.
4. Prognostic Factors
There has been little previous analysis in the literature of
the factors that are of significance in predicting outcome in
newly diagnosed epilepsy. In the present study these were
analysed by comparing the actuarial percentage of patients
achieving one year completely seizure free. The results have
been summarised in Table 3:3. Before considering some of
these in greater detail, a number of general observations
should be made.
The analysis was based on a relatively small number of
patients. It is likely, therefore, that only those factors
which were of the greatest importance would reach statistical
f
significance. Some authors (Okuma & Kumashiro, 1981; Shorvon
& Reynolds, 1982) have reported that patients who experience
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only nocturnal seizures tend to have a better prognosis. In
the present study 28 patients experienced attacks only at
night. In this group the one year remission rates were 36% by
one year, 80% by three years and 96% by -five years. In the
remaining 78 patients who experienced seizures during
waking hours the corresponding remission rates were 40%, 60%
and 80%. This difference just -failed to reach significance
with a p value of 0.09. It would be incorrect, however, to
conclude that the timing of seizures has no impact on the
prognosis in newly diagnosed epilepsy as this difference
might have reached statistical significance with a greater
number of patients. Similarly patients with a large number of
pretreatment seizures and those with diffuse slowing of
background rhythms on the initial EEG tended to do less well
on treatment but this again just failed to reach signif—
icance.
Although a number of adverse prognostic factors were
identified the observed differences in outcome between the
groups was relatively small. For example seizure type was
found to be one of the most important factors in determining
the response to treatment. In patients with tonic clonic
seizures the remission rates were high, with 96% achieving
remission by 5 years of follow up; in those with a low
pretreatment seizure frequency remission rates were 100%.
Patients with partial seizures had a significantly poorer
outcome yet even here the response was by no means
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unsat i sfactary with 737. achieving remission (compare with the
results of Schmidt et al , (19S3) shown in Table 1:12).
Despite these di ff i cul t i es the analysis gave a clear picture
of the type of patient who tended to respond poorly to
treatment at the onset of epilepsy. Patients with partial or
mixed seizure types and those with symptomatic epilepsy and
associated neurological, social and psychiatric handicaps
tended to do less well. It should be noted that these
adverse prognostic factors often occurred together in the
same patient. In patients with partial and mixed seizure
types there was a high incidence of symptomatic epilepsy.
These patients were more likely to have associated
neurological deficits. In addition to seizures these patients
could be handicapped by cognitive impairment and were prone
to develop psycological disorders and social dificulties.
Although the overall prognosis in epilepsy is good because of
the high prevalence of the disorder these patients accumulate
in considerable numbers in specialised epilepsy clinics.
In contrast to the controversy surrounding the prognosis for
seizure control, there has been a reasonable degree of
agreement in the literature on the nature of these adverse
prognostic factors. Shortly after the introduction of
bromides it became apparent that the response to treatment
was not uniform. Gowers (1B81) noted that patients with minor
seizures and those with symptomatic epilepsy and associated
neurological deficits tended to do less well. The adverse
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factors described above are in good agreement with those
identified by Rodin (1968) to be important in predicting
prognosis in chronic epilepsy (see page 87). Similarly in
newly diagnosed epilepsy the sex of the patient is of
little use in predicting prognosis. Although the initial
EEG may be of considerable help in diagnosing specific
epileptic syndromes such as the benign partial epilepsies the
overall prognostic use of the first record is limited.
The posibility that prognosis may be better in children has
been commented upon since antiquity and continues to be a
source of controversy in the modern literature. A particular
problem has been the heterogenicity of childhood epilepsy
where a number of syndromes have been identified which
collectively are not uncommon and where the prognosis is
known to differ widely (see page 94). The prognostic study
described in this Chapter was based upon patients attending
an adult neurology clinic. As might be expected the great
majority of cases develped eilepsy either in adolescence or
adulthood. Only limited conclusions relating directly to
the impact of age of onset on prognosis can be drawn from
these results. Amongst the 61 patients in whom epilepsy
developed during the second and third decades of life a
little over 80% achieved remission by eight years of
follow-up. The corresponding figure for those patients who
were aged 30 or over at the time of the first seizure was 96%
but this difference did not reach statistical significance.
Rodin (1968) -found that many authors reported that prognosis
tended to be worse in epilepsy arising in childhood. This
conclusion, however, is open to criticism due to the selected
nature of the material studied. Patients with chronic
intractable seizures accumulate in epilepsy clinics and the
longer the disease has continued the less likely it is to
remit. As the majority of prognostic studies have been based
on patients attending adult clinics those with childhood
onset will have tended to have had the longest history of
active epilepsy and subsequently a worse prognosis. Because
of this form of patient selection cross sectional studies
based on adult populations are unlikely to give reliable
results on the influence of age of onset on prognosis.
Nowhere has this been more apparent than in prognostic
studies of petit mal, the most widely studied childhood
epileptic syndrome. As was shown in Chapter one (see page 99)
many of these studies included a high proportion of cases
who were over the age of 15 at time of entry leading to a
strong bias in favour of those patients in whom the disease
remained active into adulthood.
There appear to be only two prognostic studies available in
the literature which have included both adults and children,
and which have avoided the selection bias of including a high
proportion of chronic cases. In the Japanese Multi
Institutional Study (Okuma & Kumashiro, 1981) patients aged
betwen 1 and 4, and those between 5 and 9 years of age had
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remission rates of 73 and 697. respectively. In the second and
subsequent decades, the percentages were in the order of 507..
The difference in outcome was highly significant. Annegers et
al. (1979) found that in those with idiopathic tonic clonic
seizures the remission rates were those under the age of 10
was 757, 687. for those betwen 10 and 19 and 637. for adult
onset cases. If those who were in remission and off
medication were considered the difference was more striking
being 517., 407. and 287 for the same age groups respectively.
It is passible, however, that this may have been a reflection
of a greater willingness to withdraw medication in children.
Although neither of these studies attempted to take account
of the heterogenicity of childhood epilepsy they both suggest
that epilepsy arising before the age of ten may indeed have a
significant1y better prognosis.
5. Statistical Analysis
The analysis of prognosis presented in this Chapter was based
on the prolonged prospective follow up of patients for
periods of nearly a decade. Such prolonged follow up
generates a considerable volume of data on the patterns of
seizure occurence. Furthermore the outcome in terms of
seizure control was higly variable. Some patients appeared to
experience only a few seizures in total. After starting
treatment a prolonged and sometimes permanent remission
occurred. In others epilepsy developed into a prolonged
intractable illness with seizures occurring in every interval
of -follow up. In some cases of chronic epilepsy seizures
could come in clusters and a short period o-f satisfactory
control was followed by a relapse. It is a formidable problem
to develop appropriate statistical methods to analyse these
dat a.
In the present study the total follow up period was divided
into two month intervals and patients were designated as
being with or without seizures for each interval of follow
up. This was done for partial seizures, tonic clonic seizures
and all seizures combined (see Appendix 4). Patients who had
active epilepsy were usually seen in the outpatients
department every two to three months. In addition the data
was gathered prospectively and at each visit a careful note
of the total numbers of each seizure type were recorded.
In the analysis of outcome widespread use was made of
actuarial statistics. The method of derivation of the
survival curve has been described in detail in Chapter 2. The
application of actuarial statistics to these data has a
number of advantages. Firstly different end points or
"events of interest" can be measured. In assessing prognosis
in newly diagnosed epilepsy the most useful were thought to
be first seizure recurrence on treatment and remission rates
of one and two years. As the median follow up was five and a
half years and most patients were entering remission during
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the first two years of treatment it was not possible to
examine longer periods of remission with any accuracy.
Another advantage of actuarial statistics is that it measures
the time taken for the first ever event of interest to occur.
The survival curve therefore shows the temporal relationship
of remission to follow up. This is a considerable advantage
over measuring terminal remission rates, the most widely used
determinant of outcome in previous prognostic studies (Rodin,
1968). The analysis also takes account of variable follow up
as the percentage of patients achieving the event of interest
is derived from the total number who are at risk. Allthough
the application of actuarial statistics to the data presented
in this Chapter was in general satisfactory, during the
analysis a number of deficiencies became apparent.
Survival curves, as their names suggests, were developed to
analyse death rates. Once the event of interest, that is to
say death, had occurred the further outcome is not of course
considered. This is not the case, however, when measuring
remission rates in epilepsy. Following one year remission as
many as 48"/. of patients experienced a relapse. This figure
decreased progressively with increasing periods of remission
(See Table 3:2). Although relapses were usually isolated
events they are an important element in the prognosis of
epilepsy. The use of actuarial statistics also failed to
give any information on the outcome of patients who never
achieved remission. These are an important group of patients
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as many are likely to develop intractable epilepsy.
On the basis of the data presented in this chapter a novel
statistical model was developed in an attempt to overcome
some of the difficiencies inherent in actuarial analysis
(Johnson et al, 1987). The model involves defining three
clinically relevant "states" or outcomes. Firstly remission
of seizures were defined as one or more years completely
seizure free; patients in this group are likely to have a
very good outcome and in a significant proportion treatment
may be curative. Secondly, continuous seizures where attacks
occur in every interval of follow up; in this group a high
proportion may develop intractable epilepsy. The final
group, defined by exclusion, are those with intermittent
seizures and probably contains a high proportion of cases
who comply poorly with medication. The mathematical details
of the model have been described elsewhere (Johnson et al,
1987; Johnson et al, in preperation) but in essence the
probability of transfer between each of the states is
measured and then applied to the initial distribution of
patients for each interval of follow up using a Markov chain
(see also Loiseau et al 1983). The model predicted that at
the end of follow up 707. of patients remitted, 107. had
continuous seizures and the remaining patients had
intermittent seizures. The chief advantage of this model is
that it takes account of variable follow up and also allows
patients to transfer between states thus taking account of
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the highly variable outcome in epilepsy. The model could be
extended to include different seizure types and take account
of variable prognostic factors or treatment regimens.
The development of appropriate statistical methods for
analysing seizure control in newly diagnosed epilepsy is of
considerable importance. In recent years anticonvulsant
trials are, for the first time, being undertaken in this
group of patients. There are a number of theoretical and
practical advantages of such a study design (see page 45 et
seq.) and it is likely that an increasing number will be
under- taken. It has been traditional in ant1convulsant
trials to measure changes in seizure frequency usually on
the basis of short periods of follow up. The results are
often given as the proportion of patients who experience a
507. or greater reduction in seizure frequency (see for
example Callaghan et al. 1985). In newly diagnosed epilepsy
such a measure is not only inadequate but fails to give a
sensible summary of the data or differentiate between long
and short term control of seizures. The recruitment and
follow up of into patients entered into these trials is a
major undertaking and it is of crucial importance that
appropriate statistical methods are developed for analysing
the results. A similar consideration applies to recent
proposals in which the effects of early and delayed
treatment on the long term prognosis of epilepsy would be
studied (see chapter 6). The hypothesis under consideration
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is whether early treatment in any way improves the
subsequent prognosis and reduces the number of patients
developing chronic epilepsy. The analysis of such a trial
and in particular the methods used to take account of the
highly variable outcome in epilepsy would need carefull
consideration.
6. The Early Response to Treatment
Perhaps the most striking observation to arise from the
present study has been the importance of the early response
to treatment in determining the long term prognosis in
epilepsy. This is shown by examining remission rates for all
the patients in Figure 3:3. The curves relate to the
percentage of patients achieving a period of one or two
years completely seizure free. It is apparent that the great
majority of patients who were going to remit did so early in
the course of the disorder. Seventy-five per cent of all
patients who were going to remit were entering or in
remission during the first year of follow up. As a
consequence the longer the seizures continued the less
likely was it that a remission would occur (Figure 3:5). If
a patient was still having seizures up to two years after
the start of treatment the chances of achieving a subsequent
remission had fallen by about one half. This observation
raises the question as to whether more effective treatment
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at the onset of the disorder might improve the subsequent
long term prognosis.
All prognostic studies in epilepsy have shown that the longer
seizures continue the harder they are to control. This was
commented upon even in the Hippocratic writings (see page
7B). Gowers (1881) found that the prognosis of epilepsy was
in inverse proportion to the duration of the disease, a
conclusion that was in agreement with all writers on the
subject. He went on to examine this aspect of the natural
history of epilepsy in some detail (see Table 3:6). In
patients with a duration of illness lasting less than a year
837. had their seizures arrested, results remarkably similar
to those given in this Chapter. When untreated seizures had
occurred for between 1 to 5, 5 to 9, and over 10 years the
proportion of patients who responded to treatment fell
progressively to 737., 697. and 60% respectively. Rodin (1968)
made a similar observation in his review of the modern
prognostic literature. All authors were in agreement that
the longer the illness had lasted the less likely was it that
remission would occur. Furthermore the greater the number of
seizures prior to the first visit to the physician the less
likely was it that complete control would subsequently be
obtained (see Table 3:6).
Since all the patients studied here were treated it is
impossibe to tell whether this represents the natural
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TABLE 3:6 THE INFLUENCE OF DURATION OF ILLNESS ON THE
PROGNOSIS FOR SEIZURE CONTROL IN EPILEPSY
(a). Adapted -from Gowers, 1881.
Duration of illness Percentage
Unimproved Arrested
Less than 1 year 17 83
1 to 4 years 27 73
5 to 9 years 31 69
10 years or over 40 60























history of the disorder or whether early control may indeed
affect the long term prognosis. Evidence for this possibil¬
ity could only be obtained from a randomised study involving
an untreated control group. Little is known about the
natural history of untreated epilepsy. Gowers stated over a
century ago that "spontaneous cessation of the disease is an
event too rare to be reasonably anticipated in any given
case." There is no further information in the literature on
this aspect of prognosis which will be considered in greater
detail in the next chapters.
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E. SUMMARY
1. The prognosis for seizure control has been assessed in a
group of 106 patients who were referred to an adult
neurology clinic with previously untreated tonic clonic,
partial and mixed seizure types who were followed prospect¬
ively for a median of 66 months (range 6 - 96).
2. Patients were treated with phenytoin or carbamazepine
monotherapy on a nonrandomised basis. Anticonvulsant levels
were monitored and the dosage increased if further seizures
occurred with anticonvulsant levels below the optimum range.
3. At the end of follow up
monotherapy of whom 70 were ta
drug. Ten patients were ta
discontinued treatment, 12 of
78 patients were still on
king the originally prescribed
king two drugs and 18 patients
them against medical advice.
4. Twenty-one patients experienced 2 or more seizures
despite an optimum anticonvulsant level and were considered
to have failed on monotherapy. Thirteen patients failed by
1 year of follow up, 19 by 2 years and all of them by 6
years. Nine patients continued to have seizures with
suboptimal levels despite progressive increases in dosage
presumably because of poor compliance.
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5. The total -follow up period was divided into two-month
intervals and patients were designated as being with or
without partial seizures or tonic clonic seizures or any
seizure type -for each interval o-f follow up. The percentage
of patients experiencing at least one seizure on treatment
and the percentage achieving one and two year remissions
were analysed using actuarial statistics.
6. The majority of patients experienced at least one
further seizure after starting treatment most within a
period of 1 year. Fifty per cent occurred by 6 months of
follow up, 60% by 1 year, 66% by 2 years, 76% by 4 years and
79% by 8 years.
7. F'atients with a high pretreatment tonic clonic seizure
frequency were more likely to experience a further seizure
on treatment. No other clinical or investigative feature was
significant1y associated with the probability of remaining
seizure free on treatment.
8. The prognosis for seizure control was assessed by
measuring the actuarial percentage of patients achieving a
period of 1 or 2 years completely seizure free. A 1 year
seizure free period occurred in 40% by 1 year, in 73% by 2
years, in 84% by 3 years, 88% by 4 years and 89% and 92 % by
5 and 8 years respectively. Most patients who achieved a 1
year remission subsequently went on to a second year seizure
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free, the remission rates at B years of -follow up being 82%.
9. Amongst the 89 patients who achieved a 1 year remission
the probability of relapse was 487 by 4 years of fallow up.
In patients who were in 2,3 or 4 remission the relapse rate
fell progressively to 397., 317. or 177 respectively.
10. In three-quarters of cases, relapse were isolated
events often related to poor compliance with medication.
Once a two year remission had occurred no patient developed
an intractable seizure disorder.
11. Twelve patients failed to achieve a one year remission.
In this group the outcome was poor, with seizures occurring
in 907 of the two month follow up intervals. This group
probably corresponds broadly to those with intractable
seizure disorders.
12. Prognostic factors were analysed by comparing the
actuarial percentage of patients achieving a one year period
completely seizure free. Patients with partial or mixed
seizure types, a high pretreatment tonic clonic seizure
frequency, symptomatic epilepsy, associated psychological or
social handicaps and those with positive family history of
epilepsy had a significantly poorer outcome. Age of onset
of epilepsy, the timing of seizures, pretreatment tonic
clonic seizure numbers and the features on the pretreatment
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EEG were not significant1y associated with prognosis.
13. The early response to treatment was of crucial
importance in determining the longer term prognosis.
Seventy five per cent of remissions began within the first
year of treatment. The longer seizures continued the less
likely was remission to occur. In patients who continued to
have seizures during the second year of treatment the
probability of subsequently ever achieving remission had
fallen by about one half.
14. Poor compliance with medication was assessed on the
basis of the occurrence of withdrawal seizures, failure to
achieve an optimum anticonvulsant level in the face of
active epilepsy and increased dosage and variability of
anticonvulsant levels whilst on a given dose of a drug.
Forty-patients had evidence of one or more of these factors.
Patients who were taking phenytoin and those with a history
of one or more episodes of acute toxicity showed a higher
incidence of poor compliance. It was not possible to
document an adverse effect of poor compliance on prognosis,
possibly because it was equally prevalent amongst those
whose seizures were well controlled.
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CONCLUSIONS
1. The prognosis -For seizure control in newly diagnosed
epilepsy is good. As many as SOX o-f patients rapidly enter
a prolonged period o-f seizure control most within a year o-f
starting treatment. Relapses are usually isolated events
often related to poor compliance and the longer the period
o-f remission the lower the probability o-f experiencing a
•further seizure.
2. Previously prognostic studies of epilepsy have all been
based on the cross sectional selection o-f patients attending
specialised neurology or epilepsy clinics and have given an
unduly gloomy view o-f prognosis. Patient selection is the
single most important reason -for the controversy surrounding
the prognosis in epilepsy.
3. Patients with partial seizures, a high initial seizure
•frequency, symptomatic epilepsy and associated psychol ogi cal
and social handicaps have a significantly worse prognosis at
the onset of the disorder. This finding is in good
agreement with the prognostic factors identified in patients
experiencing a recurrence following a first seizure, in
determining outcome in chronic epilepsy and in predicting
relapse rates following anticonvulsant withdrawal. Although
only one quarter of patients with these adverse prognostic
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-factors -failed to respond to treatment because of the high
prevalence of epilepsy they accumulate in considerable
numbers with chronic intractible seizure disorders.
5. The early response to treatment is of crucial importance
in determining the long term prognosis in epilepsy. Seventy
five per cent of all remissions occur within the first year
of treatment, and the longer seizures continue the harder
they are to control. The natural history of untreated
epilepsy is largely unknown but these findings raise the
possibility that more effective treatment at the onset of




PROGNOSIS FOLLOWING A FIRST TONIC CLONIC SEIZURE
A. INTRODUCTION
Epidemiological surveys have shown that as many as 57. of
the population will experience at least one afebrile
seizure at some time during their life (Hauser & Kurland,
1975). The patient who presents with a single seizure is a
common clinical problem yet the outcome in this group of
patient has received only scant attention in the published
literature. This has led to continuing uncertainty
concerning the subsequent prognosis for seizure recurrence,
a lack of clear data on the nature of possible adverse
prognostic factors and widely differing treatment policies
(Reynolds, 1934).
In this Chapter an analysis of the probaility of seizure
recurrence will be presented in a consecutive series of 214
patients who were consecutively referred to a neurology out
patients department because of recent onset of tonic clonic
seizures. The study was undertaken with the following aims:
i. To analyse the prognosis for seizure recurrence
following a first tonic clonic seizure.
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ii. To identify factors that are of
importance in predicting a seizure
prognostic
recurrence.
B. PATIENTS AND METHODS
The patients studied were all consecutivly referred to the
adult neurology clinic at Kings College Hospital over a
five year period between 1978 and 1983. During this period
a total of 328 patients were seen who had experienced one
or more previously untreated seizures. Cross-sectional
selection was avoided in that patients already attending
the department for treatment of epilepsy were not
considered. Some patients, although presenting with recent
onset of seizures, gave a history of one or more attacks,
often occuring many years previously. These were considered
for inclusion only if they had never previously received
anticonvulsant medication.
The following groups of patients were excluded from the
study; patients with evidence of a progressive neurological
disorder apparent at the time of first diagnosis; those
with seizures occurring in the context of acute central
nervous system disorder such as meningitis or stroke;
patients with significant metabolic disorders such as
hypoglycaemia or uraemia; seizures caused by drugs or
occurring in the context of alcohol dependence. Patients
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who gave a past history of febrile convulsions and
subsequently presented with a history of apparently
unprovoked seizures were included. Those who had previously
experienced attacks relating to any of the factors listed
above were, however, excluded.
After exclusion of the above categories a total of 236
patients remained. Seventy two patients had myoclonic,
petit mal or partial seizures without secondary
generalisation. These patients had almost invariably
experienced multiple attacks that could not be accurately
dated at the time of first assessment in the outpatients
department. The remaining 214 patients with tonic clonic
seizures form the basis of this study.
At the time of first assessment in the neurology
outpatients department a history and examination were
undertaken in the usual manner. A description of the
seizure type, the dates of the first and second seizures,
the past medical, social and psychiatric history, the
results of general and neurological examination and of
pretreatment investigations were recorded on a proforma for
each patient (see Appendix 1). The clinical details and
follow up data for all 214 patients are given in Appendix
5. The number of seizures the patient had experienced at
the time of very first presentation was recorded. This
information was obtained retrospectively from interviewing
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the patient and -from the general practitioner's or casualty
officer's letter. In a significant proportion of cases the
patient presented initially with a single seizure, either
to their general practitioner or a casualty department, but
had subsequently developed epilepsy when first seen at the
neurology outpatients department.
In analysing the prognosis after a first seizure the
following definitions were used. A first seizure was
defined as the first ever afebrile tonic clonic seizure.
Multiple seizures occurring within 24 hours were considered
to be a single episode. Patients with a previous history of
other seizure types such as partial seizures that had
previously gone unrecognised or petit mal attacks in
childhood were not included. A second seizure was defined
as the next seizure that occurred, whether partial or
generalised.
It was the policy of the department, throughout the period
of the study, not to treat patients who had experienced
only one seizure. A few patients were started on treatment
by their general practitioner or by a casualty officer and
were still taking medication at the time of first
assessment at the hospital. In others, particularly
children in whom the initial convulsion was prolonged,
treatment was started immediately following the first
attack.
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Patients who, in December 1983, had been discharged -from
■follow-up and had still experienced only one attack were
recalled to the clinic to assess recurrence. If the patient
failed to attend, a letter was sent to their general
practitioner requesting further information. Thirty seven
patients were lost to follow up after a median interval of
three and a half months. The follow-up period was divided
into one month intervals, starting from the time of the
first seizure. The probability of seizure recurrence was
assessed using Kaplan Meier survival curves (Kaplan &
Meier, 1958). Prognostic factors were assessed by comparing
the actuarial percentage of patients experiencing a seizure
recurrence. Significance values were based on the log rank




The characteristics of the 214 patients with tonic clonic
seizures are shown in Table 4:1. Just over halt the
patients were male. Sixty four patients (.30'/.) were aged 16
or less, the median age at first seizure being 22 years.
Thirty patients (14%) had symptomatic seizures. The
commonest aetiology was cerebrovascular disease. Eight
patients had a history of completed stroke which in two
cases were due to emboli secondary to congenital heart
disease. In a further four patients evidence of focal or
generalised atrophy was seen on CT brain scan. One of
these gave a history of transient ischaemic attacks, one
was diabetic and two were hypertensive. Six patients had a
history of birth injury and another six had previously
experienced a significant head injury. A tumour was the
cause of seizures in four patients. One experienced a
seizure twelve months after removal of a convexity
menningioma. In two patients mass lesions were found
incidentally on CT scan, both of which were thought to be
benign. A further patient developed signs of raised
intracranial pressure three months after a first tonic
clonic seizure and was subsequently found to have a glioma.
Two patients gave a past history of menningitis.
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TABLE 4:1 CLINICAL FEATURES OF 214 PATIENTS WITH TONIC
CLONIC SEIZURES SEEN CONSECUTIVELY AS NEW REFERRALS OVER A
FIVE YEAR PERIOD. A COMPARISON OF PATIENTS WITH SINGLE
SEIZURES AND THOSE WITH EPILEPSY.
Clinical All One Epilepsy
Charactetistics patients seizure
N (7.) N ("/.) N (7.)
All Patients 214 64 <30) 150 (70)
Male 112
Female 102
Median Age at First
Seizure, Years(range) 22
Age at First Seizure,
= or < 16 years 64
























EEG performed 169 49 <29) 120 (71)
Normal Record 63 19 (30) 44 <70)
Epi1eptiform 47 13 <28) 34 <72)
Non-specific 80 20 (25) 60 <75)
Follow-up (months)
1 -12 77 (36)* 42 (66)* 35 (23) *
13-24 45 <21) 12 <19) 33 <22)
25-36 31 (15) 6 (9) 25 <17)
37-48 20 (9) 4 (6) 16 (11)
>48 41 (19) 0 (0) 41 <27)
Median Follow-up,
Months, (range) 21 (1-228) 8 (1-61) 26. 1in
* percentages refer to all patients
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An associated neurological handicap was present in 22 cases
(10"/.). Seven patients had cognitive deficits of whom three
were mentally deficient and four had an acquired dementing
illness. Twelve patients had a hemiparesis which had been
present since birth in five cases. One patient was deaf
and dumb, one had choreoathetosis and one had a right
hommonomous hemianopia.
Twenty patients (9"/.) gave a family history of epilepsy in
first degree relatives and 42 (20%) had experienced all
their seizures during sleep. An initial EEG was undertaken
in 169 patients (79%). In 63 patients (37%) the record was
normal, 47 (28%) showed epileptiform abnormalities and in
80 of the records (47%) there were non specific slow wave
changes. Seventy-seven patients (36%) were followed for
between 1 and 12 months, 45 (21%) for between 13 and 24
months, 20 (9%) for between 37 and 48 months, and 41
patients (19%) for more than 4 years. The median follow up
from the time of the first seizure was 21 months.
At the end of the study 64 patients, or 30% of the total
had experienced only a single seizure and 150 (70%) had 2
or more attacks. The clinical characteristics of these
two groups are shown in Table 4:1. Patients who had
experienced a single seizure were followed for a shorter
period of time, but otherwise the two groups did not appear
to differ in any major respect. Amongst patients who were
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aged 16 or under, 167. had a single seizure and 847.
developed epilepsy. Similarly amongst patients who
experienced symptomatic seizures 177. had a single attack
and 837 had recurrent seizures. Both these
differences were significant at the level p < 0.001
(Pear son V Test).
The Prognosis for Seizure Recurrence in Patients
Presenting Following a First ever Seizure
Out of the 214 patients with tonic clonic seizures, 146
presented to medical attention following a first ever
seizure. Eighty were seen in the Accident and Emergency
Department and 66 by their Family Practioner. The median
interval from first seizure to first presentation was one
day. The clinical characteristics of the patients are shown
in Table 4:2. After a median follow up of 15 months the
cumulative probability of seizure recurrence was 197. by one
month, 307 per cent by three months, 447 by six months, 607.
by one year, 697 by two years and 717. by three and four
years (see Figure 4:1).
Patients were seen in the neurology outpatients department
at a median interval of one month from the time of the
first seizure. During this interval 43 of the original 146
patients had already experienced a seizure recurrence. The
clinical characteristics and prognosis in the remaining 103
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TABLE 4:2 CLINICAL FEATURES DF PATIENTS WHO PRESENTED
ESkLQWING A FIRST EVER TONIC CLONIC SEIZURE; PATIENTS AT
INITIAL PRESENTATION <N=146) AND PATIENTS SEEN IN THE
NEUROLOGY OUTPATIENTS DEPARTMENT (N=103).
At Initial At Neurology
Prenentation Outpatients













Median Age at First
Seizure, Years (range) 21 (2-78) 22 (4-7
Age at First Seizure,










Symptomatic Seizures 20 (14) 12 (12)
Neurological Handicap 13 (9) 9 (9)
Family History
of Epilepsy 12 (8) 7 (7)
Nocturnal Seizures 29 (20) 18 (17)
EEG performed 115 (79) 88 (81)
Normal Record 49 (43) 33 (32)
Epi1eptiform 27 (23) 20 (19)
Non-specific 50 (43) 38 (37)
Follow-up (months)
1 -12 65 (45) 45 (44)
13-24 36 (25) 27 (26)
25-36 18 (12) 12 (11)
37-48 13 (9) 9 (9)
>48 14 (10) 10 (10)
Median Follow-up,
Months, (Range) 15 (1-69) 15. 5 (1-69)
Totals 146 (100) 103 (100)
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FIGURE 4:1 CUMMULATIVE PRDBABILLITY OF SEIZURE RECURRENCE
IN PATIENTS PRESENTING FOLLOWING A FIRST EVER TONIC CLONIC
SEIZURE
I I 1 I
12 3 4
yea rs
at 146 38 18 11 8
risk 103 36 18 11 7
Solid lines = Patients seen within a median interval of one day
following the first seizure
Broken lines = Patients seen within a median interval of one
month following a first seizure
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patients is shown in Table 4:2 and Figure 4:1 respectively.
The cumulative probability of seizure recurrence was 107. by
three months, 247 by six months, 447. by one year, 537 by
two years and 567. by three years.
3. Treatment
Thirteen patients were treated following the first seizure,
of whom five (387) experienced a recurrence. In the
remaining 133 patients who were untreated the recurrence
rate was 207 by one month, 327 by three months, 407 by six
months, 627 by one year, 697. by two years and 717 by three
and four years.
4. Prognostic Factors
Prognostic factors were analysed in the 146 patients who
presented following a first seizure by comparing the
actuarial percentage of patients experiencing a recurrence,
(see table 4:3). Patients who were under sixteen at the
time of the first seizure had a higher recurrence rate (j(
= 5.8, d.f. = 1, p = 0.01) and patients with symptomatic
seizures ( .8, d.f.=l, p=0.02) also had a worse
prognosis. Sex, neurological handicap, timing of seizures,
the presence of a family history or EEG features were not
of prognostic significance.
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TABLE 4:3 PROGNOSTIC FACTORS FOR SEIZURE RECURRENCE IN
146 PATIENTS PRESENTING FOLLOWING A FIRST EVER SEIZURE.
THE ACTUARIAL PERCENTAGE OF PATIENTS EXPERIENCING A
SEIZURE RECURRENCE BY 1, 2 AND 4 YEARS OF FOLLOW-UP.
Percent Recurrence
Number of at
Patients lyr 2yrs 4yrs
Sex
Mai e 79 63 73 73
Female 67 54 62 66
Age at First Seizure
=<16 41 75 79 -
>16 105 51 62 62
Aetiology
Idiopatic 126 56 66 68
Symptomatic 20 76 77 —
Neurological Handicap
Present 13 54 54 54
Absent 133 59 69 71
Family History of Seizures
Present 12 50 67 67
Absent 134 60 68 70
Timing of Seizures
Nocturnal 29 70 70 70
Diurnal 117 56 67 70
EEG Features
Normal 49 60 72 72
Epi1eptiform 27 49 56 63
Non Specific 50 56 69 73
All patients 146 59 68 70
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5. Precipi tating Factors
Amongst the 146 patients, 35 were identified in whom an
immediate precipi tating event appeared to be of possible
significance in causing the first seizure. Ten patients
reported being uder some kind of stress at the time of the
initial attack. This was a specific event in four patients;
during a dental extraction, whilst having ears pierced, in
the course of fitting an intra uterine device and shortly-
after being stung by a wasp. Nine patients reported a
disturbence of sleep rhythms immediately before the first
seizure, caused for example by overnight travel or shift
work. Seven patients said they had consumed an unaccustomed
amount of alcohol shortly before the seizure. This was
often accompanied by lack of sleep, an all night party
being the usual cause. Five patients had seizures
precipitated by flashing lights of whom four showed photo-
convulsive responses on the EEG. Four patients had seizures
during the course of intercurrent illness, usually
associated with fever. Amongst the total of 35 patients,
15(40%) experienced a seizure recurrence.
It can be difficult, even on the basis of a careful
witnessed history, to distinguish an epileptic seizure from
the convulsion that may follow a period of cerebral anoxia.
Of the four patients in whom the initial attack immediately
followed a painful or unpleasant event none had epileptic
abnormalities on an EEG or subsequently developed
unprovoked seizures. It is possible in these cases that
the primary event was, in fact, syncope.
2.03
D. DISCUSSION
1. Comparison with Previous Prognostic Studies
The recurrence rate following a first seizure has been
reported to vary widely from between 27 and 64'/. (see Table
1:8). There are a number of possible reasons for these
differing results. Some authors, as in the present study,
have included only those patients with tonic clonic
seizures as these form the majority of patients who present
following a single seizure (Todt et al,1985). Others series
have contained a significant proportion with other seizure
types (Hauser et al, 1982; Camfield et al, 1985; Annegers
et al, 1986). As in all prognostic studies duration of
follow-up is of crucial importance in determining the
results. Todt et al (1985) only included relapses that
occurred within one year of the first seizure. Many authors
have failed to take account of variable follow-up and given
only crude relapse rates rather than actuarial probabilit¬
ies (Thomas, 1959; Saunders & Marshall, 1975; Cleland et
al, 1981; Camfield et al, 1985). A further difficulty has
been widely differing treatment policies with a number of
more recent surveys showing that as many as two thirds of
patients were given anticonvulsants following the first
seizure (see Table 1:10).
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Each o-f these -factors have lead to di-f-f i cul t i es in
comparing the results of prognostic studies reported in the
literature. An even more important source of error,
however, has probably been the exclusion of patients who
experience an early recurrence. In patients with establish¬
ed epilepsy, Gowers (1881) found that the second seizure
followed the first within a month in one third of cases.
(These findings have been confirmed in Chapter 5 of this
thesis, see table 5:2.) In the present study the cumulative
probability of recurrence was already 19% by one month and
30% by three months. If a significant period of time
elapses, therefore, between the first seizure and entry into
the study then patients will be excluded because they have
already had a recurrence and are therefore ineligible for a
study of patients with single seizures. The remaining
patients, with what might be termed an isolated seizure
(Cleland et al , 1981), will have a significantly better
prognosis. Because the recurrence rate is highest in the
months immediately following a seizure, patients who remain
seizure free during this period will obviously have a better
prognosis. In the present study 146 patients presented
following a first seizure but 43(29%) had already developed
epilepsy when seen in hospital a month after the initial
event. In these patients the recurrence rate was
considerably lower (see figure 4:1).
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The influence of this form of patient selection on the
results of prognostic studies of patients presenting with a
single seizure is shown in Table 4:4. In the study by
Cleland et al (1981) the interval between the first seizure
and inclusion into the study was six weeks, which
corresponded to the time taken for the patient to be seen in
a neurology outpatients department. In this study the
recurrence rate was 39%. A similar form of selection is
likely to have taken place in two earlier studies (Thomas,
1959; Saunders & Marshall, 1975), both of which were based
on patients attending EEG departments and where one third of
patients subsequently developed epilepsy. In the most
extensive study so far published, Hauser et al (19B2)
unfortunately failed to supply this crucial piece of
information. Two hundred and fourteen patients with a single
"unprovoked" seizure were followed for a median of 22 months
and the recurrence rate was 27% by three years. It is
likely, however, that a similar form of selection occurred
as 435 patients who had experienced two or more seizures at
the time of first diagnosis were excluded.
A similar consideration is the most likely explanation of
the higher recurrence rate reported by more recent studies.
Todt et al (19B5) assessed the probability of seizure
recurrence in 147 children who were seen in an EEG
department within two weeks of a first ever tonic clone
seizure. Although follow-up information was only given for
206
TABLE 4:4 PROGNOSIS FOLLOWING A FIRST SEIZURE. THE
INFLUENCE ON RECURRENCE RATE OF THE DELAY BETWEEN THE
FIRST SEIZURE AND ENTRY INTO THE STUDY.
Interval from
Author first seizure Recurrence
to entry. Rate (X)
Saunders and Marshall, 1975 h weeks 33
Cleland et al, 1961 6 weeks 39
Todt et al, 1985 2 weeks 59
Hopkins et al, 1988 8 weeks 22
1 week 52
Present Study 1 day 71
4 weeks 53
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one year the reported recurrence rate was 597.. The
importance that this -form o-f patient selection may have on
prognostic studies has recently been demonstrated by Hopkins
et al (1988). In this study, in patients seen within one
week o-f a -first seizure the recurrence rate was 527 by 3
years o-f follow up. In those in whom a period of 8 weeks had
elapsed before inclusion only 227. developed epilepsy.
2. Community Based Surveys
From the discussion considered above it is apparent that
that the timing of the initial presentation and the
subsequent referral patterns are likely to have an important
impact on the results of prognostic studies of patients
presenting with a single seizure. All except one of the
studies summarised in Table 1:9 were hospital based and it
is possible that a number of possible sources of bias could
arise from this study design. In the present study patients
were selected from a consecutive series of new referrals to
a neurology outpatients department seen over a five year
period. Those who presented following a first seizure were
identified retrospectively. If, however, patients with more
than one seizure are more likely to be referred to hospital
this could lead to an over estimation of recurrence rates as
the hospital population would be biased towards those with
multiple attacks.
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It is unlikely however that this was a major source of
error. Available evidence suggests that between 80% and 95%
of patients presenting to general practitioners in South
East England with one or more seizures are referred to
hospital for investigation ( Hopkins & Scrambler, 1977;
Goodridge & Shorvon, 1983). Furthermore, in this study
patients selected on the basis of consecutive referrals to a
hospital department appear to be broadly similar to those
identified in community surveys. From a total of 214
patients seen over a five year period, 64 (30%) experienced
only one attack. Goodridge & Shorvon (1983) retrospectively
identified from general practice records patients who had at
any time in their life experienced one or more seizures. In
this study 19% experienced only a single attack. Comparable
figures from the epidemiological surveys of Hauser & Kurland
(1975) and Juul-Jensen & Foldspang (1983), were 17% and 24%
respectively. These results are in broad agreemnt with those
presented here, derived from patients consecutivley referred
to a hospital department.
Another possible source of error is that the identification
of patients who presented following a first seizure was, by
necessity, retrospective. This was established either on the
basis of an interview with the patient or from the referral
letter from the general practitioner or casualty officer. It
is posible, therefore, that a number of patients who
presented with a single seizure were overlooked. If this
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occurred in a significant proportion then this would lead to
an underestimation of seizure recurrence.
A further factor that may influence recurrence rates is the
proportion of patients who following the onset of seizures
actually seek medical help after the very first attack. The
impact that this may have on results of prognostic studies
does not appear to have been considered previously. In the
present study, out of a total of 214 patients seen as
consecutive referrals to a neurology outpatients department,
146 (6B"/0 were retrospect i vel y identified as having
presented following a first seizure. Although the recent
onset of generalised seizures might be expected to be a
dramatic event it appears that nearly one third of the
patients had experienced two or more attacks before
consulting a doctor. In the community based survey by
Annegers et al (1985), which included patients with partial
seizures, this occurred in one half of the patients who were
identified using the records linkage system of the Mayo
Clinic. It is possible that an initial noctural seizure
might be more unlikely to go unnoticed. In other instances
the importance might not be appreciated if an isolated
episode of loss of consciousness occurred without the
presence of a witness. Presumably the local availability and
access to medical facilities could also be a factor.
It is apparent, however, that if a greater proportion of
patients sought help following the first attack then the
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observed recurrence rate would be correspondingly higher.
This issue could only be clarified with certainty by a
prospective community based survey which identified patients
at the onset of the disorder. If effective management
strategies are to be developed then the proportion of cases
who seek help early will need to be established.
3. Prognostic Factors
A number of prognostic factors were analysed by comparing
the actuarial percentage of patients experiencing a seizure
recurrence. Patients with a symptomatic first seizure had a
higher recurrence rate, in keeping with the findings of most
other reports (Hauser et al, 1982; Camfield et al, 1985;
Annegers et al, 1986). Age at first seizure was also an
important prognostic indicator but sex of the patient, the
presence of neurological deficits, EEG features, the timing
of seizures and the presence or absence of a family history
of epilepsy did not significantly affect outcome.
In assessing prognostic factors it is important to emphasise
that patients with single seizures are a selected group and
differ from those with epilepsy in a number of important
respects. Patients with partial seizures are largely
excluded because the majority have experienced multiple
attacks when first seen. Similarly there is likely to be a
lower incidence of symptomatic seizures; in the present
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study, amongst patients presenting with single seizures, the
incidence was 14"/., compared to 33% -for those with
established epilepsy considered in the previous chapter.
These two -features, which are amongst the most important
prognostic -factors in patients with epilepsy (see Chapter
3), will be selected out in series o-f patients with
single seizures.
In the present study patients who were aged 16 or less had a
recurrence rate of 79% compared with adults of whom 62%
developed epilepsy. These findings were based on patients
referred to an adult neurology outpatients department, over
two-thirds of cases being aged over 16 years. It is
possible that general practitioners and casualty officers
might have been more likely to refer children to an adult
clinic if they had epilepsy rather than just a single
seizure. Further examination of the data did not suggest any
such source of bias. The proportion of patients with
single or multiple seizures for all the 214 patients was
similar for both the adult and paediatric populations.
Patients who were aged 16 or less at the time of the first
seizure did not have a higher incidence of symptomatic
epilepsy or neurological handicaps. Annegers et al (19B6)
found that age of onset did not significantly affect
prognosis following a first seizure. The age structure in
this study was curious with over half the patents apparently
aged 55 or over suggesting that children were, for some
212
reason, largely excluded. Three childhood studies by Hirtz
et al (1984), Todt et al (1985) and Cam-field et al (1985)
have stated that children are more likely to experience a
recurrence -fallowing a -first seizure. These claims, however,
are also di-f-ficult to intrepret. Earlier prognostic studies,
all o-f them based on adults, showed recurrence rates of the
order of 307. (Thomas, 1959; Saunders & Marshall, 1975,
Cleland et al, 1981; Hauser et al, 1982). These results
however are not strictly comparable to those of Todt et al
(1985) for the reasons of patient selection discussed above.
Similarly the children identified by Hirtz et al (1984) came
from a population study and all such studies, whether in
adults or children, have shown higher recurrence rates.
The features of the initial EEG were not of value in
predicting prognosis but this must be interpreted with
caution as a number of patients did not have this
investigation performed. Again there is little agreement in
the literature on the value of this procedure in assessing
recurrence following a first seizure. The most carefully
documentated study in this respect is that by Camfield et al
(1985), based on a paediatric population. The presence of
either slow wave abnormalities or generalised spike and wave
had no effect on outcome. The prognosis was worse in a sub
group of patients with focal epileptiform features, 687
experiencing the recurrence as opposed to 527 for the
remaining patients. Annegers et al (1986) found that none
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of these -features when considered separately a-f-fected
prognosis whilst Hauser et al (19S2) found a higher
recurrence rate only amongst a small group of patients with
generalised spike and wave. Hopkins et al (1988) has




1. The prognosis -following a -first seizure has been
assessed in a series o-f 214 patients who were consecutively
referred to a neurology outpatients department over a 5 year
period because of recent onset of one or more tonic clonic
seiz ures.
2. After a median follow up of 21 months, 150 patients
(70%) had experienced recurrent seizures and 64 patients
(30%) had had only a single attack. Patients who developed
epilepsy were more likely to have symptomatic seizures and
to be under the age of 16, but otherwise the two groups did
not appear to differ in any major respect.
3. One hundred and forty six patients were retrospectively
identified who had presented to medical attention within a
median interval of 1 day following a first tonic clonic
seizure. Thirteen patients were treated following the first
seizure. The cumulative probability of seizure recurrence
was 197. by 1 month, 30% by 3 months, 447. by 6 months, 60% by
1 year and 71% by 3 and 4 years.
4. Forty-three patients had relapsed by the time of first
attendance at the neurology outpatients department. Amongst
the remaining 103 patients the cumulative probability of
seizure recurrence was 107. by 3 months, 247. by 6 months, 427.
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by 1 year, 54'/. by 2 years and 57'/. by 3 years.
5. Patients who were aged 16 years or less at the time o-f
the -first seizure and those with symptomatic seizures had a
significantly higher recurrence rate. Sex, neurological
handicap, timing of seizures, the presence of a family
history or EEG features were not of prognostic signficance.
CONCLUSIONS
Following a first seizure the majority of patients are
likely to develop epilepsy. The second seizure follows the
first in rapid succession and most patients experience a
recurrence within one year. Patients with symptomatic
seizures are more likely to experience a recurrence but
there is little agreement on the nature of other adverse
prognostic factors.
Many prognostic studies of patients presenting with a single
seizure have considerably underestimated recurrence rates by
excluding patients who experience an early recurrence. The
results presented here, based on consecutive referrals to a
neurology outpatients department, are in broad agreement
with those from epidemiological surveys which have shown
that seizures are likely to be recurrent in as many as 607.
to 807. of cases.
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CHAPTER X VE
INTERVALS BETWEEN UNTREATED TONIC CLONIC SEIZURES IN
PATIENTS WITH NEWLY DIAGNOSED EPILEPSY.
A. INTRODUCTION
Remarkably little is known about the patterns of seizure
recurrence at the onset of epilepsy. Apart from some
observations in the historical literature (Gowers, 18B1)
there appears to have been no study of this aspect of the
prognosis of epilepsy in either treated or untreated
patient s.
In thi5 Chapter an analysis of patterns of seizure
recurrence prior to the onset of treatment in a series of
1S3 patients with tonic clonic seizures will be presented.
The data has been analysed with the fallowing aims:
i. To analyse the intervals between the first and
second untreated seizures in patients with
epi1epsy
ii. To assess the influence of subsequent seizures on
inter-seizure intervals
iii. To assess the impact of the early patterns of
seizure recurrence on the subsequent prognosis of
epi1epsy.
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B. PATIENTS AND METHODS
The patients considered -for inclusion into the study were
all referrals to the the Neurology Outpatients Department
at Kings College Hospital with newly diagnosed previously
untreated epilepsy. Between 1978 and 1984 a total of 388
patients were seen. D-f these, 127 experienced partial
seizures without secondary generalisation, petit mal or
myoclonic seizures and the remaining 281 patients had
tonic clonic seizures.
As was described in Chapter two, during this period the
Department had a major interest in identifying patients
with newly diagnosed epilepsy -for inclusion into trials o-f
monotherapy using the major established anticonvulsant
drugs. Both adults and children were recruited for the
trials. Patients with a progressive neurological disorder
which was apparent at the time of first referral and those
in whom seizures were caused by an acute metabolic or
neurological disturbance, drugs, alcohol or fever were
excluded.
Details of the patients' seizure history, past medical,
social and psychiatric history and the results of the
examination and pretreatment investigations were entered
onto a proforma (Appendix 1). Patients were initiated on
treatment if they had experienced at least two tonic
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clonic seizures within the space o-f one year or a
sufficient number of partial seizures to warrant
medication, in accordance with standard clinical practice.
In assessing the early patterns of seizure recurrence only
those patients in whom the dates of individual seizures
could be accurately ascertained were studied. This
information was recorded at the time of the first
attendance at the Neurology Outpatients Department. The
letter from the general practitioner or casualty officer
was often of considerable use as the date of initial
presentation and the timing of subsequent seizures had
often been recorded by the referring doctor. It became
apparent that patients who had experienced partial
seizures without secondary generalisation, petit mal or
myoclonus had almost invariably had a large number of
attacks that could not be accurately dated. Although the
intervals between individual seizures were known in a
small number of patients with complex partial seizures,
these were excluded in order that a uniform series of
patients with tonic clonic seizures could be studied.
The first tonic clonic seizure was defined as the first
ever afebrile tonic clonic seizure. Patients with a past
history of other seizure types, such as petit mal or
partial seizures that had previously gone unrecognised
were not included. Patients who developed another seizure
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type prior to treatment were also excluded. The intervals
between individual seizures were measured in weeks and the
difference between consecutive intervals were assessed
using parametric analysis. The influence of the early
patterns of seizure recurrence on the subsequent prognosis
was analysed by measuring the actuarial percentage of





The patients considered -for inclusion into the study were
all new referrals to the Neurology Outpatients Department
with newly diagnosed previously untreated epilepsy.
Between 1978 and 1984 a total of 281 patients were seen
who had experienced two or more untreated tonic clonic
seizures. Amongst these patients it was possible to
accurately measure the intervals between individual tonic
clonic seizures in 183, and these patients form the basis
of this study (see Appendix 6). The characteristics of
these patients and the 98 patients in whom the intervals
were unknown are shown in Table 5:1. Ninety-nine patients
(547.) were male and 84 (467.) were female. Twenty patients
(117.) had symptomatic epilepsy and 18 (107.) had associated
neurological handicaps. The median age at first seizure
was 17 years, range 2 to 65. One hundred and one (557)
had experienced 2 pre-treatment seizures, 53 (297) had 3,
18 (107.) had 4 and 11 (67.) had 5 or more.
There were 98 patients in whom the dates of individual
tonic clonic seizures were unknown. Amongst these
patients the pre-treatment interval and total number of
seizures could be ascertained in 76. A comparison of the
two groups of patients is shown in Table 5:1. The
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TABLE 5:1 CHARACTERISTICS OF 281 PATIENTS WITH TWO OR
MORE UNTREATED TONIC CLONIC SEIZURES. A COMPARISON OF
PATIENTS WITH KNOWN (N=183> AND THOSE WITH UNKNOWN (N=98)
SEIZURE INTERVALS
Patients With Patients With
Known Intervals Unknown Interval
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pre-treatment seizure frequency was 0.5 seizures per month
in the 1S3 patients with known seizure intervals compared
with 0.85 for those in whom the dates of individuals were
unknown. The patients with unknown seizure intervals
had experienced a larger number of attacks occurring
over a longer period of time. Amongst the patients with
unknown seizure intervals nearly one half had experienced
5 or more seizures, compared to only 10% for the other 183
who were entered into the study.
2. Intervals Between the First and Second Seizures
An analysis of the intervals between the first and second
seizures in the 183 patients is shown in Table 5:2. In 56
patients (31%) the interval was equal to or less than one
month. In 19 patients (10%) it was between one and two
months and in a further 18 (10%) between two and three
months. In 66 patients (36%) it was greater than three
months but equal to or less than one year. The interval
between the first and second seizures exceeded one year in
24 patients (13%).
3. Intervals Between Subsequent Seizures
The median interval between
clonic seizures decreased
occurred (Table 5:3). The
successive untreated tonic
with each seizure that
median interval between
TABLE 5:2 INTERVALS BETWEEN THE FIRST AND SECOND UNTREATED
TONIC CLONIC SEIZURES IN 183 PATIENTS WITH EPILEPSY
Interval Beteen First
Two Seizures N (7.)
Equal to or less than 1 month 56 (31)
Between 1 and 2 months 19 (10)
Between 2 and 3 months 18 (10)
Between 3 and 12 months 66 (36)
Greater than one year 24 (13)
Between 1 and 2 years 14 (8)
Between 2 and 3 years 4 (2)
Greater than 3 years 6 (3)
Totals 183 (100)
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first and second seizure was 12 weeks, between the second
and third it was 8 weeks , between the third and fourth it
was 4 weeks and between the fourth and fifth it was 3
weeks. When patients with three, four or five pretreatment
seizures were considered separately a similar trend was
seen. In 53 patients who experienced three seizures the
interval fell from 12 weeks between the first and second
seizure to 8 weeks between the second and third. In
patients with 4 pretreatment seizures it fell from 22 to
16 to 6 weeks with each successive seizure. In 11 patients
with 5 pretreatment seizures the interval between the
first and second was 24 weeks, between the second and
third it was 4 weeks, between the third and fourth it was
4 weeks and between the fourth and fifth it was 3 weeks.
A parametric analysis of the difference in successive
seizure intervals was undertaken. Eighty-two patients
experienced at least three untreated seizures; in these
patients the interval from the first to the second seizure
was on average 18.1 weeks longer than the interval between
the second and third, with 95% confidence levels at 5.4
and 30.7 weeks. The mean difference between the second and
third intervals was 4.1 weeks and between the third and
fourth intervals was 22.5 weeks. The decrease between
these seizure intervals was not statisticaly significant.
The majority of patients were treated -following the second
or third seizure (table 5:1). However it was possible to
compare the interval between any two seizures with that
between the subsequent two on 122 occasions (Table 5:4);
the interval between the first and second seizure with
that between the second and third in 82 patients; the
second to the third with the third to the fourth in 29
patients and third to the fourth with fourth to the fifth
in 11 patients. In 71 instances (587.) the interval
decreased, in 25 (217.) it remained the same and in 26(217.)
it increased.
4. The Influence of the Interval between the First and
Second Seizures on the Subsequent Prognosis on Treatment.
The influence of the interval between the first and second
seizures on the subsequent prognosis on treatment was
assessed for three groups of patients: those in whom the
interval between the first two seizures was equal or less
than 4 weeks (N=56), those in whom it was between 5 and 24
weeks (N=72) and the remaining 55 patients where it
exceeded 24 weeks (N=55). The outcome on treatment for the
last two groups of patients was very similar and only the
data relating to those with shorter interseizure intervals
are given in the Table and Figures below. The prognosis
was analysed by comparing the actuarial percentage of
227
TABLE 5:4 AN ANALYSIS OF 122 SUCCESSIVE SEIZURE
INTERVALS IN PATIENTS WITH UNTREATED TONIC CLONIC
SEIZURES. THE PROPORTION OF CASES IN WHICH THE SEIZURE
INTERVAL DECREASED, REMAINED THE SAME OR INCREASED
Successive Seizure Intervals
1st to 2nd 2nd to 3rd 3rd to 4th Totals
v. v. v.
2nd to 3rd 3rd to 4th 4th to 5th
N (7.) N (7.) N (7.) N (7.)
Decreased 48(59) 17(59) 6(55) 71(58)
The same 16(19) 5(17) 4(36) 25(21)
Increased 18(22) 7(24) 1 (9) 26(21)
All 82(100) 29(100) 11(100) 122(100)
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patients remaining seizure -free and the cumulative
probability of achieving a one year remission on
tr eatment.
Amongst the 56 patients in whom the initial interval
between the first and second seizures was equal to or less
than four weeks, five were untreated and in a further
eight follow up details on treatment were not available.
In 72 patients the interval between the first and second
seizure was between 5 and 24 weeks. In this group five
patients were untreated and no follow up was available in
seven.
The clinical characteristics of the two groups are
summarised in Table 5:5. There was no difference in the
total pretreatment seizure numbers. In patients with a
short initial interseizure interval the median pretreat¬
ment period was 2.5 months and the seizure frequency was
0.97 seizures per month. In the patients with a long
interseizure interval the corresponding figures were 6
months and 0.31 seizures per month. The median follow up
from the start of treatment was 21 and 13 months
respectively.
The probability of remaining seizure free from the start
of treatment for the two groups is shown in Figure 5:1. In
patients in whom the interval between the first two
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TABLE 5:5 THE INFLUENCE OF THE INTERVAL BETWEEN THE FIRST
AND SECOND SEIZURES ON THE SUBSEQUENT PROGNOSIS :
A COMPARISON OF THE CLINICAL CHARACTERISTICS OF THOSE WITH
SHORT AND LONG INTER SEIZURE INTERVAL
Intervals Between 1st and 2nd Seizure
= or less between 5
than 4 weeks and 24 weeks
(N=56) <N=72>
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Totals 56 (100) 72 (100)
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FIGURE 5:1 THE INFLUENCE OF THE INTERVAL BETWEEN THE
FIRST AND SECOND SEIZURES ON THE ACTUARIAL PERCENTAGE OF




















■Jroken lines = Patients in whom the interval between the first
two seizures was greater than one month.
*olid lines = Patients in whom the interval between the first
two seizures was equal to or less than one month
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seizures was between one and -four months the cumulative
probability o-f subsequently remaining seizure-free on
treatment was 507 by 3 months, 427 by 6 months, 297 by 1
year and 25'/. by 2 years. The corresponding figures for
patients with a long initial interseizure interval were
78"/., 64"/., 46"/. and 38"/. 5.4. d.f.=l, p= 0.02).
Patients in whom the second seizure followed the first
within a month were also less likely to remit on treatment.
Amongst these patients the cumulative probability of
achieving a 1 year remission on treatment was 277. by 1
year, 357. by 18 months, 507. by 2 years and 61'/. by 3 years
(figure 5:2). In patients in whom the interval between the
first two seizures was between 4 and 24 weeks, the
remission rates were 557. by 1 year, 627. by 18 months, 847.
by 2 years, and 94"/. by 3 years ( K = 4.3, d.f = l, p= 0.05).
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FIGURE 5:2 THE INFLUENCE DF THE INTERVAL BETWEEN THE
FIRST AND SECOND SEIZURES ON THE ACTUARIAL PERCENTAGE OF
PATIENTS REMAINING SEIZURE-FREE FOR ONE YEAR ON TREATMENT
risk 43 28 9
-Solid lines = Patients in whom the interval between the
■first two seizures was equal to or less than one month
-Broken lines = Patients in whom the interval between the
■first two seizures was greater than one month
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D. DISCUSSION
It is curious that amongst the considerable volume of
literature on the prognosis o-f patients with epilepsy,
there has been virtually no study o-f the patterns of
seizure recurrence at the onset of the disorder. An
understanding of this neglected area is of considerable
importance. According to the figures of Hauser and Kurland
(1975), at least 5"/l of the population can be expected to
experience at least one afebrile seizure at some time
during their life. A lack of clear prognostic data has led
to continuing uncertainty about the probability of seizure
recurrence, little information on the nature of adverse
prognostic factors and widely differing management policies
(Hauser, 19B6; Elwes & Reynolds, 19S8).
An analysis of the intervals between the first and second
seizures in 183 cases of epilepsy has been presented in
Table 5:2. The second seizure followed the first within a
month in one third of cases, by three months in half of the
patients and within a year in over four fifths. In patients
with established epilepsy therefore the second seizure
follows the first in rapid sucession. It was argued at some
length in the previous Chapter that many prognostic studies
in patients presenting with a single seizure have failed to
take account of this and excluded a significant proportion
of cases who experienced an early recurrence.
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Although over half the patients were treated -fallowing the
second seizure, it was possible to observe the intervals
between multiple untreated seizures in a number o-f cases.
Fi-fty-three patients had experienced 3 pretreatment
seizures, IS had had 4, and a further 11 had 5 or more
seizures before receiving medication. When four or more
seizures had occurred the median interval between attacks
was of the order of one month (see Table 5:3). The only
comparable data is to be found in the historical
literature. Gowers (1881) reported that in 880 cases of
"confirmed" epilepsy, the majority untreated, the interval
between seizures was of the order of one month in 807. of
cases. Herpin and Reynolds, writing prior to the widespread
introduction of bromides quoted similar results (see
Paskind & Brown (1939) for a review of the early
1iterature) .
1. Decreasing Seizure Intervals
A striking observation to arise from this study was the
tendency for the intervals between successive untreated
seizures to decrease with each seizure that occurred. The
median interval between the first and second attack was 12
weeks whilst between subsequent seizures it decreased
progressively to 8, 4 and 3 weeks. A similar trend was seen
when patients with 3, 4 or 5 seizures were considered
separately. It was possible to observe successive seizure
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intervals on 122 occasions. In three—f i f ths of cases the
interval decreased, in one-fifth it remained the same, and
in the remaining fifth it increased.
There are, however, two possible sources of bias that must
lead to a cautious interpretation of these results. There
were 98 patients excluded from the analysis because the
precise intervals between untreated seizures could not be
accurately ascertained. These tended to be patients who had
experienced a much larger number of attacks with a higher
seizure frequency, of the order of 0.8 seizures per month.
In comparison the seizure frequency for the 183 patients
who formed the basis of the analysis was 0.5 per month.
Because the group who were selected for the study had a
lower seizure frequency, they might appear on follow up to
have an increasing seizure frequency because of regression
towards the mean. This is a well described occurrence in
many biological systems where some form of bias is
introduced into the initial selection of the sample
(James, 1973). A second difficulty with the results is
that the timing of the initiation of treatment was not made
on a randomised basis. For example following
initial presentation a period of one month might elapse
before treatment was started. This would roughly
correspond to the time when investigations were being
undertaken. A number of patients might experience a
relapse during this period and therefore the sample would
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be biased towards those in whom subsequent attacks
occurred in rapid succession.
It is difficult to be certain to what extent both of these
considerations could have affected the results. In
patients with 2 or 3 pretreatment seizures, the median
interval between the first and second attack was equal for
both groups. This does not suggest that in these patients
(who formed over four-fifths of all those studied) that any
important selection bias had ocurred. There is no doubt on
the basis of clinical observation that there were a number
of striking cases in whom it was possible to document the
occurrence of decreasing seizure intervals in some detail.
This is well illustrated by the following case histories.
1. C.P., a 12 year old girl was initially seen in the
department in December 1981 having been referred because of
a single seizure. Her birth and early development had been
normal and her past history was blameless. There was no
family history of epilepsy. She was of high intelligence
and neurological examination revealed no abnormality. A
C.T. brain scan was normal and the EEG showed generalised
spike and wave evoked by photic stimulation. Treatment was
withheld and she was given a follow up appointment but her
parents failed to attend. She was readmitted to hospital on
7.1.1983 in status epilepticus having experienced 7
seizures without regaining consciousness. Following
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intravenous diazepam her seizure were controlled and she
■fortunately made a full recovery and has subsequently
responded well to treatment with sodium valproate. It
transpired that for the previous year her parents had taken
her to a herbalist who instructed them to keep a diary of
all seizures that occurred. The unfortunate child experienc¬
ed multiple seizures extending over the period of a year.
Although the intervals between the initial seizures
increased she subsequently had clusters of attacks with
decreasing intervals between the episodes culminating in
status epilepticus one year after the initial seizure. There
is little doubt that if effective treatment had been
instituted immediately she would have remained largely
seizure-free.
ii. D.M., a 48 year old man developed seizures secondary to
an arterio-venus malformation which came to light fallowing
a subarachnoid haemorrhage in 1967. His first seizure
occurred seven years after the haemorrhage and the second
attack five years later. According to his wife the next
seizure occurred after two years and successively at
intervals of 18, 6, 2.5, 2, 2, and 1.5 months at which time
he was treated with diazepam. Following this the intervals
fluctuated and occurred at intervals of around 3 months. He
was subsequently given carbamazepine and has achieved a
satisfactory remission of seizures.
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It is, of course, uncertain what proportion of cases
would have a similar outcome if treatment were witheld.
Turner (1907) in his book on Epilepsy described the
phenomenon of decreasing intervals between multiple
untreated seizures in some detail. Bowers (1881) stated
that seizures were self propagating, each attack
predisposing to the next and that spontaneous remission
of the disorder was exceptional1y rare. For the reasons
discussed above the results presented here must be treated
with caution as there is likely to be a major source of
bias introduced by inescapable ethical and practical
considerations. However the findings are in agreement
with Gowers' hypothesis and do not suggest that many
patients would be likely to remit spontaneously, at least
at the onset of epilepsy. Further studies are needed to
examine the initial patterns of seizure recurrence in
epilepsy. It would be of considerable interest to
document the impact of treatment on the intervals between
seizures, particularly if the decision to start or withold
treatment was made on a randomised basis. The possibility
of undertaking such a trial will be discussed in greater
detail in the next Chapter.
239
2. The Early Patterns of Seizure Recurrence Determine the
Long Term Prognosis o-f Epilepsy.
A related question that has received little attention in
the literature is the influence of the early patterns of
seizure recurrence on the subsequent prognosis of epilepsy.
In Chapter 3 it was found that pretreatment tonic clonic
seizure frequency was the single most important factor
determining the probability of remaining completely seizure
free from the start of treatment (see figure 3:2).
Similarly patients with a high initial seizure frequency
were less likely to achieve a prolonged period of seizure
control (see Table 3:3). A number of other authors have
reported that a high pre-treatment seizure frequency is a
poor prognostic sign (Strobos, 1959; Kuhl et al, 1967;
Okuma & Kumashiro, 1981; Schmidt et al, 1983). These
results, however, are open to a number of difficulties in
interpretation as all except Schmidt et al (1983) did not
distinguish between different seizure types. It is
important that patients with generalised convulsions be
considered separately from those with partial seizures. In
the latter group, who are known to have a poor prognosis,
seizures almost always occur in greater numbers, and often
at a higher frecqency.
In the present Chapter the influence of the interval
between the first and second tonic clonic seizure on the
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subsequent prognosis was studied. This is a more precise
measurement than seizure frequency as the latter will
depend to some extent on the timing of initiation of
treatment. In patients in whom the interval between the
first and second seizures was equal to or less than a month
25% remained completely seizure free on treatment. The
comparable figure for patients in whom the interval was
between 4 and 24 weeks was 38%. Similarly in patients with
a short initial interseizure interval 61% remitted on
treatment compared to 94% for those patients with a longer
interval. This is an important observation and suggests
that the initial seizure interval may determine the
duration of time for which epilepsy is likely to remain
active. The possibility arises that early treatment
following the first seizure might delay the occurrence of




1. The intervals between untreated tonic clonic seizures
have been analysed in a consecutive series of 183 patients
with newly diagnosed epilepsy. One hundred and one
patients had experienced 2 pretreatrnent seizures, 53 had 3,
18 had 4 and a further 11 had had 5 or more attacks before
treatment.
2. The second seizure followed the first within a month in
307. of cases and within 3 months in 517.. The interval
between the first two seizures exceeded 1 year in 137..
3. The median interval between the first two seizures was
12 weeks, between the second and third it was 8 weeks, 4
weeks between the third and fourth and 3 weeks between the
fourth and fifth. When patients with 3, 4 or 5 or more
seizures were analysed separately a similar decreasing
interval between successive attacks was seen. Using
parametric analysis the decrease between the first three
seizures was significant at the 95^ level. It was possible
to observe intervals between successive seizures on 122
occasions. In three-fifths of cases the interval decreased,
in one-fifth it remained the same and in one-fifth it
increased.
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5. The influence of the interval between the -first and
second seizure on the subsequent prognosis on treatment was
examined. In patients in whom the second seizure -followed
the -first within a month 25"/. remained seizure free at 2
years of follow up. In those in whom the first
interseizure interval was between 5 and 24 weeks 38"/.
remained seizure free. Amongst patients with a shorter
initial seizure interval 61'/. achieved one year remission by
3 years of follow up whilst those with a longer interval
94"/. achieved remission.
CONCLUSIONS
In established epilepsy the second tonic clonic seizure
follows the first in rapid succession, within a month in
one third of cases and within three months in one half of
patients. The interval between successive untreated
seizures appears to decrease with each seizure that occurs.
Patients in whom the second seizure follows the first
within four weeks have a signficantly worse prognosis on
treatment. These findings suggest that the early patterns
of seizure recurrence are of considerable importance in
determining the subsequent prognosis of epilepsy. Further
prospective studies are needed to clarrify these issues
and to determine the effects of early and delayed tretment




A. DIFFERING CONCEPTS OF PROGNOSIS IN EPILEPSY
The prognosis of patients with epilepsy has always been a
subject of considerable controversy. The literature, both
historical and modern, is full of conflicting statements.
The Ancients felt that prognosis in epilepsy was generally
gloomy. Epilepsy dating from birth was thought to be
incurable and if it started after the age of 25 years, it
usually lasted until death. Epilepsy that began in old age
was usually fatal . Flowever it was recognised, even in the
Fli ppocrat i c writings, that the prognosis might be better in
childhood and that in general it was important to treat
the disease before it became chronic (Temkin, 1971).
Similarly, many writers in the Nineteenth Century also felt
that prognosis was poor. Reynolds, Delasuive, Esquirol,
Heberden and Fere all emphasised the poor response to
treatment, although as Temkin (1971) has pointed out, many
of these authors based their experience on institution¬
alised patients. In contrast to these views, Flerpin's work
caused considerable controversy when he claimed to cure
half of his patients and ameliorate seizures in another one
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quarter using zinc oxide (see page 78).
During the second halt of the 19th century a major advance
in the treatment of epilepsy occurred. The credit tor the
introduction ot bromides has been given to Sir Charles
Lowcock tollowing a remark made at a meeting ot the Royal
Medical and Chirurgical Society in 1857 (Sieveking, 1857).
Within tour years Wilks (1861) stated that the drug was
used in all new cases ot epilepsy and that it was
"singularly etticacious". Gowers (1881) thought that the
prognosis ot epilepsy had been "materialy changed" by their
introduction and they were ettective in cases which had
previously been considered most unpromising (see page 36).
As late as 1953 Livingston claimed that they were highly
ettective in childhood epilepsy. A number ot carefully
documented clinical trials are available in the 20th
century literature comparing their efficacy favourably with
currently available drugs (Pollock, 1938. Arieff, 1951.
Livingston & Pearson 1953.)
Although the subsequent introduction of phenobarbitone in
1912 (Hauptmann, 1912) and phenytoin in 1938 (Merritt &
Putnam, 1938) were important advances, largely because
these drugs were felt to be less toxic, there is
surprisingly little evidence that they were any more
effective than bromides in controlling seizures. Following
their widespread usage, the opinions of many authoritative
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authors in the -first hal-f o-f this century, such as Gibbs
(1947), Livingston (1958) and Lennox & Lennox (1960) was
that as many as three quarters o-f patients were either
improved or completely controlled on medication.
It might have been hoped that with the widespsread usage of
drugs of undoubted efficacy clear evidence as to their
beneficial effects on the prognosis of epilepsy would have
been established. It is curious, however, that Rodin (1968)
in an authoritative review written a century after the
introduction of bromides, could find little evidence that
this was indeed the case. He criticised the opinions of
previous authors because their observations were based on
inadequate follow up of patients and that furthermore the
great majority has failed to define clearly what
constituted control of seizures. He found that all the
prognostic studies that overcame these methodological
problems showed that at most only one third of patients
could expect to be controlled for a period of one year or
more (see Table 1:11). Furthermore because of the tendency
of the disease to relapse epilepsy was likely to be a
chronic disorder in 807. of cases.
Rodins' work, and the prognostic studies on which he based
his authoritative and widely quoted review are open to a
number of important criticisms. As was discussed in
Chapter 3 differing methods of classification, retrospect-
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i ve analysis and poor documentation of treatment methods
have led to difficulties in interpretation of the results.
The single most important criticism, however, has been
patient selection. Because of the highly variable outcome
in epilepsy selection of patients is of crucial importance
in determining the results of prognostic studies. Patients
with intractable seizure disorders are likely to accumulate
in specialised neurology or epilepsy clinics. Follow up
studies based on a cross sectional selection of
patients attending such clinics is likely to give an unduly
gloomy view of prognosis. In some of the studies quoted by
Rodin (see Table 3:5) the mean duration of epilepsy prior
to entry was greater than ten years. Unfortunately not all
authors have clearly stated the methods of patient
selection but there is little doubt that patients with
chronic epilepsy have been strongly over represented.
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B. THE PROGNOSIS FOR SEIZURE CONTROL IN NEWLY DIAGNOSED
EPILEPSY
There is almost a complete dearth in the literature of
prognostic studies that have examined the initial response
to treatment and the prognosis during the early years o-f
the disorder. Only one study has commented upon initial
remission and relapse rates, and this was undertaken with
special reference to traffic security (Kuhl et al, 1967).
Prognostic studies based on the follow-up of consecutive
new cases are, of course, harder to undertake. Unless a
multicentre design is used patient recruitment takes a
prolonged period of time. Furthermore there are
difficulties in maintaining prolonged follow-up. Many
patients with de novo onset of seizures are referred to
hospital primarily for diagnosis and investigation. A
considerable number subsequently default from follow up or
are discharged back to the care of their family
practitioner.
The prognostic study described in Chapter 3 was unique in
that patients were identified as a group from the time of
diagnosis. Follow up was prospective for periods of almost
a decade. Not only was a detailed record kept of the
timing and number of seizures experienced but a consistent
policy of treatment was maintained throughout the period of
follow up. Patients were treated with monotherapy with
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widespread use o-f anticonvulsant level monitoring to assess
optimum treatment and poor compliance with medication. A
number of important conclusions arise -from this work which
will be considered below.
1. First Seizure Recurrence on Treatment
The majority o-f patients with newly diagnosed epilepsy
experience at least one -further seizure on treatment. Out
of the 106 patients considered in Chapter 3, 80 experienced
a further seizure on treatment, most occurring within the
first year of follow up. On the basis of actuarial
pr obabi 1 i t i es (see Figure 3:1) 607. could be expected to
have a recurrence during the first year of treatment and a
further 197. during the next seven years of follow up.
A number of anticonvulsant trials in newly diagnosed
epilepsy have been published in recent years (see Table
1:4). These have all been analysed by examining the
proportion of patients remaining seizure free from the
start of treatment. Those with short periods of follow up
(Strandjord & Johannessen, 1980; Feely et al, 1982) have
shown that approximately 207 of patients experience a
seizure recurrence. In the study by Turnbull et al (1982),
where all the patients were followed for at least one year,
427. experienced further seizures. In the Veterans
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Administration Trial (Mattson et al, 1985) patients were
■followed -for periods of up to six years and the relapse
rates reported were very similar to those given here. These
findings emphasise that in analysing outcome in newly
diagnosed epilepsy duration of follow up is of crucial
importance in determining the results. When there is
variable follow up actuarial probabilities rather than
crude relapse rates should be used.
2. Remission and Relapse Rates in Newly Daignosed Epilepsy
Although most patients experienced at least one further
seizure after starting treatment the subsequent prognosis
for seizure control was extremely good. Ninety two per
cent of all patients achieved a one year remission by eight
years of follow up. Most patients whose seizures were
controlled for one year subsequently went on to a second
year completely sei zure-f ree. At the end of follow up B27.
of patients achieved a two year remission. The duration of
follow up was not long enough to allow accurate
determination of longer periods of remission but it was
apparent that once a remission had occurred the subsequent
prognosis was extremely good. There were 76 patients who
achieved a two year remission in whom further follow up was
available (See page 146) and of these 25 experienced a
relapse. In three-quarters of cases these were isolated
often related to poor compliance with medication. Most
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patients who relapsed subsequently went on to a -further
prolonged period of remission. Once a two year remission
had occurred no patient subsequently developed an
intractable seizure disorder.
These findings are almost a complete reversal of the
conclusions reached by Rodin (1968) who found that 807. of
patients are likely to have a chronic seizure disorder. In
contrast it appears that in patients followed prospectively
from the onset of the illness as many as four-fifths will
experience a prolonged and sometimes permanent remission of
seizures. Rodin's other main conclusion was that the
percentages of patients who are regarded in terminal
remission stand in marked indirect relationship to the
length of follow up. In the present study the prognosis
improved with increasing duration of follow up (see Figure
3:3) and furthermore the likelihood of relapse decreased
the longer seizures were controlled (see Table 3:2).
It is likely in the present study that the treatment
methods had a significant impact on seizure control.
Patients were started on treatment with either phenytoin or
carbamazepine monotherapy and the dosage increased with the
help of anticonvulsant level monitoring. If further
seizures occurred the dosage was increased until optimal
anticonvulsant levels were obtained. Unlike all other
prognostic studies a consistant policy of treatment was
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used throughout the period of -follow up thus ensuring that
drugs were used to their maximum effect.
A more important reason for the good results, however, is
likely to be patient selection. All previous prognostic
studies reported in the literature have been based on the
cross sectional selection of cases attending specialised
neurology or epilepsy clinics. Such methods of selection
will lead to cases of chronic epilepsy being strongly over
represented and give rise to an unduly gloomy view of
prognosis.
There are a number of important pieces of evidence that
support the conclusion that epilepsy is likely to have a
good prognosis in a high proportion of cases. Firstly those
prognostic studies which have examined epilepsy of short
durations have tended to show a better outcome. Kuhl et al
(1967) found that in patients with recent onset of seizures
(within 5 years from the time of entry into the study) 617.
achieved remission. These results approach those found in
the present investigation. In the largest prognostic study
yet published Okuma & Kumashiro (1991) used a similar
method of case selection and found that 587. of patients
remitted on treatment.
Probably the strongest evidence to support the conclusions
presented here comes from the epidemiology of epilepsy. It
is possible to study the natural history o-f a disorder by
comparing the incidence and prevalence rates. In a disease
in which the majority of cases become chronic the sum of
the incidence rates over a whole life time (the so called
cumulative life time incidence) should equal or approach
the point prevalence. As the mortality rates in epilepsy
are not high (Hauser, 1975) it is reasonable to use this
approach to study the natural history of epilepsy
(Zielinsky, 1982; Juul-Jensen & Foldspang 1983). Hauser &
Kurland (1975) measured the annual incidence rates for
epilepsy in Rochester, Minnesota as 50 per 100,000 of the
population. Assuming a 70 year life expectancy this implies
that 3.57. of the population could be expected to develop
epilepsy at some time during their life. If patients with
single seizures were included the figure rose to 5.97. In a
survey of the epilepsies in general practice in England and
Wales (Research Committe of the College of General
F'r act i t i oner s , 1960) the cummlative life time incidence
for new cases of epilepsy was 4.37. Results of a similar
order of magnitude have also been found in prospective
follow up studies of cohorts of live births. In the most
extensive of these Ellenberg et al (1984) found that even
after exclusion of neonatal seizures 1.37 of children had
experienced one or more seizures by the age of 7 years. In
comparison the prevalence rates for active epilepsy
(usually defined as seizures within the last two years or
continuous medication over the same period) are of the
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order of 4 to 10 per thousand (Zielinsky, 1982). The ten
•fold difference between the cumulative incidence and
prevalence rates in epilepsy suggest that in only a small
proportion of cases does the disease remain active. Studies
of epilepsy in the community have been of considerable
importance in clarifying our understanding of the prognosis
and natural history of epilepsy. Two such studies have been
undertaken in adults (Annegers et al, 1979; Goodridge &
Shorvon, 1983) and although they were retrospective, the
results were in remarkably close agreement to those
reported here. Both showed that in patients drawn from an
unselected population prolonged and often permanant
remissions occurred in as many as three quarters of cases.
3. Prognostic Factors in Newly Diagnosed Epilepsy
Epilepsy is a very heterogeneous illness and it is
possible to subdivide the disorder into different groups
in which the prognosis may vary widely. The principal
division, as proposed by The Commission on Classication and
Terminology of the International League against Epilepsy
(1981 &1985), is into partial and generalised epilepsies
(see Page 21). In clinical practice this is usually made on
the basis of seizure type and supported by the results of
the electroencephalogram and radiological investigations.
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The partial and generalised epilepsies are -further
subdivided into idiopathic and symptomatic cases in
accordance with the presumed aetiology.
There has been no previous attempt to study in detail the
importance o-f these possible subdivisions in predicting
the prognosis from the onset of the disorder. In the
present study seizure type was one of the most important
prognostic indicators. Patients with partial seizures,
with or without secondarily generalised attacks, had a
significantly poorer outcome. Seventy-three per cent of
patients with this seizure type experienced a remission
compared to 977. for those with tonic clonic seizures alone
(see Table 3:3). Patients with symptomatic epilepsy and
associated social and psychiatric handicaps also had a
worse prognosis. Although a substantial proportion of
patients with any one of these adverse factors still had a
good prognosis, a clear picture emerged of the type of
patient who responded poorly to medication at the start of
the disorder. These were patients in whom there was a high
incidence of structural brain disease as shown by a
tendency to partial or mixed seizure types, symptomatic
epilepsy and associated cognitive and neurological
deficits. The initial EEG was of little use in predicting
prognosis but those with difusely abnormal background
rhythms tended to do poorly, possible because this finding
was again associated with cerebral damage. Despite the
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overall good prognosis in epilep
to accumulate in specialised
intractable seizure disorders
prevalence of the disorder
management problem.
sy these patients will tend
epilepsy clinics with
and because of the high
they represent a major
In marked contrast to the controversy that has existed in
the literature on the overall prognosis in epilepsy there
has been good agreement on the nature of these adverse
prognostic factors. Gowers (1881) found, shortly after the
introduction of bromides, that patients with minor
seizures and those with neurological deficits such as
haemiplegia tended to have a worse prognosis. Rodin (1968)
concluded that those with temporal lobe seizures had been
consistently reported to have a poorer outcome and he also
emphasised that the occurrence of multiple seizure types
was a particuarly poor prognostic sign. In addition those
with a low IQ and an abnormal neurological examination
tended to do less well. These adverse prognostic factors
are broadly similar to those identified as being of
importance in predicting a relapse following a first
seizure and a recurrence following anticonvulsant
withdrawal (see pages 72 and 107).
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4. The Initial Response to Treatment Determines the Long
Term Prognosis in Epilepsy
Perhaps one of the most striking observations to arise
from this study was the importance of the early response
to treatment in determining the long term prognosis of
epilepsy. All other studies, being strongly biased towards
cases with long standing established seizure disorders,
have failed to examine the remission rates at the onset of
epilepsy. In the present study three-quarters of all
patients who were going to remit were either in or
entering a one year remission during the first year of
treatment (see Figure 3:3). A further 15% entered
remission during the second year of treatment and after
this time only occasional cases were subsequently
controlled. As was explained above, following a one year
remission most went on to a second year seizure free and
the subsequent prognosis was extremely good. Thus for the
great majority of patients the long term pattern of
seizure control was established during the first two years
of treatment. Overall 92% of patients achieved a one year
remission. In patients who continued to have seizures
during the first year of treatment 72"/. subsequently
remitted and of those with seizures in the second year 527.
subsequently achieved a one year remission. Thus the
longer the seizures continued after the start of treatment
the harder they were control (see Figure 3:5). In patients
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who -failed to achieve a one year remission the outlook was
very poor. Ninety per cent had seizures during every two
month interval of follow up and most of them went on to
develop chronic intractable epilepsy.
If the initial years are of such importance in determining
the long term prognosis in epilepsy the question arises as
to whether more effective treatment at the onset of the
disorder might improve the subsequent outcome and reduce
the proportion of those developing chronic epilepy. In
the present study patients were treated if they had
experienced two or more tonic clonic seizures particularly
if these occurred during the space of one year. This is
likely to conform to the current practice of most
neurologists in this country. In practice, however, many
patients had experienced a surprisingly large number of
seizures before treatment was given. In Chapter 4 the
referral patterns were analysed in a consecutive series of
214 patients with one or more tonic clonic seizures seen
over a five year period. Sixty eight per cent of patients
presented to medical attention following a first ever
seizure which was usually to their general practitioner or
a casualty officer within 24 hours of the attack. However,
in 43 patients a further seizure occurred during the
interval between the first attack and the time of first
being seen in the neurology outpatients department. A
further delay occurred during which pretreatment
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investigations were undertaken. From the data presented in
Chapter 3 (see Table 3:3) nearly half of the patients with
newly diagnosed epilepsy had experienced four or more
tonic clonic seizures before treatment was actually
started.
It is possible that such a delay in initiating treatment
could lead to a subsequent worsening of prognosis. In
patients who experienced four or more pretreatment tonic
clonic seizures 83V. subsequently remitted (see Table 3:3).
In those with two or three seizures the corresponding
figures were 96% and 95% respectively. Although this just
failed to reach statistical significance it does suggest
that prognosis may deteriorate with increasing number of
pretreatment seizures.
A number of authors have also reported that prognosis
deteriorates with increasing duration of illness and the
total number of seizures. Gowers (1881) found that in
patients treated with bromides within one year of the
onset of the illness 83% had their seizures arrested.These
patients are likely to correspond broadly to those with
newly diagnosed epilepsy described in Chapter 3. It is
striking that his results are almost identical to those
reported here using phenytoin and carbamazapine. In those
patients with an initial duration of illness lasting 1 to
5 years, 5 to 9 years and greater than 10 years, the
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proportion controlled decreased progressively to 73%, 69%
and 60% respectively (see Table 3:6). It is o-f coarse
impossible to be certain that the drugs used prior to
bromides were ineffective but there appears to be good
agreement in the historical literature that bromides were
considerably superior to anything that was previously
available (Shorvon, 1987). Gowers' career spanned the
introduction of bromides so he was able to observe the
outcome in those with a long history of untreated seizures
and to subsequently document the dramatic effect that this
drug had on the long term prognosis. It is this which made
his observations of such particular interest. He
subseqently went on to hypothesise that seizures were self
propagating, each attack predisposing to the next, a
theory hie thought to be of importance since he placed it
on the first page of his book (Gowers, 1881). A number of
modern authors have also found that prognosis deteriorates
with increasing number of pretreatment seizures. In the
carefully documented Japanese Multi-institutional Study
pretreatment seizure number was a highly significant
prognostic factor, those with multiple attacks having a
worse prognosis. Others have reported similar findings
(Maldonando et al, 1987; Johnson, personal communication),
and indeed Rodin (1968) included it as one of his major
findings following his comprehensive review of the
literature (see page 87).
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C THE EARLY PATTERNS OF SEIZURE RECURRENCE IN EPILEPSY
There has been no previous attempt in the literature to
analyse the patterns o-f seizure recurrence at the onset of
epilepsy or to determine the effects that this may have on
the subsequent prognosis. Although a number of authors
have examined prognosis in patients presenting following a
first seizure the results have been widely conflicting
(see Table 1:8) and at variance with the data obtained
from the epidemiology of the disorder. This has led to
continuing uncertainty about the probability of seizure
recurrence, a lack of clear data as to the nature of
adverse prognostic factors and widely differing treatment
policies.
1. Prognosis following a First Seizure
Estimates of the cumulative incidence of epilepsy suggest
that at least 57. of the population will experience one or
more afebrile seizure at some time in their life (Hauser &
Kurland, 1975). The patient who presents with a single
seizure is a common clinical problem yet until recent
years there have been relatively few studies that have
examined this aspect of prognosis. In the earlier
prognostic studies shown in Table 1:8 (Thomas, 1959;
Johnson et al, 1972; Saunders & Marshall, 1975; Cleland et
al, 1981) the documentation of clinical characteristics
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was generally poor and the numbers of patients studied
insufficient to allow -for accurate determination o-f
prognostic factors. Many have analysed results by
measuring crude relapse rates rather than using actuarial
probabi1ities to take account of variable follow up.
Treatment policies have differed widely with recent North
Americal surveys (Hauser et al, 1982; Camfield et al,
1985; Annegers et al, 1986) reporting that as many as
two-thirds patients were given medication following a
first seizure.
In Chapter 4 the prognosis following a first ever tonic
clonic seizure was assessed in a series of patients
referred to a neurology outpatients department. Over a 5
year period 214 patients were consecutively referred with
one or more tonic clonic seizures. An initial analysis
was undertaken to determine the probability of recurrence,
regardless of whether the patients had presented with one
or more attacks. After a median follow up of 21 months
from the time of the first seizure 64 patients (30%) had
experienced only a single seizure and the remaining 150
(70%) had two or more. Patients who developed epilepsy
were more likely to have symptomatic seizures and to be
under the age of 16 years but otherwise the two groups did
not appear to differ in any major respect.
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This analysis may have over estimated recurrence rates as
it is possible that patients with more than one seizure
were more likely to be referred to hospital. In certain
instances general practitioners or casualty officers may
fail to refer a number of patients who had experienced
only a single attack. Studies of how doctors in the
community deal with patients who have experienced seizures
suggest, however, that this is indeed the case in only a
minority of instances (Hopkins & Scrambler, 1977;
Goodridge and Shorvon, 19Q3). The results of epidemiology
surveys that have included cases with single seizures are
broadly similar to those presented here based on
consecutive referrals to a neurology outpatients
department. These have all shown that amongst patients
identified from an unselected population seizures are
likely to be recurrent in 607 to SO*/, of cases (Table 1:7).
The prognosis of patients who actually present to medical
attention with a single seizure will depend crucially upon
two factors. Firstly the proportion of those who,
following the onset of seizures, actually seek help
following the first attack. In the present study 146
patients or 6S7. of the total were seen by their G.P. or in
a casualty department usually within 24 hours of the
event. It appears that even with readily available medical
facilities about one-third of patients do not seek help
until two or more seizures have occurred, possibly because
263
the -first event was not witnessed or occurred during
sleep. Others have reported similar -findings. In the
community based survey of prognosis following a first
seizure reported by Annegers et al (1985) 50'/. of the
patients were excluded because they had experienced two or
more seizures when first assessed. Clearly if a greater
proportion of patients present following the first attack
then the observed recurrence rate would be correspondingly
higher.
The second factor that can influence the results is the
interval of time that elapses between the first seizure
and entry into the prognostic study. In the patients
described in Chapter 4, 148 were seen within 24 hours of
the initial attack. Of these 71% experienced a recurrence
by 4 years of follow up. However from this initial 148
patients 43 had already experienced a recurrence by the
time of first being seen in the out patients department
after a median interval of one month. The remaining 103
patients had a better prognosis with 56% experiencing a
further attack by 4 years of follow up (see Figure 4:1).
In many of the prognostic studies shown in Table 1:8 a
considerable delay, often of one to two months, occurred
before patients were entered into the study. For the
reasons explained above these patients are likely to have
a signifcantly better prognosis by virtue of the fact that
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they have remained seizure -free -for an appreciable period
o-f time. Todt et al (1985) found that in children seen
within two weeks of an initial seizure 59% experienced a
recurrence, even after exclusion of any seizures that had
occurred after the first year of follow up. Hopkins et al
(1988) has recently reported that in patients seen within
a week of the first seizure, 52% subsequently developed
epilepsy, but in those who remained seizure free after
eight weeks the recurrence rate was 22%.
In the present study a number of prognostic factors were
analysed by comparing the actuarial percentage of patients
experiencing a recurrence. In assessing prognostic factors
it is important to emphasise that patients who present
with a single seizure are a selected group and differ from
those with epilepsy in a number of important respects.
Those with partial seizures will be largely excluded as
the great majority have had multiple attacks when first
seen. Similarly there is likely to be a lower overall
incidence of symptomatic seizures and associated
handicaps. For this reason the very factors that have been
most consistently reported to be of prognostic
significance in patients with epilepsy will be largely
excluded in series of patients presenting following a
single seizure. In the present study those with
symptomatic seizures had a worse outcome which is the only
factor which has been consistently reported as being of
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prognostic importance by those authors who have examined
its significance (Hauser et al , 1982; Cam-field et al ,
1985; Annegers et al, 1986). In clinical practice the time
that has elapsed since the initial seizure occurred is
likely to be of more use in predicting a subsequent
recurrence.
2. Intervals between Untreated Seizures in Patients with
Established Epilepsy
In Chapter 5 the intervals between consecutive untreated
seizures were analysed in a further 183 cases with two or
more tonic clonic seizures. One hundred and one patients
experienced two pretreatment seizures, 53 had 3, 18 had 4
and 11 had experienced 5 or more. Amongst all 183 patients
the second seizure fallowed the first in one month in a
third of cases, within three months in half the patients
and within a year in over four-fifths. In patients in whom
the interval between the first and second seizure was less
than a month the subsequent prognosis on treatment
deteriorated. In addition to being less likely to remain
seizure free on treatment the proportion achieving
remission was also significantly lower (see Figures 5:1 &
5:2). These findings are in keeping with the observation
made in Chapter 3 that pretreatment seizure frequency is
an important determinant of the subsequent prognosis on
epi1epsy.
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A striking finding was that in most patients who
experienced multiple attacks the median interval between
seizures decreased with each seizure that occurred. For
all 183 patients the median interval between the -first and
second seizures was 12 weeks, between the second and third
it was 8 weeks, between the third and fourth it had fallen
to four weeks and between the fourth and fifth the median
interval was 3 weeks. A similar trend was noted when
patients with three, four or five seizures were considered
separately (see Table 5:3). It was possible to observe
consecutive seizure intervals on 122 occasions. In
three-fifths of cases the interval decreased, in one fifth
it remained the same and in the remaining fifth it
increased.
This finding, however, must be considered preliminary and
should be interpreted with caution. A significant number
of cases, 98 in all, had experienced a large number of
seizures that could not be accurately dated and these were
excluded from the analysis. In these patients the
pretreatment seizure frequency was 0.85 attacks per month
compared with 0.5 seizures per month for the 183 patients
who were studied. Because of the bias introduced into the
initial selection of cases the subsequent seizure
intervals might appear to decrease because of regression
towards the mean. Furthermore, the timing of initiation of
treatment was not made on a randomised basis as it was not
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-felt ethically justified to withhold treatment in those
who had experienced multiple seizures. It is o-f course
possible that i-f treatment had been withheld the intervals
might have lengthened in a significant proportion of
cases.
Apart from the data presented here and some observations
made by Gowers there appears to be no other study that has
analysed this aspect of the early prognosis of epilepsy.
The initial results suggest that the early patterns of
seizure recurrence are of considerable importance in
determining the subsequent prognosis in epilepsy.
Goodridge & Shorvon (1983) have reported in cases
identified from the community that epilepsy is usually a
short lived disorder with most patients experiecing about
ten seizures in total. The findings presented here suggest
that the interval between the first and second seizure
might be an important determinant of the length of time
during which the illness is likely to remain active.
Further studies are needed both in treated and untreated
patients to examine the early patterns of seizure
recurrence in patients with newly diagnosed epilepsy and
to clarify the possible effects on subsequent prognosis.
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3 The Natural History of Untreated Epilepsy
It was shown in the previous sections that following the
initiation of anticonvulsant medication the majority of
patients with epilepsy rapidly enter a prolonged period of
seizure control, usually within one to two years of
starting treatment. The subsequent outlook is extremely
good and in a significant proportion of cases the
remission of seizures may indeed be permanent. In
contrast, in those who continue to have seizures, the
prognosis deteriorates the longer the disorder remains
active. It remains uncertain, however, to what extent
these findings represent the natural history of the
disorder and what proportion of cases might, without
treatment, have remitted spontaneously.
The clearest statement on the prognosis of untreated
epilepsy was written by Gowers over a century ago. In
describing the course and prognosis of epilepsy he paid
particular attention to the onset of the disorder. He
stated clearly that following a first seizure the majority
of patients will develop epilepsy. He went on to give an
analysis of the intervals between the first and second
seizures in a 160 cases and concluded that the second
seizure followed the first within a month in one third of
patients, within a year in another third and exceeded one
year in the remaining third (see Table 1:6). Furthermore,
269
when the disease was con-firmed and multiple attacks had
occurred the interval -from freedom from seizures did not
exceed one month in 80'/. of cases. This observation was
based on clinical data from 688 patients, the majority
untreated. Bowers went on to say, in a widely quoted
statement that spontaneous remission of epilepsy was "an
event too rare to be reaonably anticipated in any given
case".
There are always difficulties in interpreting information
in the historical literature. It is uncertain as to the
precise group of patients Gowers was referring to when he
made this statement. The literature is full of erroneous
conclusions concerning the prognosis of epilepsy based on
selected or unrepresentative groups of patients. It is
unlikely, however, that he was referring exclusively to
those with chronic intractable epilepsy. It had been known
for centuries that these patients would not remit, either
with or without treatment. Gowers practice was evidently
enormous and his diligence and clarity of clinical
desription unequalled. He studied the early prognosis of
epilepsy in considerable detail and his conclusions, or at
least those which have been possible to test, have proved
largely correct. His observation that the introduction of
bromides had a dramatic effect on prognosis suggest that
in discussing the natural history of epilepsy he was not
confining himself to patients with intractable seizures.
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With the current provision of medical services the great
majority of patients who develop epilepsy receive
effective treatment early in the course o-f the disorder.
Our ability to study the natural history o-f untreated
epilepsy is severly limited. Zielinsky (1976) has reported
in a -field study carried out in Warsaw that as many one
third o-f patients who developed seizures did not appear to
receive any treatment. Similar results were -found in a
•field survey in Iceland (Gumundsson, 1966). The patients
identified by Zielinsky were largely unknown to the
established medical facilities and the prognosis was not
commented upon. It is likely furthermore that patients who
do not seek help from doctors will be a selected sample,
perhaps containing a high proportion of cases with acute
symptomatic seizures such as those occurring in the
context of alcohol withdrawal. Similarly epidemiology
surveys carried out amongst primitive populations where
modern drugs are not freely available have not commented
upon prognosis (Mathai et al, 196S).
Shorvon et al (1935) have argued that because of these
uncertainties there is reasonable grounds for conducting a
placebo controlled trial of anticonvulsants in newly
diagnosed epileptic patients comparing the outcome in
those treated and untreated. The possibility of
conducting such a trial will be considered in a later
section but suffice it to say there appears to be
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insurmountable ethical objections to withholding a
treatment of known efficacy from patients with established
epi1epsy.
The data on the early patterns of seizure recurrence
reported here suggest that at the onset of epilepsy
spontaneous remission is likely to be an unusual event.
Despite the controversy which has existed in the
literature it does indeed appear that following a first
seizure the majority of patients will experience a
recurrence. It seems most unlikely, therefore, that a
significant proportion of those patients with two, three
or more seizures would remain seizure free without
treatment. Indeed in patients with established epilepsy
(defined here as two or more attacks occurring within the
space of one year) nearly four-fifths experience at least
one more seizure, even with effective treatment (see
figure 3:1). The decreasing interval between successive
untreated seizures and the high seizure frequency in
patients with multiple attacks also suggest that
spontaneous remission is unlikely.
It is possible that in some patients the natural history
may be a burst of seizures, perhaps four or five attacks
occurring within the space of a year, followed by
spontaneous and permanent remission. This could not be
excluded on the basis of the current knowledge of the
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early prognosis of epilepsy. Presumably such cases could
only be identified with certainty by witholding treatment
in a series of patients with newly diagnosed epilepsy.
There are a number of patients where isolated seizures
appear to occur, sometimes separated by a period of many
years. These probably account for no more than about one
tenth of cases of epilepsy (see Table 5:2). In the
author's experience patients in whom multiple seizures
occur in rapid sucession followed by a period of prologed
remission are exceptionally rare in clinical practice. It
must be admitted that the arguments considered above are
all of an indirect nature, but on the basis of an analysis
of the patterns of seizure recurrence at the onset of
epilepsy, there is little evidence to suggest that many
patients would remit spontaneously.
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D. IMPLICATIONS FOR THE TREATMENT OF EPILEPSY
A number of important conclusions concerning the treatment
of epilepsy arise from the observations on the early
prognosis of epilepsy considered above. As was shown in
Chapter 1 many unsatisfactory and irrational aspects of
the drug treatment of epilepsy remain. There is
remarkably little reliable information to be found in the
literature on the relative efficacy and toxicity of the
major established anticonvulsant drugs (Coatsworth, 1971;
Gram et al, 19S2; Shorvon et al 19B1; Chadwick and
Turnbull, 1985). In patients who fail on the initial drug
there has been no prospective evaluation of the proportion
of patients who subsequently respond to additions or
changes in medication. The widespread use of polytherapy
continues to be a feature of the treatment of epilepsy
despite the fact that there is little evidence of its
value (Reynolds & Shorvon, 1981). The disadvantages in
terms of drug interactions, chronic toxicity and
deterlorating seizure control, however, have been
manifestly proven.
Once treatment is initiated continuous medication is given
over a number of years and those with intractable seizure
disorders may receive lifelong treatment with large number
of drugs often given in combination. The timing of the
initiation of treatment has never been the subject of
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prospective evaluation although it is apparent that the
early prognosis of epilepsy is o-f considerable importance
in determining the subsequent outcome. A rational basis
■for the early treatment of epilepsy must be based on an
understanding of the early patterns of seizure recurrence
yet this aspect of the natural history of epilepsy has
received scant attention in the literature.
1. The Design and Analysis of Anticonvulsant Trials
The most important reason for the lack of clear data on
the comparative efficacy and toxicity of the established
drugs has been the deficiencies in design of anti¬
convulsant trials. In his review of the literature
Coatsworth (1971) concluded that sufficient studies were
not to be found to confidently test the relationship
between the use of a drug and its influence on a
particular seizure type. Gram et al (1982) reached a
similar conclusion and identified a number of deficiencies
in design which included marked heterogenecity of patient
groups, "add on" designs with concurrent treatments being
changed during the course of a trial and cross over
studies which failed to include a wash out period. Shorvon
et al (1981) have emphasised the difficulties in making
appropriate comparisons between drugs on the basis of
reduction in seizure frequencies measured over short
periods of time.
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The most striking deficiency, however, has been that
anticonvulsant trials are usually undertaken in patients
with chronic intractable seizure disorders. It must
surely be unlikely that meaningful results concerning the
efficacy of a particular treatment will be established if
trials are conducted in a group of patients who are
essentially drug resistant. Esquirol's experience at the
Salpetriere over a hundred years ago is still relevant
(Temkin, 1971). Twice a year thirty patients were
subjected to some new form of treatment. Although seizure
control improved for one or two months after this period
they invariably returned and a cure was never obtained
(see page 80). This is a common experience to anyone who
has conducted anticonvulsant trials in drug resistant
patients. Rodin (1982) has emphasised that even after
admission to hospital and a period of intensive assessment
using ail the modern facilities available, the great
majority of patients failed to achieve a lasting
improvement in seizure control.
Some of these difficulties may be overcame by carrying out
anticonvulsant trials in newly diagnosed patients with
previously untreated epilepsy. The drugs are given as
monotherapy avoiding unpredictable drug interactions and
the need to employ cross-over designs and wash out
periods. Similarly it is only in this manner that a clear
under standing of the comparative toxicity of individual
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compounds will be established. As was shown in Chapter 3
the early years of treatment are of considerable
importance in determining the outcome in epilepsy as the
great majority of remissions occur during the first one to
two years. It is only by comparing the drugs during this
crucial period of the natural history of the disorder that
meaningful data on the comparative efficacy will be likely
to be established.
A number of trials have now been undertaken, or are
currently in progress, and important indications are
beginning to emerge. Turnbull et al (19S2) found that
sodium valporate and phenytoin were equally effective in
controlling tonic clonic seizures. Mattson et al (1985) in
a larger trial comparing phenobarbitone, primidone,
phenytoin and carbariazapine in patients with previously
untreated epilepsy. Although clear conclusions concerning
control of partial seizures were not available in the
first of these trials there were twice as many treatment
failures in patients with this seizure type who received
sodium valproate. In the latter study, treatment outcome
appears to have been more closely related to the
occurrence of acute toxicity as all patients had
anticonvulsant levels within the optimum range and dosages
were increased until toxicity occurred. Despite this
difficulty it was found that treatment with carbamazapine
was more likely to lead to complete control of partial
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seizures than barbiturates, with phenytoin being of
intermediate efficacy.
The undertaking of these trials call for a considerable
investment of time and effort as patients must be
recruited over a number of years and prolonged and
prospective follow up is needed. Analysis of outcome in
terms of complete seizure control from the start of
treatment is probably not ideal as although the majority
of patients experience at least one further seizure after
starting treatment the majority subsequently achieve a
prolonged period of remission. The outcome in those who
fail on the initial drug has not been analysed in detail.
Mattson et al (1985) reported that only 11% responded to a
second added drug and that improvements in seizure control
usually occurred at the cost of increased toxicity. This
trial also included the use of primidone which is not
widely used to treat epilepsy at least in this country.
The initial indications that there may be significant
differences between the drugs in controlling partial
seizures are of considerable importance. It is this group
who are more prone to develop chronic intractable
epilepsy. If these results are confirmed in more extensive
studies, involving both children and adults, they will
have considerable implications for the treatment of
epilepsy. If there is indeed no difference between the
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major established drugs in controlling tonic clonic
seizures then the choice of drug will have to be made on
the basis of other factors such as price, dosaging and
pharmacokinetic properties and in particular drug
toxicity. Amongst the latter, effects on cognitive
functions may be of particular importance as there are
already indications that there are signficant differences
between the drugs (Reynolds et al, 19B3).
2. A Randomised Study of the Effects of Early and Delayed
Treatment in Newly Diagnosed Epilepsy
Perhaps the single most important question to arise from a
study of the early prognosis of epilepsy is whether
earlier or more effective treatment at the onset of the
disorder might improve the prognosis and enhance the
probability of obtaining a cure. The theoretical basis for
such a hypothesis has already been considered in the
previous sections.
Although there is considerable heterogenecity of outcome
in epilepsy there is good evidence that in the majority of
cases spontaneous remission of the disorder is an unusual
event. Following a first seizure between 60V. and BOX of
patients are likely to experience a recurrence and if left
untreated the intervals between consecutive attacks appear
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to decrease with each seizure that occurs. If the
tendency of the disorder at the onset is to undergo
spontaneous remission then a high proportion o-f cases
would remain completely seizure free after starting
treatment. This, however, does not appear to be the case
as at least SOX of patients are likely to experience at
least one more attack. In comparison once treatment has
been started over SOX rapidly enter a period of prolonged
remission. There is evidence from epidemiological and
community based surveys that in a substantial proportion
of cases remission of seizures may indeed be permanent.
The implication of these two observations must be that
anticonvulsants not only suppress seizures but in doing so
they may actually alter the natural history of epilepsy
and bring about a cure.
Shorvon (1984) has pointed out that Gowers was aware of
this implication when he observed that spontaneous
remission was very unusual and that the introduction of
bromides had a very major impact on the prognosis of
epilepsy. Indeed it is probably on this basis that he went
on to propose that seizures were self propagating each
attacks predisposing to the next.
It is the current practice of most neurologists, at least
in this country, to await the occurrence of two or more
seizures before starting treatment. There is a strong
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intuitive appeal for this position as epilepsy is, by
definition, the occurrence of two or more seizures and it
would appear reasonable to withhold treatment until the
disease is established. This practice, however, has never
been universal, nor does it appear to be founded upon any
reasoned discussion anywhere in the literature. Herpin's
conclusions on the efficacy of zinc oxide were subjected
to scathing criticism by Delasuive on the basis that he
treated patients following a first seizure (Temkin, 1971).
A number of recent prognostic studies of patients
presenting with a single seizure have reported that as
many as two-thirds were treated (see Table 1:10). Reynolds
(1984) has observed that this practice may be based more
upon medico-legal considerations rather than a sound
understanding of the early prognosis of epilepsy. Current
neurological practice in this country may be a reflection
of the fact that the majority of patients are seen months
after the first seizure when the majority of patients will
have already developed epilepsy.
In this respect it is of interest to analyse the referral
and treatment practices in patients with one or more
seizures referred to a district general hospital
neurological department. Out of a total of 214 patients
with tonic clonic seizures seen over a four year period
described in Chapter 3, 146 or 68/1 of the total had
presented to medical attention following a first attack.
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This may well have been an underestimate as the analysis
was by nature retrospective. The occurrence of a first
ever tonic clonic seizure is likely to be a dramatic event
and the majority of patients would be expected to seek
help early. Indeed half of them were seen within hours in
the casualty department and the remaining contacted their
general practitioner within 24 hours. In comparison once
the disorder was established there appeared to be a
certain lack of urgency in initiating treatment. Only 13
were treated following the first attack. Amongst the 256
patients with tonic clonic seizures considered in Chapter
4, 6? had 3 pre-treatment seizures, 33 had 4, and 46
suffered 5 or more, often occurring over a considerable
period of time (see Table 5:1). These data were gathered
during a time when the department was actively engaged
with the rapid identification and investigation of newly
diagnosed epileptic patients for inclusion into randomised
trials of anticonvulsant medication.
The hypothesis that early treatment could favourably
affect the prognosis of epilepsy could only be tested with
certainty by mounting some form of trial which involved a
group randomised to early intervention. There are a
number of different designs.
The possibility of carrying out a placebo controlled trial
in newly diagnosed epilepsy has been the subject of debate
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(Shorvon et al, 1985). There is, however, insummountable
ethical objection to such a study. The hypothesis under
question is not whether anticonvulsants work, -for there is
ample evidence -from a variety o-f sources that they do, but
whether early treatment improves the long term prognosis.
The only basis on which such a trial could be mounted
would be that a significant proportion o-f cases might
remit spontaneous! y and that the disadvantages o-f
treatment particuarly in terms o-f anticonvulsant toxicity
outweigh the possible advantages. Although it is feasible
to argue that such considerations might apply in certain
childhood epilepsies such as rolandic epilepsy or petit
mai, there is little evidence to support this position in
the majority of cases arising in either adults or
children. Furthermore the great majority of patients with
newly dignosed epilepsy experience only minimal anti¬
convulsant toxicity if the drugs are given as monotherapy
with the increases in dosage made with the help of
anticonvulsant level monitoring (Elwes 8< Reynolds 19B8) .
It is only feasible to mount a trial where current medical
practices are open to question on theoretical or practical
grounds. This does appear to be the case with the current
practice of those with responsibility in primary care
withholding treatment in cases of recent onset of seizures
and referring patients to hospital for investigation.
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Hopkins et a1 (1988) have recently observed that these
investigations are of limited use in either establishing
the aetiology or predicting the subsequent prognosis. The
recurrence rate with patients with one attack seen within
days is of the order of 607.-807.. Ironically, the
conclusion that a single seizure was likely to be an
isolated event of little clinical significance arose from
experience based on these very same practices with
specialists seeing the patients months after the initial
event.
Such a study would have to be community based, or carried
out in close association with casualty officers or
general practitioners, with the decision to give or
withhold treatment made on a randomised basis. Although
such a study would provide information as to whether
treatment reduces the probability of recurrence following
a first attack (a question which has never been the
subject of a randomised trial) it need not necessarily be
confined to patients with single seizures.
The practical difficulties in design and analysis and the
possible consequences of such a trial require careful
consideration. There are certain circumstances in which
it is more appropriate on clinical grounds to withhold
treatment. In a high proportion of cases referred to
hospital with episodes of loss of consciousness the
284
diagnosis is syncope rather than epilepsy. In those with
undoubted seizures there may be a clear history of
significant precipitating -factors such as lack o-f sleep,
alcohol or drug abuse. Treatment may also be withheld on
the grounds that the patient would be considered likely to
comply poorly with medication. It would have to be
accepted that if treatment were begun by those with less
experience in assessing possible cases of epilepsy, then
the decision to treat would be wrong in a higher-
proportion of cases. The tendency to propagate the
unsatisfactory practice of trials of medication would have
to be resisted. This difficulty may not be insurmountable
as in those cases in which there is little doubt as to the
diagnosis the majority are likely to have been correctly
assessed prior to hospital referral. Furthermore, such a
trial would be likely to enhance diagnostic accuracy.
Another consideration is that treating single seizures
would de facto imply a diagnosis of epilepsy leading to
unnecessary adverse consequences. This need not be the
case, however, as the definition of epilepsy for the
purposes of driving and insurance would not be under
question. Indeed, if early treatment was effective in
reducing a seizure recurrence, a number of patients would
escape the diagnosis altogether. A similar consideration
applies to possible difficulties with employment as the
assumed handicap relates to the occurrence of seizures
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themselves particularly if they lead to injuries or occur
at work.
A more difficult objection to the study would be the
selection bias of patients entered and the possible impact
of poor compliance with medication. The patients
identified for early treatment would, more likely, be
those who had experienced tonic clonic seizures. The
majority of these patients suffer from idiopathic epilepsy
and remission rates are likely to be extremely high, even
with the current practice of withholding treatment until
multiple attacks have occurred. Although early treatment
might shorten the duration of what, in a high proportion
of cases, may be a curable disorder, it would not test the
hypothesis as to whether early treatment stops the
development of chronic intractable epilepsy. Furthermore
because of the highly variable outcome in epilepsy careful
consideration would need to be given to the methods of
analysing such a trial.
There is evidence from the data presented in Chapter 5 and
other analyses (Shope, 1981; Liske & Green, 1985) that
poor compliance with medication is an important cause of
treatment failure in epilepsy. This consideration has
proved to be a major obstacle in establishing the use of
prophylactic medication following head injuries (Blackwood
& McQueen, 1983). Although not strictly comparable, a
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study involving treatment following a single seizure might
encounter similar problems.
Despite these possible difficulties, a randomised study of
the effects of early and delayed treatment on prognosis is
likely not only to be feasible but of much theoretical
interest and practical importance. If Gowers' hypothesis
proves to be correct it would be an important advance in
our understanding of epilepsy and would have considerable
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APPENDIX 1 DEMOGRAPHIC, CLINICAL AND FOLLOW-UP
DETAILS RECORDED FOR PATIENTS ENTERING THE PILOT








-Source of Referall (GP or Casualty Officer):












-Dates of First and Subsequent Untreated Seizures:
-Total F'retreatment Seizure Number:




























-Head Injury requiring Hospital Stay of >43 hours


















-Date of Clinic Visit

















APPENDIX 2 ACTUARIAL ANALYSIS. COMPUTER PROGRAMME FOR
DERIVATION OF SURVIVAL CURVES WRITTEN IN BASIC LANGUAGE.
The -following parameters are used in the programme.
NUM = Total number o-f patients entering -follow-up period
A(A) = Interval to event o-f interest, eg -first seizure or
remission
D(A) = Interval to end o-f follow-up
SFUW = Number of patients starting follow-up interval well
CPS = Cummulative probability of survival
LFU = Longest follow-up interval
EFU = number ending follow-up in interval "I"
AR = Number at risk
PD = Probability of dying
PS = Probability of surviving
CPS = Cumulative probability of surviving
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APPENDIX 2 contd
10 PRINT "TOTAL NUMBER OF PAT IENTS="
20 INPUT NUN
100 D* = REM CTRL-D
120 PRINT D$"GPEN FILE"























158 FOR A = 1 TO NUM
160 INPUT A(A) ,B(A) ,C(A) , et seq
170 NEXT A
ISO PRINT D£"CLOSE FILE"
410 SFUW = NUM
412 LOST = O
420 CPS = 1
430 REM: SET DIM P(NUM) TO O
450 FOR X = 1 TO NUM
460 P(X) =0
470 NEXT X
500 REM: FIND LONGEST FOLLOW-UP
510 LFU = 0
520 FOR X = 1 TO NUM
530 IF D(X) > LFU THEN LFU = D(X)
540 NEXT X
600 REM: OPEN ACTUARIAL FOR INTERVALS 1 TO LFU
610 FOR I = 1 TO LFU
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APPENDIX 2 contd
700 REM: MEASURE EFU FDR THIS INTERVAL
710 EFU = O
720 FOR X = 1 TO NUM
722 IF P(X) = 1 GOTO 740 :REM DISCOUNT THOSE ALREADY
DEAD
730 IF D(X) = I THEN EFU = EFU + 1
740 NEXT X
910 AR = SFUW - EFU/2
920 IF AR < 1 GOTO 1400
1000 REM: COUNT DYING
1004 DYING = O
1010 FOR X = 1 TO NUM
1020 IF A C X) = I THEN DYING = DYING + 1
1030 NEXT X
1100 F'D = DYING / AR
1120 PS = 1 - PD
1130 CFS = CPS * PS
1140 PRINT I,AR, ( INT (CPS*100))/100
1200 REM: CALCULATE SFUW FOR I +1
1210 REM: SET DIM PCX) TO O IF LOST
1220 LOST = DEAD OR EFU
1230 FOR X = 1 TO NUM
1240 IF A(X) = 1 THEN PCX) = 1
1250 IF D(X) = I THEN THEN PCX) = 1
1260 NEXT X
1300 LOST = 0
1310 FOR X 1 TO NUM
1320 IF PCX) = 1 THEN LOST = LOST + 1
1330 NEXT X







OF 106 PATIENTS WITH NEWLY
Characteristic Legend number
1). Seizure type.
Complex partial seizures. 1
Simple partial seizures. 2
Tonic clonic seizures. 3




Four or more. 6




4). Nocturnal seizures only. 9
5). Symptomatic epilepsy. 10
6). Neurological deficit 11
7) Familly hisory of epilepsy 12
S). Social Handicap 13
9). Psychiatric Handicap. 14
10). EEG Characteristics.
Normal. 15
Minor slow wave changes. 16
Moderate or severe slow
wave changes. 17
Epileptiform abnormalities. 18
x = present o = absent - = not applicable
Notes
i. Patient numbers 13, 44, 70 and 93 experinced partial
seizures and a single secondarily generalised seizue.
ii. In patient number 28 the pretreatment tonic clonic
seizure frequency was unknown.
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Appendix 3 contd.
No. Sex Ape Legend number.
1 2 3 4 5 6 7 3 9 10 11 12 13 14 15 16 17 If
1 m 29 X G G G o o - - o o G o o o o X o X
r> -f 41 o o X o X o X o o Q a Q o o X o a o
o m 14 D D X o X G G X X G o X o o o G X G
4 m «""» T O O X X o o X o o G o o o o o X o G
5 m 31 O O X X G o X G o o o o o o X G G o
6 i 65 O O X o X o X o X o o o o a Q X a o
7 m 63 D D X X o G a X X X o X o o o X o o
8 m 77 D a X o X Q a X X o o o Q o a o X a
9 -f 22 X X X o G X o X G o o X o o o X o D
10 m nn X o X o o X X o o o o Q a G o X o o
1 1 ■f 25 D o X X G G X G G X o o o X G V o o
12 ■f 18 D a X a X o X o o X a o o c o o X a
13 rT 21 X o X o o o - - o X o o o a G o X X
14 m 18 D a X Q X o X a X Q o o o o o X o X
15 m 99 Q o X G o X X o X X o o G G o o X X
16 m 20 O D X X o o o X o o X X o o o Q X o
17 ■f 17 D X X X G o X G o X X G o G o G X G
18 m 75 X o o a a c - - Q X o o a X o X Q Q
19 m 49 o D X X o o X o o X V o o X G o X o
20 f 13 X O X o X a X o o o o o X v/ X o Q G
21 m •» " o O X o o X X o o o o X X X o X G o
■f 27 X o o a o o - - o o a o X X a a o a
23 -f- 19 o o V o X G X o X G G G X X G o X X
24 -f T•_u xL D o X G o X G X X o o X a o o G G X
<~}Cr m 20 D o X X o G X o G o o Q o o V o G o
26 -f 34 X a X o o X o X c o Q o X X o X Q o
27 m 13 O o X G o V a X Q o G G X G o G X X
28 m 27 X D X o o X - - o X o a a o o a X X
29 m 14 X D o o G G - - G X G G o X Q G X o
30 -f 19 o O X X o o o X G o o a a a o o X X
31 m 13 X O X X o G o X a X X G o o o X o G
T9 m 09 a D X o o X o X X o o X o X o X o o
33 m 10 X a X X G o G X o X G o G o o D X X
34 ■f ■ j> i o a X a X o o X o G o a o o o o X X
35 ■f 75 X o D o o Q - - o X X o a X o G X X
36 m 40 o o X o Q X o X o X o a o a X a a G
T"7
•_» / f 32 D D X o o X o X G o G G G X o X G o
38 f 31 X D a o a a - - G o a a X o o o X
39 m 19 X O G G o o - - o X o o Q G X o o o
40 ■f 12 X D o o o Q - - o X o X a o Q Q X o
41 m 39 o X X o o X X o o X o G X X o o V o
42 m 61 X a o o o o - - o X X o o o o o o o
43 m 13 X o o o G o - - X G G o o o G X o X
44 -f 30 X D X o o o - - X o o o o Q o X o o
45 ■f 06 D D X o o X o X o o G o X o o o X o
46 m 29 X D X a o X X o o Q X o X o Q o X X
47 •f 18 X O o o o o - - o o X X X X o o X X
4e m 26 x a X o o X o X o o o o o X X o G o
Appendix 3 contd.
No. Sex Age Legend number.
1 n 3 4 crO 6 7 8 9 10 11 12 13 14 15 16 17 If
4 9 •f 23 o o X X O o o X o o o o o o o o X X
50 i 13 X o o o O o - - o o o o o o o o X X
cr -»
i_> 1 i 07 X o o o O o - - o X o X o Q o X o X
er r~t
Uxi m 24 o o X o X a a X o X X o o o o X o o
53 •f 18 X o o o o o - - o o o o o o o X o o
54 f 69 o a X o o X o X o X o o a o o o X o
55 i 45 X o o o O o - - o o o X o o o o X X
56 m
> err
X-U o a X o V o X o o o o o X X o o o X
cr-j
_J / m 32 X o X o O X X o o X X o X o X o o o
5S i 38 X o o o o o - - X X o o o X o o X X
59 t 15 o o X o X o X o X o o o o o o X o o
60 m 42 o o X o X o O X o o o o o o a o X X
61 ■f 20 o o X o X D o X o o o o o a o o X X
62 m 26 o o X o X O o X o o o o o Cs o X o o
63 ■f 43 o o X o X O O X X o o o o o o o X o
64 -f 63 o X X o O X V o o X a o o o o # * o o
65 m 56 o o X o X o V o X X o o X o o X o o
66 15 o a X V o a X o V o a X X a o o X X
67 ■f 25 o X o o o a - - o X o a o o o o X X
68 m 35 o o X o a X X o X o a o a X o o o X
69 ■f 10 o o V o O X X o o X o X X o o o X X
70 m 17 V o V c a a - - O X a X X o X o o o
71 •f 18 o o X o X O O V#-V o o o o o o o o X X
72 m 39 X a X o o X X o X X o o X X a o X X
73 m IB X o X o X o X o o o o o X X X o o o
74 m 10 X o X a o X o o o o o a o o V o o
75 -f 40 X o X a o X o X o o o X o o X o o o
76 f 17 o o X Vr * o D X o X a o o o o o o o X
77 •f 65 o o X o o X O Vr\ o o o o o X o o X o
78 f 7 X o a o o o - - o X o X X o o X o o
79 m 28 o o X o X o V o o X o o o X o o X o
80 i 27 o o X D a X o X X o a o o o X a o o
81 m 59 X o o Q o o - - o X o a o o o o X X
82 m 16 o o X VJ c o V o a o o o a o o X o o
83 ■f 21 o o X O X o X o X X o o X X D X o o
84 m 12 X o a a o a - - a a o o a o o o X X
85 m 9 o o X o o X X o X D o o o X o X o X
86 m TT■w>0 Q o X o X o X o o o o o o o X o o o
87 m 35 o o X X o o o X X o o o o o o X o X
88 -f 24 o o X o o X X o a X o X o o o X o X
89 * 49 o o X X o O X o X o o o o X o X o X
90 m 66 o o X o o X o X c o o a o D o X o X
91 -f 19 X o X X o o X o X o X o o o o X o o
92 ■f 37 o o X a X o X o o o o o o o o o o o
93 f 41 X o X o O o - - o o o o X X o o X o
94 m 19 o o X o o X X o o a o X o □ o o o X
95 m 1 1 o o X o X o X o o o o o o o o X o o
96 ■f 17 X o X X a O o X o o o D a o o o o X





98 i 4 o
99 m 30 o
100 •f 36 X
101 i 10 □
102 m 31 o
103 ■f 23 □
104 i 20 X
105. •f 23 X
106 m 16 o
Legend number.
4- 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1!
o X o o X o X X X o o □ o o o X o
o X X □ o X o X o □ o o □ o □ X X
o V X □ o o X □ o o o X X X o o □
o X o o X X o o o o X X a o o o X
o X X o □ X o X o □ X o o o o X o
o X o o X X o o a □ X □ X o X o o
o X X o o □ X o □ o o o o o X o o
o o o □ o - - o o o o X X o X o X
o X X o □ X o o □ o o X X o o X o
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APPENDIX 4 THE PROGNOSIS FOR SEIZURE CONTROL IN 106
PATIENTS WITH NEWLY DIAGNOSED EPILEPSY. THE OCCURRENCE
OF PARTIAL, TONIC CLONIC AND ALL SEIZURE TYPES BY EACH
TWO MONTH PERIOD OF FOLLOW UP
Notes:
i. Each column relates to a two month interval of
follow up.
o = no seizure occured
>: = one or more seizures occured
li. Seizures that could be related directly to poor
compliance have been excluded from the tables showing
partial and tonic clonic seizures alone. In the final
table showing all seizures combined those caused by
poor compliance are marked by an asterix.
APPENDIX 4
THE OCCURRENCE OF PARTIAL SEIZURES BY EACH TWO MONTH INTERVAL
OF FOLLOW UP
No Two month intervale

















17 XXX OOX X X OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
IS XXX oooooooooooooooooooooooooooooooooooo
19 0000000000000000000000000000000000000000000000
20 OOX OOOOOOOX X X X X X X X X X X X X X X X X XOOOQX X X X X X XX OX X
21 oooooooooooooooooo







29 OX X XX OCOQOOOOOOOOOOOOOOOOOOOOOOOOOO
30 OOOCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOQOO
31 XXX oooooooooooooooooooooooooooooox xxxxxxxx
32 ooooooooooooooooooooooooooooooooooo




37 oooooooxoooooooooox ooooxoooooox o
38 X OX X X X X X X X OX OOQOOOOOOOOOOOOOOOOOOOO
39 XX OQXX XXXXXXXX XX XXX xxxxxxxxxxx
40 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
41 xxxxxxxxxxxxxxxxxxxxxxxx






























































96 ox oooox ooooooooooooooooooooooo












THE OCCURRENCE OF TONIC CLONIC SEIZURES BY EACH TWO MONTH
OF FOLLOW UP
No Two month intervals



















19 ooox x x x x xxoax oxox x aooaoooooooooooooooooooooooo
20 OOXOODODOOOOOX ooooooox X X X X X X X X X X X X X X X X X XX oo
21 XXxoaxOODOOOQOOOOO
22 oooooooooooooaooooooooooooooooooooooooooooo
23 ox ooooooox x ooox ooaox ooooooooox ooooaooooooooa
24 OOOOOOOQOOOOOOOOOOOOOOOOOOOOOOOOOOOOODO
20 ox oooooax aooox x ox x ox x ox x ox x ox x ax x ox x ox x ox x x x x x x
26 ooooooooxX OOOOOOOOX X X X X X X XX X X X X XX X XX X X X X X X X
27 X OOOOOOOOOOOOOOOOOOCOOOOOOOOOOOOOOOOOOOOOOOOO
28 OX X XOOXOOXxxxxxxxxxxxxxxxxxxxxxxxxxx
29 ooooaaaoooaoaooaoaoaaoaoooaooaooooo


















<lyr _><2yr _ ><3yr_ ><4yr _><5yr_ ><6yr_ ><ZYE_2:S§yc2'


































79 XX X X OX X OOOQOOOOOOOOOOOQDOOOOOOOOOOOOCO
80 OOOOOOOOOOODOOOOOOOOOOOOOOOOOQOOD
81 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO































THE OCCURRENCE OF ALL SEIZURES BY TWO MONTH INTERVALS
OF FOLLOW UP
NO Two month intervals

















17 XXX OOX X X OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
IS xxx 000000000000000000000000000000000000
19 0000000000000000000000000000000000000000000000
20 OOX OOOOOOOX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X OX X
21 XXXOOXOOOOCOOOOOQO
22 X X X X X X X OX X OX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
23 OX OOOOOOOX X OOOX OOOOX OOOOOQQOOX OOOOOOQOOOOOOO
24 0000000000000000000000000000000*0000000
25 OX OOOOOOX OOOOX X OX X OX X OX X OX X OX X OX X OX X OX X OX X X X X X X
26 x x x x >; x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
27 X OOOOOOOOOOOOOOOOOQOOOOOOQOCOOOOOOOOOOOOOOOOO
2S X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
29 OX X X X 0000000000000000000000000*0000
30 OOOOODOOOOQOOOOOOO*OOOOOOOOOOXooooox oooooooooox
31 OOOOOOOOOOOQOOOOOOOOOOOOOOOOOOOOOX X X X X X X X X
32 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOQOOOO




37 OOOOOOOXOOOOOOOQOOX ooooxoooooox o
3E x ox x x x x x x x ox 00000000000000000000000
39 XX oox xxxxxxxxxxxxxxxxxxxxxxxxx
40 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
41 xxxxxxxxxxxxxxxxxxxxxx
42 OOX OOOOX OOOOX X OOOOOOOOOOOOOQOOOOO
43 X 00000000000000000000000000000
44 0000000000000000000000000000000000000000000000





























































< l.^r_><2yr_><3yr_><4ijr_><5yr_><6yr _><7^r_><8yr >
96 ox oooox 000000000000*0000000000
97 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X OOX X X o
98 X X ooooooooooooooooooooooooooooooo
99 X X X X X X X X X X
100 X ooooooooooooooooo
101 X X X X X X X X XODD






APPENDIX 5 CLINICAL CHARACTERISTICS AND FOLLOW-UP


















B. NUMBER OF SEIZURES AT PRESENTATION, SEIZURE




Number of Seizures at Presentataion
At First Ever Presentation
At Neurology Outpatients Department
Interval between first and second
seizures (months)
Interval between first seizure and
first presentation (days)
Interval between first seizure and
presetation to neurology OPD (months)
Interval between first seizure and










Patients treated following a
79, 88, 91, 93, 95, 98, 108,
first seizure:
112, 130, 136.
Nos. 18, 38, 60,
APPENDIX 5 contd.
No Sex Age Legend number.
1 ,_1 4 5 6 7 8 9 10 11 12 13 14
1 -f 10 o o o o X X o o X X 17 1 1 19
m 57 o o o o X o o X X X 0 1 1 1
.jl ■f 13 o o o o X o o X X X 7 1 2 32
4 i 38 o o o o X X o o X X 12 11 2 26
5 ■f 26 o o o o X X a o X o Vz. 1 3 19
6 ■f 16 a X o o X X o o X o 1 1 46
7 ■f 11 o o D o X o X X X X 28 48
j—t
JL 46
a m erUj- X o o X o o o o X o 1 1 2 13
9 -f 45 X o o o y% X o o X X 3 1 i 9
10 m 20 o o o o X c a X X X 19 1 i 39
11 m 14 o o o o X o X X X o 1 1 i 19
12 m 15 o o o o X a o X X X 2 1 i 33
13 i 48 o o o o o o o o X o 9 1 2 23
14 m 14 X o o o X o o X X o 1 1 3 8
15 •f 44 o o o o X X o o X X 52 1 3 54
16 i 17 o o o o o o o o X X 9 1 1 16
17 -f 13 o o o o X X o o X o 5 1 5 16
18 •f 4 o o o o X o o X X X 7 1 2 16
19 f 16 X X o X V X o o X X 3 1 1 6
20 m 6 o X o o X o X o X X 5 1 4 7
21 m 10 o o o o V o o X X X 4 1 4
22 ■f 1 1 o a X o X o a X X o 1 l r-? CT
.ji m 1 1 o o o o v o o X X o 1 1 l 14
24 ■f 10 o o o a X o V-' X X X T 1 i 34
cr
JLU ■f 15 o X o o o o o o X X 8 1 l 31
26 m r->crxLU o o X o X o a V X X 3 1 l 12
27 m 37 o o o o X X o o X o 9 1 9 16
28 i 25 X a c X X V o a X X 3 1 JL 20
29 m 28 X X D X X X o o X o r-y 1 O 16
30 •f 16 a o o o X X o o X o 1 2 9
31 mi 18 o o X o X X o o X X 17 1 J- 20
T r"? -f 20 o o o o X X o o X X 0 1 1 15
33 m '—i '""IJLJL o o o o o o o o X X 0 1 1 1
34 f 17 a o a a X o o X X 23 1 23
35 ■f 43 o o D o X o o X X X 0 1 ji 51
36 m 20 o o X o X o o X X X 0 1 3 4
37 m 33 o o Q o X o o X X X 0 njL 3
38 w 29 a X o o o o o o X X 0 1 1 2
39 m 49 o o o o X o o X X X 0 1 1 o
40 m 15 o X o o X X o o X o 1 1 1 13
41 m 12 X o o o X X D o X X 5 1 60
42 m 38 o o o Q X o o X X X 0 1 1 15
43 i 20 o o o o X o X X X X 0 *~y 45
44 m 13 a X o o o o o o X X 0 1 1 15
45 m 15 o o X o X o o X X X 0 16 2 10
46 ■f 51 o o o o X o X o X X 0 1 1 5
47 m .ji.j» o o o o X o o X X X 0 10 5 7
48 m OC-JLU o o o o X X o o X X 0 1 2 40
AF'FDEN I X 5 contd.
No Sex Age Legend number.
123456789 10 11 12 13 14
49 m 25 X o o o X D D X X X 7 2 1 58
50 m 34 X a Q Q X a a X X X 4 14 2 7
51 m 24 Q o o a X D a X X X 0 1 X- 3
er
s-JxL f 29 O a a a X D a X X X 0 1 6 7
53 m 17 D o D D X o o X X X 0 1 i 31
54 f 38 X X o o o o D o X X 0
T ~T
55 -f 38 D D D o X X o a V X 0 1 1 20
56 m 21 a a c D X X D o X X 0 1 1 7
57 m 18 D o o a X D X o X X 6 1 2 36
58 f 13 O D o o X a X o X X 0 1 1 4
59 m 45 o a D D X X D D X X 0 1 Xi
60 f 21 □ D Q o o a o a X X 0 1 xL 2
61 -f 40 o D D o X X D o X o 1 1 3
62 ■f 21 a X O D X X D o X D 1 1 3 3
63 -f 22 o D D D X D o X X X 5 i 18
64 (Ti 29 o O D o X o a X X o 1 1 i 65
65 + 30 o X O o X X D D V D 1 4 14
66 m 13 a O □ o a o o o X a 6 1 6 10
67 f o X O D D D D D V D 6 1 45 54
6E -f 1 1 a o D a X a J.; a X X 2 1 1 24
69 r 5 a o O o X o D X X X 11 1 5 45
70 m 19 X o X X X o a X o 1 3 11
71 m 69 X y o D X X D D X D 10 1 12 55
~7 *~i/ m
cn
X a o o o o a o X o 1 1 1 1
73 ■f 17 o o o D X o D X X D 1 1 1 9
74 m 23 o a a D X a X X X Q 1 1 1 8
75 m 38 D X D o X X o D X X 11 1 1 IB
76 m 17 O a □ o X o a X X o 1 1 7 9
77 (Ti 33 D o D o D o o D X a 7 1 12 34
78 m 36 a X o a o a a a X X 8 1 1 11
79 rn 4 o X D c D D o o X X 0 1 1 7
80 m 6 o a a a X X a a X X C_ 1 4 39
81 -F 64 o D o D X o D X X X 5 1 1 13
82 m 15 a o X o X a a X X D 2 1 3 11
83 m 19 o o o o X X D o X o i 1 4 4
84 m 64 X o o X o o D D X X X- 1 1 9
85 m 16 a D o D X X D O X X 0 1 3
86 i 62 o o D D o a o O X X 0 1 i 12
87 ■f 20 D X O D X o X O X X 0 1 i 12
88 m 66 X o O X X X a O X X 0 1 l 13
89 m 55 D D O D o D D D X o 1 1 •j 47
90 m 13 D o a D X X o O X X 6 1 i 7
91 -f 22 O D o D D D o D X X 0 1 2 8
92 m 30 O o a o o a a O X o 1 1 1 r>
93 m 15 X D D X X o X O X o xL 1 nXL 4
94 m 40 o D o o X o X O X o 1 1 1 6
95 m 35 o D o o X o o X X X 0 1 xL o
96 ■f 42 a a o o D o o o X X 13 1 l 15
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APPENDX 5 contd.
No Bex Age Legend number .
1 4 ET_> 6 7 8 9 10 11 12 13 14
97 -F 24 D O o D X X o D X X 0 1 1 XL
98 m 30 X a D V a D D O X X 0 1 3 5
99 f 38 o D D D D D o Q X X 0 1 1 6
100 f 19 Q o D o a o a O X V 0 9 2 XL
101 m 12 O o X D X D X D X K* 0 3 1 21
102 -F 64 O o o o o a o O X o 6 1 6 09
103 m IB D D D o w o X X X Q 1 1 7 9
104 f 15 O X O D X X o a X X 0 1 n 20
105 iTl 17 o o D O X X o D X X 0 1 1 3
106 -f o V a o X o X a X X 0 1 l £>4
107 m 21 o o D D D o o o V X 0 1 .ji 31
108 -F 13 o a a D X D o X X X 6 1 29
109 •f 78 X o o X X D X X X X 0 1 6 18
110 i 19 D a Q D X X o a X X 0 1 1 63
1 1 1 m 6 o X D D V X o D X o 5 1 7 36
1 12 m 24 a a o a X o X X X X 0 1 1 50
1 13 m 24 o X o D o o D D X V 0 5 18
1 14 f 38 o v o D D o a a X X 0 1 1 1
1 15 •f 17 D O D D X □ D X v.; X 0 1 1 69
1 16 m 1 1 D D O a X X o o X X 0 1 1 26
1 17 •f 12 o X Q D X D X D X D 2 1 x~ 47
1 18 m 14 Q Q X a X X a a X X 0 2 XL 5
119 m 17 D D D o X X o D X 0 1 l 4
120 ■f 7 O a a □ X a Q X X X 0 1 T■_» 7
121 m 15 D o o o X D X o X X 0 1 31
122 f 31 O o o o X a X o X 0 1 1
~T
1 23 m 22 O o o X o X o X X 0 1 1 4
124 f 1 1 O X o o X o X o X o 9 1 15 49
125 f 55 X X o D D D D o X a 1 1 3 1
126 37 o a o a X Q a X X 8 1 n 53
127 m 51 o o o D X X o D X D 2 1 n 41
128 •f 25 o o Q X X Q X o X X 0 6 4 47
129 -f 40 X Q D X X o o X X X 0 1 1 14
130 m 17 o O O a X a X v; X X 24 1 1 24
131 m 8 o X O D X D X o X X 10 1 5 35
132 m 57 o X a D V o a X X 6 1 r> 47
1 33 m 30 D o D D o D D D X X 0 1 1 49
134 m 64 O o a o X X o a X X 0 1 nxL 18
135 ■f 24 O o D o X X D a X X 0 1
n
136 m 3 D o o □ o o D a X a 1 1 ■7; 3
137 -f 20 O D o o X X o o X X 0 7 XL 20
138 ID 15 O Q o o X X o a X X 0 6 3 6
139 •f D D o o X X o o X X 8 1 i 28
140 m 15 O O X o X o o V X o 2 1 2 8
141 f nn D O X o X o o X X X 0 1 4 48
142 ■f 17 O o o Q X a X X X X 0 1 1 9
143 m C-1Ux- O D X D X X o o X o 1 1 1 13
144 -F 31 O X o o X X a o X 0 1 1 25
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APPENDIX 5 contd.
No Sex Age Legend number.
1 *7 3 4 e-_l 6 7 8 9 10 11 12 13 14
145 m 74 o o D X X o o X X X 0 1 1 5
146 f 65 o Q o o X o o X X o 1 1 2 XL
147 i 20 o o X o X o X o o o 75 - 154 171
143 m 43 Q o o o X o o X O o - - 120 132
14? ■f 21 O o o o X o X o o o - - 120 144
150 17 O o a o X X o O o o 7 - 9 9
151 m 16 X o o V X X o o o o 4 - 7
T-»
152 m 11 o o X V X a o X a O 60 - 60 96
153 f o D G o O o o o O o - - 4 36
1 cry1 jn ■f 24 o O D X a o V o o 1 - 4 oir
155 m 1? a o o X X o O X o o nXL -
n 23
156 m 34 a a o o X o o X o o 1 - 1 40
157 •f 18 o X o X X o O X o o 1 - 6 19
153 m 17 o o o o X o X X o a - - .3 10
15? m 3 o o o o X X o o o o 1 - 13
160 i 6 o a X a X a o X o o 9 - 7 55
161 m 13 o o o o X o X o D o 1 - jO
162 i 8 o o o o X a o V o a - - 48 84
163 m 11 o o o o X o X X o o 12 - 13 46
164 f 9 o a o o X a X o o o 1 - 2 34
165 m 8 o o c D X o X X o O 7 - 13 42
166 m 5? o a o O o o o o o o 3 -
~r
•—> 26
167 •f 7 o o o O X O X o o o 1 - 1 9
163 ■f *9 a X X O o X o o O - - — —
16? ■f 14 o X O o O O o o o 3 - 5 37
170 -f 12 o a o o X a X o o o 1 - 2 28
171 i 12 o o o X X o O X o O - - 3 36
172 •f OV X a o o V o o Vf \ o o - - u
r-x-y
o
173 rn ncrXLU o o o o X V o o o o 1 - i 4
174 m 65 o X o o V a a X o O - - err ncxLU
175 m 5 o o o o X Q X X o o 1 -
<—> 26
176 m 4 41 1 o o a a X o X X o o 4 - 1 47
177 m 82 o X o o o o o o o o - - 4 15




179 i 6? o a o X X X G o o o - - 6 15
180 i 56 a a o O X o o X O o - - - -
181 t 1 1 G o o o o o o o o o - - - -
132 f 13 o o o o X a O X a o 1 - 9 47
183 m 30 o o o o o D o o o o 1 - l 1
134 i 38 o o o O a O o o o CD - - - -
185 m 17 CJ o o o X X o o D a - - 4 34
186 ■f 41 o X a o o D o o o o 1 - 1 74
187 ■f 16 o o o o o O o o o o - -
*-» 50
188 ■f 20 o a X o o a o o o o rrO - 4 22
18? •f 5? o o o o X o o X o o 1 - 1 31
1?0 m 24 o o a a X X o O o o - - 60 120
1?1 m 21 a D o o X o O X o o - - - -
192 ■f 18 o o o a X o X X o a 48 - 48 91




194 m 13 X
195 m IS o
196 ■f 31 X
197 ■f 54 X
198 m 20 o
199 -f 12 a
200 ■f 28 X
201 i 19 a
202 m 16 a
203 m 25 o
204 m 24 o
205 m 16 a
206 m 27 o
207 * 12 c
208 rn 51 o
209 m 44 X
210 i 20 o
211 ■f 33 o
r-} ^ r~. ■f 17 ;;
213 -f 14 Q
214 m 44 O
Legend number.
2 3 4 vr 6 7 8 9 10 1 1 12 13 14
D D D X □ X X D D 60 — 67 84
O O a X o o X □ D 4 - 55 65
D X o X o X D O D 75 - 118 147
X D o X a o X D O 43 - 56 67
D D o D o D Q O O 96 - 96 104
O a Q X o X D O a 24 - 25 48
X o D X X D O D D 204 - 204 228
o a a X X O O O a 48 - 52 79
o o D yj o X X O D 72 - 72 105
X a o X o o X O o 24 - 25 27
D o D X X o o D D 156 - 157 169
O a X X o X X O D 60 - 60 87
X D D X X o o o O 72 - 60 144
X o O X X o a a o 132 - 132 144
o o D X X D a a o 37 - 39 86
Q o D X D X X o a 192 - 192 197
X o D X o o X o o 24 - 36 67
D a Q X o o X a o 132 - 132 182
X o X D o o X o o 96 - 96 132
a X a O D c a a o 24 - 24 24
o a o X vy D o a D — —
— —
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APPENDIX 6 CLINICAL CHARACTERISTICS AND FOLLOW-UP INTERVALS








Interval, Seizure 1 to 2 5
Interval, Seizure 2 to 3 6
Interval, Seizure 3 to 4 7
Interval, Seizure 4 to 5 B
B. FOLLOW UP ON TREATMENT
Time to First Seizure 9
Time to First 1 Year 10
Remission
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97 ■f 20 D o 5
98 m 35 O o 4
99 m 36 o o
100 i 17 o Q 6
101 i 18 D D 5
102 m 17 a X ~7_1
103 ■f 57 D D 4
104 iTl 33 D O 4
i05 m 31 o O n
106 m 27 o O 3
107 i IB o O 4
108 m 24 o a 2
109 -F n-r. •> o D ~7
1 10 m 14 o V 3
11 1 m 28 o D 4
112 -f 17 o O n
113 m 1 1 o O T1
114 in 21 D o 7«—»
115 ni 10 X 3
116 -f 30 D o 3
117 m 6 o o n
1 13 •f 6 X o 4
119 m 6 a o 3
120 f 1 1 a o 5
121 m 51 o D 3
-t
1 xlxl ■f 14 c O o
123 m 14 o O o
124 -f 13 o o "7*
125 f 12 Q o 4
126 m 1 1 O a 2
127 m 10 C o 3
123 i 4 o a n
129 m 3 o D 4
130 m 3 o c
131 -f 8 o o 9
132 •f 2 o D 4
133 m 13 D D nX_
134 m 14 O O 4
135 ■f 10 D D 6
136 m 15 a D 5
137 m 14 a a 9
138 i 15 o X 3
139 -f 12 o o *9
140 3 D a 5
141 i 12 o D 2
142 m 3 o D ._•»
143 m 10 o o
144 ■f 11 o o 3
145 m 7 X o 9>X_
Legend number.
5 6 7 8 9 10 12
75 64 152 5 7 0 13
36 16 8 0 0 12 13
25 0 0 0 11 0 12
crn
»_f xl 8 2 3 6 0 11
4 20 3 9 7 0 12
4 28 0 0 *-»XI 0 8
24 20 24 0 0 0 10
48 8 8 0 0 0 10
1 0 0 0 0 0 0
140 8 0 0 1 0 1
40 4 n 0 0 0 8
4 0 0 0 X X V
3 16 0 0 0 0 0
72 24 0 0 0 0 0
4 16 4 0 1 0 n
10 0 0 0 0 0 1
10 0 0 0 8 20 42
48 4 0 0 4 32 33
44 7 0 0 0 12 25
16 12 0 0 20 12 29
1 1 0 0 0 1 1 23 '~>TXlO
36 40 1 0 0 1 0
28 n 0 0 18 12 32
.ji 9
4
1 1 1 13 31
20 4 0 0 28 12 35
4 4 0 0 1 27 30
4 4 0 0 1 0 32
4 4 0 0 1 0 29
20 16 7 0 28 12 30
9 0 0 0 4 0 23
14 1 0 0 0 12 20
26 0 0 0 0 12 19
24 8 o 0 0 0 5
4 0 0 0 1 0 17
n
xl 0 0 0 0 0 7
28 168 36 0 13 12 13
23 0 0 0 4 0 4
5 1 41 0 1 0 9
36 12 4 4 5 0 9
9 4 2 *■> 3 0 6
24 0 0 0 4 0 5
2 1 0 0 1 0 1
5 0 0 0 0 0 1
24 4 8 4 0 0 0
9 0 0 0 3 0 10
200 3 0 0 11 26 32
2 0 0 0 1 0 30
56 5 0 0 1 20 34






















































No Sex Age Legend number.
1 3 4 5 6 7 8 9 10 12
146 -f 5 V X
n
Xm 4 15 0 0 0 1 13 13
147 m 5 o O X. 5 20 0 0 0 0 12 15
148 i 9 o O 4 n
n 2 1 0
n
jL 0 11
149 m 7 o o 3 l l 1 0 0 0 0 7
150 •f 1 1 o o 4 39 48 48 36 0 0 0 10
151 f 4 o X
~r
o 84 T•J 0 0 0 0 7
152 m 5 o o n -2 5 0 0 0 0 0 5
153 ■f 10 o o erwJ 9
-rn
■J2 1 1 1 0 0 8
154 m 8 o o 3 4 1 14 0 0 1 0 6
155 rn 13 o Q T 2 1 4 0 0 1 0
156 -f 15 o o *"9 4 16 0 0 0 0 0 0
157 m 30 X X
n
-2 4 0 0 0 0 0 0
15S + 22 o o 12 40 0 0 0 0 0 1
159 -f T *-»•J»xl o a 9 erwJ 15 0 0 0 0 0 4
1 60 i 17 o o 4 X. 2 0 0 0 0 8
161 ■f 30 o o 4 1 0 0 0 0 0 3
162 -f 40 o o 9} 3 11 0 0 0 0 0 3
163 m 31 o a To 4 10 4 0 0 0 0 6
164 m tiO o o 9? 9 24 0 0 0 8 0 6
165 ■f 33 a o *"5J&. 9 28 0 0 0 0 0 8
166 f 37 o X 2 1 1 0 0 1 0 9
167 ■f 49 o o 9? 3 5 0 0 0 0 0 8
163 rn 16 o o JL 8 16 0 0 0 5 0 7
16? -f 29 a o T•_> 12 28 6 0 0
CT
u 0 1 1
170 m IB o o 6 26 12 4 72 4 0 0 10
171 m 41 o o 9? 6 8 0 0 0 r> 0 0
172 T 19 o o O 6 0 0 0 0 0 12
173 "f 19 a a 6 17 24 4 16 2 0 0 11
174 (Tl 53 o X jC 1 3 0 0 0 0 0 10
175 "f 14 o o 3 36 76 crir? 0 0 0 12 12
176 11 D o n o 8 0 0 0 0 0 1
177 •f 4 a o ™T crx-J 4 4 0 0 0 0 0
178 <T: 9 D o 3 5 12 0 0 0 0 5
17? m 15 o o 2 5 4 0 0 0 1 0 4
180 -f 9 o o 3 2 8 4 0 0 0 12
181 •f 11 a a 4 25 16 64 22 0 0 0 3
182 m 5 X X 3 9 24 8 0 0 0 0 7
183 m 12 o o •3 4 6 6 0 0 6 0 9
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PROGNOSIS AFTER A FIRST UNTREATED
TONIC-CLONIC SEIZURE
R. D. C. Elwes P. Chesterman
E. H. Reynolds
Department of Neurology, Institute of Psychiatry and King's College
HospitalMedical School, London
Summary The prognosis for seizure recurrence was
assessed in 133 patients who presented at a
median of 1 day after a first-ever tonic-clonic seizure. The
cumulative probability of recurrence was 20% by 1 month,
28% by 2 months, 32% by 3 months, 46% by 6 months, 62%
by 1 year, and 71% by 3 and 4 years. After a first seizure
epilepsy is likely to develop in the majority of patients.
Introduction
The patient presenting with a single tonic-clonic seizure is
a common clinical problem. Estimates of the cumulative
incidence of epilepsy have suggested that as many as 5% of
the population will experience at least one afebrile seizure at
some time during their life.1 Little is known, however, about
the early prognosis of epilepsy, and opinions on the risk of
subsequent seizures after the initial attack have differed (table
I).2"7 Four studies2'4'6,7 found that about a third of patients
who present with a single seizure will have a second, but in
other studies the prognosis was worse.3'5
Patients and Methods
Between 1978 and 1983, 328 newly referred patients with
previously untreated seizures were seen in our neurology outpatient
department. In 42 patients the seizures were related to alcohol
withdrawal, drugs, acute metabolic disturbance, or fever. 72
patients had myoclonic, petit mal, or partial seizures without
TABLE I—STUDIES OF PROGNOSIS AFTER FIRST TONIC-CLONIC
SEIZURE
Recurrence Mean (range)
Ref n (%) follow-up (mo)
2 48 27 NK (42-102)
3 77 64 36
4 39 33 26(10-48)
5 74 56 36
6 70 39 57(36-120)
7 244 27 22 (6-55)
NK = not known; n = number of patients.
2
secondary generalisation. Of the 214 patients with tonic-clonic
seizures, 133 first presented to medical attention after a single
seizure. 73 were seen in accident and emergency departments and
60 by their family practitioner. No patient was treated after the
initial seizure. Patients who were seizure-free when discharged were
recalled to the clinic in January, 1984, or contacted by letter to assess
seizure recurrence. The patient characteristics and follow-up times
are summarised in table II.
The aetiology of the seizures was vascular in 7 patients, birth
injury in 3, post-traumatic in 3, and brain tumour in 3. 5 of the
patients had hemiparesis, 3 cognitive deficits, and 2 other
neurological deficits. The cumulative probability of seizure
recurrence in 1-month periods was assessed by Kaplan-Meier
survival curves.8
Results
The median time between first seizure and first
presentation was 1 day and median follow-up from the time of
the first seizure was 15 months. The cumulative probability
of seizure recurrence (see figure) was 20% by 1 month, 28%
by 2 months, 32% by 3 months, 46% by 6 months, 62% by 1
year, 69% by 2 years, and 71% by 3 and 4 years.
Discussion
Cleland et al6 found that epilepsy subsequently developed
in 39% of patients who presented with an isolated seizure in
adult life; a seizure was labelled "isolated" if the patient had
not experienced a second attack by the time offirst attendance
at a neurology outpatient department, some 6 weeks after the
event. Two earlier studies,2'4 both based on patients
attending electroencephalography departments, had similar
results. However, the time between first and second seizures
is likely to be less than a month in at least a third of patients




Median (range) age at first afebrile seizure (yr) 21 (2-74)
Symptomatic seizures 16 (13)







Median (range) follow-up 15 (1-69)
3
Risk 133 63 35 25 17 14 10
Cumulative probability of seizure recurrence in 133 patients
presenting with a single seizure.
with established epilepsy.9 In our study the recurrence rate
was already 28% by the second month of follow-up. At the
time of first attendance at a hospital clinic, therefore, a
considerable proportion of patients would have been
excluded from analysis in these studies2,4,6 because epilepsy
had already developed. Hauser et al7 studied 244 patients
with one unprovoked seizure; the cumulative probability of
seizure recurrence was 27% by 36 months. However, 435
patients who had had two or more seizures at first diagnosis
were excluded from analysis. Unlike our patients, 69% were
treated after the first seizure, which may also have
contributed to the low recurrence rate.
We do not know what proportion of patients who
experience a single seizure are not referred to hospital. A
survey10 of life-time general-practice records of6000 patients
suggests that it is low; furthermore, of patients with seizures,
only a fifth were found to have had a single attack. Our results
in patients referred to a neurology outpatient department are
similar and support Gowers' statement in 1881 that epilepsy
is likely to develop in the majority of patients after a first
seizure.9
It appears to be the current practice ofmost neurologists
not to treat a single seizure.11 Livingston12 has stated that
seizures recur in 91% of children without treatment and in
only 19% of those given anticonvulsants. Hauser et al' found
no difference in prognosis between patients treated or
4
untreated for a single seizure. However, they treated only
those patients considered by the referring clinicians to be at
high risk of recurrence.13 Neither report gave details of
whether the drugs were taken or moftitored. Although the
outlook for seizure control in newly diagnosed epilepsy is
good,14 it is possible that immediate treatment after a first
seizure might reduce the recurrence rate and improve
subsequent prognosis.15 There has, however, been no
adequate investigation of the value or otherwise of treating
single seizures.
Correspondence should be addressed to E. H. R., Department ofNeurology,
King's College Hospital, Denmark Hill, London SE5 9RS.
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THE PROGNOSIS FOR SEIZURE CONTROL IN NEWLY DIAGNOSED EPILEPSY
Robert D. C. Elwes, M.B., Ch.B., Anthony L.Johnson, Ph.D., Simon D. Shorvon, M.D.,
and Edward H. Reynolds, M.D.
Abstract We assessed the prognosis for seizure control
in 106 patients who were referred to an adult neurology
clinic with previously untreated tonic-clonic, partial, or
mixed seizures and were followed prospectively for a
median of 66 months (range, 6 to 96). Twenty-six pa¬
tients remained completely free of seizures for as
long as they were followed. Actuarial analysis showed
that 35 per cent of patients could be expected to enter
a seizure-free period of at least two years at the start
of treatment, 73 per cent would have had a two-year sei¬
zure-free period at the end of four years, and 82 per cent
would have had a two-year seizure-free period at the end
STUDIES of the prognosis for seizure control in epi¬lepsy have given widely conflicting results (Table
1). In an authoritative review Rodin6 found that if
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of eight years. Of 79 patients whose seizures were com¬
pletely controlled for at least two years, 51 subsequently
remained seizure-free. If seizures continued for up to two
years after the start of treatment, the probability of subse¬
quent seizure control fell by half. The presence of partial
seizures; a high frequency of tonic-clonic seizures before
treatment; a neurologic, social, or psychiatric handicap;
and a family history of epilepsy each indicated a worse
prognosis.
We conclude that the long-term pattern of seizure con¬
trol is largely established during the first two years of treat¬
ment. (N Engl J Med 1984; 311:944-7.)
control was defined as complete freedom-from all sei¬
zures for at least one year, then about two thirds of
patients with epilepsy were likely to have a chronic
seizure disorder. However, more recent studies have
suggested a better prognosis. In a retrospective survey
of patients from 20 institutions9 in whom the outcome
for seizure control was assessed up to 10 years after
the onset of the illness, 58 per cent were found to
have been completely free of seizures for more than
three years. Two retrospective community-based sur-
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Table 1. Studies of the Prognosis for Seizure Control in Patients
with Epilepsy.
No. of Seizure-Free %
Study Patients Period (Yr) Seizure-
Alstrom, 1950' 897 3 22
Strobos, 19592 228 2 38
Kiorboe, I9603 130 4 32
Trolle, I9604 799 2 37
Juul-Jensen, 19635 969 2 32
Rodin, 19686 90 2 32
Currie et al., 19717 * 666 1 40
Annegers et al., 19798 t 457 5 70
Okuma & Kumashiro, 19819 1868 3 58
Goodridge & Shorvon, 198310 t 122 4 69
*Temporal-lobe epilepsy only.
tCommunity surveys.
veys8'10 showed that the prognosis for about three
quarters of patients was good.
There are many difficulties in interpreting these
apparently conflicting results. Definitions of remis¬
sion, durations of follow-up and classifications of
seizures have differed. None of the studies used a con¬
sistent treatment plan with extensive monitoring of
serum anticonvulsant levels throughout follow-up to
assess either optimal use of medication or poor com¬
pliance.
The greatest problem, however, has been patient
selection. Epilepsy is a disorder with a widely varying
outcome, and hospital clinics tend to accumulate pa¬
tients with chronic intractable seizures. Previous hos¬
pital-based studies have used a cross-sectional sample
of patients. The prognosis in chronic epilepsy is prob¬
ably very poor," and inclusion of patients with chron¬
ic disease could well account for much of the disagree¬
ment. We performed a prognostic study in previously
untreated patients who were newly referred for epilep¬
sy and followed for up to eight years.
Methods
Between 1974 and 1979, 106 consecutively referred patients at¬
tending the Adult Neurology Clinic at King's College Hospital,
London, were entered into the study. Each patient had had two or
more tonic—clonic or partial seizures (or both) in the previous year.
Patients with seizures induced by alcohol, metabolic abnormalities,
or drugs and those with a progressive neurologic disorder at diagno¬
sis were excluded. Seizures were classified clinically in accordance
with the international classification.12 The clinical characteristics
and follow-up intervals are summarized in Table 2. A family history
of epilepsy was defined as epilepsy in first degree or second-degree
relatives. The frequency of tonic—clonic seizures before treatment
was assessed in 79 patients with tonic-clonic seizures alone or with
mixed seizure types. A high seizure frequency was defined as two or
more seizures a month. A neurologic handicap was defined as the
presence of focal neurologic signs, mental retardation, or an un¬
equivocal abnormality on a CT scan; a psychiatric or social handi¬
cap was defined as a problem of sufficient severity to warrant refer¬
ral to a psychiatrist or social worker.
Sixty-one patients were treated with phenytoin, and 45 with car-
bamazepine. Serum levels of anticonvulsants were monitored, and if
seizures continued the dosage was increased until they were con¬
trolled. The occurrence of two or more seizures despite an optimal
serum level of anticonvulsant was taken as evidence of failure of
single-drug therapy. The treatment methods and responses to sin¬
gle-drug therapy in 94 patients after a median interval of 32 months
have been reported previously.13 Two patients with drug-induced
skin rashes, two with tumors developing during treatment, and
eight who were lost to follow-up are included in the present analysis.
Statistical Analysis
The follow-up period was divided into two-month intervals, and
patients were designated as being with or without tonic—clonic or
partial seizures for each interval. Kaplan—Meier survival curves14
were used to analyze the percentages ofpatients who were complete¬
ly free of seizures for one- and two-year periods. Significance values
are based on the log-rank test.15 The percentages shown in the
figures are actuarial.
Results
At completion of the study, eight patients had been
lost to follow-up after a median interval of 1.9 years.
Of the remaining 98 patients, 62 were still taking their
original drug, 18 had successfully stopped taking
medication, and 18 had changed their treatment.
Treatment failed in 21 patients — by one year in 13,
by two years in a total of 19, and by six years in
another 2.
Twenty-six patients remained completely free of sei¬
zures for a median follow-up period of64 months after
the beginning ofanticonvulsant treatment. Among the
80 patients who had a recurrence of seizures, 35 had a
Table 2. Characteristics of the 106 Patients Entered in the Study.
Actuarial % Seizure-Free
Feature No. (%) * for One Year


























































































Total 106 (100) 40 73 89
*Figures are numbers and percentages of patients except where otherwise indicated. See text
for definitions.
recurrence by two months, 44 by four months, 51 by
six months, and 62 by one year. One patient was sei¬
zure-free and lost to follow-up at six months. Twelve
patients had seizures that could all be related to poor
compliance with medication.
The actuarial percentage of patients with complete
suppression of all seizures for periods of one and two
years is shown by duration of follow-up in Figure 1. A
one-year seizure-free period occurred in 40 per cent by
one year, 73 per cent by two years, 84 per cent by three
years, 88 per cent by four years, 89 per cent by five
years, and 92 per cent by eight years. The pattern for
two-year seizure-free periods was similar, occurring in
35 per cent by two years, 57 per cent by three years, 73
per cent by four years, 79 per cent by five years, and 82
per cent by eight years. There were 79 patients in
whom seizures were controlled for two years, and sub¬
sequent follow-up data were available in 76. Fifty-one
remained completely seizure-free for the rest of follow-
up. Twenty-five had a recurrence of seizures, which
consisted of one or two attacks in 17 and was related to
poor compliance in 16.
Factors of prognostic importance were investigated
by analysis of the actuarial percentage of patients who
were completely seizure-free for one year (Table 2).
The presence of partial seizures (log-rank statistic:
X2 = 9.1, d.f. = 2, P = 0.011); a family history of epi¬
lepsy (x2 = 5.4, d.f. = 1, P = 0.02); a high frequency
of tonic—clonic seizures before treatment (x2 = 5.3,
d.f. = 1, P = 0.022); or a neurologic (x2 = 3.8,
d.f. = 1, P = 0.05), social (*2 = 11.6, d.f. = 1,
P<0.001), or psychiatric handicap (x2 = 4.3, d.f. = 1,
P = 0.038) predicted a worse prognosis. Age at onset
of seizures; number of tonic—clonic seizures before
treatment; nocturnal or diurnal timing of seizures; and
the presence of epileptic, focal, or background abnor¬
malities on the pretreatment electroencephalogram
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Figure 1. Actuarial Percentage of Patients Completely Free of Seizures for One Year
(Solid Lines) and Two Years (Broken Lines).
The influence of early response to treatment on sub¬
sequent seizure control was also assessed (Fig. 2).
Ninety-two per cent ofall patients had a one-year peri¬
od in which they were completely seizure-free. In 63
patients who had seizures during the first year of treat¬
ment, 77 per cent were controlled, and in 32 who con¬
tinued to have seizures during the second year, 57 per
cent were controlled. If seizures continued for up to
two years after the start of treatment, the probability
of a subsequent one-year period completely free of sei¬
zures had fallen by about half.
Discussion
In this prolonged prospective follow-up study of
newly diagnosed epileptic patients, the outlook for sei¬
zure control was good. Twenty-six patients remained
completely free ofseizures for a median follow-up peri¬
od of 64 months, and 82 per cent had a two-year peri¬
od in which they were completely seizure-free. These
findings contrast sharply with those of previous hospi¬
tal-based studies,6 which have shown that about two
thirds of patients with epilepsy are likely to have a
chronic seizure disorder.
The most important explanation for the good prog¬
nosis in our patients is that we followed them from
the time of diagnosis and therefore avoided the selec¬
tion bias of previous cross-sectional studies, all of
which included patients with chronic epilepsy. Our
study also differed from previous ones in that a con¬
sistent pattern of treatment was maintained through¬
out follow-up, with extensive use of serum anticonvul¬
sant monitoring. In patients who took their prescribed
medication, treatment was therefore optimized, and
this may have contributed to the good prognosis.
The suggestion that the prognosis in epilepsy is far
better than previous hospital-based studies have
shown is strongly supported by epidemiologic and
community-based surveys. Although more than 5 per
cent of the population have at least
one afebrile seizure at some time
during their lives,16 the prevalence
rates for active epilepsy are on the
_ , order of 4 to 6 per thousand,17 sug¬
gesting that remissions occur in
many patients. Two recent retro¬
spective community-based surveys
have supported this suggestion.810
In both surveys about three quar¬
ters of patients entered a prolonged
seizure-free period, and the progno¬
sis improved with increasing time
after diagnosis.
Partial seizures; a high frequen¬
cy of tonic—clonic seizures before
treatment; a neurologic, social, or
7 2 psychiatric handicap; and a family
history ofepilepsy were each associ-
4 ated with a poorer prognosis for sei¬
zure control. These factors have
also been associated with a poorer











lapse on attempted withdrawal of 100
anticonvulsants,18 and seizure re¬
currence after a single seizure.19
Characteristics of the pretreatment
electroencephalogram and age at
onset of seizures were not associat¬
ed with prognosis.
The longer seizures continued
after the start of treatment, the
less likely was control. If seizures
were continuing after two years of
treatment, the probability of ever
achieving a one-year seizure-free
period had fallen by half. Since all
patients were treated it is impossi¬
ble to tell whether this reflects the
natural history of the disorder or
whether early control may indeed
affect long-term prognosis. Evi¬
dence for this possibility could only
be obtained from a randomized
study involving an untreated con¬
trol group. Little is known about
the natural history of untreated epi¬
lepsy. Gowers stated over a century
ago that "spontaneous cessation of
the disease is an event too rare to be reasonably antici¬
pated in any given case."20 His career spanned the
period when bromides (probably the first effective
treatment for epilepsy) were introduced, and he
thought the drugs had a major impact. He also sug¬
gested that seizures might be self-promoting, each one
predisposing to the next. It is possible, therefore, that
anticonvulsants not only suppress seizures but actual¬
ly alter the natural history of the disorder.
Although the overall outlook for seizure control is
good, about a quarter of patients do not respond to the
initial drug used, and our experience has been that the
disorder in most of these patients is not subsequently
controlled despite additions or changes in medica¬
tion.21 These patients are treated in hospital or spe¬
cialized epilepsy clinics for chronic intractable epilep¬
sy, and because of the high prevalence of the disorder,
they present a major management problem, using
most of the available resources for the treatment of
epilepsy. The pattern of seizure control, however, is
established within the first one or two years. This,
surprisingly, is an area of research that has been large¬
ly neglected. Further study is needed to establish
whether more effective treatment at the onset of sei¬
zures may prevent the development of chronic intract¬
able epilepsy.22
We are indebted to Drs. S. Brown, D. Chadwick, C. Dellaportas,
A. Galbraith, and M. McGowan for clinical assistance.
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